The germline and somatic landscape of Familial Intestinal Gastric Cancer: search for a cause by Celina Beatriz Teixeira São José
 
 
 
 
 
 
  
 
 
Celina Beatriz Teixeira São José 
 
 
 
The Germline and Somatic Landscape of Familial Intestinal Gastric 
Cancer: Search for a Cause 
 
Dissertação de Candidatura ao grau de 
Mestre em Oncologia submetida ao 
Instituto de Ciências Biomédicas de Abel 
Salazar da Universidade do Porto. 
Orientador – Doutora Carla Oliveira  
Categoria – Investigadora Sénior1, Líder do 
Grupo Regulação de Expressão em 
Cancro1 e Professora Afiliada2 
Afiliação – 1Instituto de Inovação e 
Investigação em Saúde / Instituto de 
Patologia e Imunologia Molecular da 
Universidade do Porto, 2Faculdade de 
Medicina da Universidade do Porto,  
Co-orientador – Doutora Joana Carvalho  
Categoria – Investigadora pós-doutoral  
Afiliação – Instituto de Inovação e 
Investigação em Saúde / Instituto de 
Patologia e Imunologia Molecular da 
Universidade do Porto 
 
 
 
  
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
 
i 
Celina Beatriz Teixeira São José 
Agradecimentos 
Durante a realização desta dissertação contei com o apoio de várias pessoas, sem as quais 
a sua concretização não seria possível. 
À minha orientadora, Carla Oliveira, que me acolheu de braços abertos, gostaria de 
agradecer toda a dedicação e apoio. Não posso deixar de agradecer todos os 
ensinamentos para a realização da tese e um pouco mais para ter na bagagem. 
À Joana Carvalho, obrigada por todo o apoio, dedicação e, principalmente, por me ajudares 
sempre. Obrigada por tudo que me ensinaste e por estares sempre disponível. 
À Patrícia Oliveira obrigada por estares sempre pronta para me ajudar e pela paciência, 
tens sempre razão!  
À Diana e ao Necas, agradeço a companhia ao almoço, a transcrição do que conseguimos 
viajar para escrito apenas diminuiria o seu verdadeiro valor. 
A todo o grupo ERiC (com marca registada), um enorme obrigada por me receberem tão 
bem, por toda a entreajuda e dinâmica incríveis. Em especial, à minha colega de bancada, 
Sara Teles, a entreajuda tem um significado especial contigo. Juntas no Pentas! Não podia 
deixar de agradecer à Sara Rocha, porque ”um título vale mais do que mil palavras”. 
Um especial agradecimento aos meus pais, por tudo que fizeram por mim e, principalmente 
por nunca me cortarem as asas e sempre me apoiarem. Aos meus avós, que mesmo 
distantes, têm sempre uma palavra de apoio e consolo. 
Ao João, que tive a sorte de conhecer no início deste percurso e que teve o azar de me 
aturar até então. Obrigada por estares comigo nas melhores e nas piores alturas, dás-me 
força quando mais preciso. 
À Mafalda e à Raquel viro-me e digo: aturar-me durante 10 anos é obra! Obrigada por 
acreditarem sempre em mim e por estarem sempre a ouvir-me, por mais longa que possa 
ser. 
Não posso deixar de agradecer aos meus conterrâneos bioquímicos e colegas do mestrado 
que me acompanharam em todo o meu percurso académico, obrigada por todo o apoio. 
Agradeço em particular ao Molezas, Sázona, Mafalda, Tero, Nuno, Diana, Jocina, Beja, 
Escaca e T-tus (sem qualquer ordem de preferência!) por sempre me ouvirem e ajudarem, 
mas principalmente por todas as gargalhadas e aulas práticas.  
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
ii 
Celina Beatriz Teixeira São José 
Index 
Abbreviations .................................................................................................................. xiii 
Abstract ......................................................................................................................... xvii 
Resumo .......................................................................................................................... xix 
I. Introduction .................................................................................................................... 1 
1. Cancer ...................................................................................................................... 1 
1.1. Carcinogenesis ................................................................................................... 1 
2. Gastric Cancer .......................................................................................................... 4 
2.1. Clinical and Histological Features ....................................................................... 4 
2.2. Sporadic Gastric Cancer ..................................................................................... 5 
2.3. Familial Gastric Cancer ....................................................................................... 6 
2.4. Other Hereditary Cancer Susceptibility Syndromes Associated with Gastric Cancer 
Risk ..........................................................................................................................10 
II. Rational and Objectives ............................................................................................14 
III. Materials and Methods ................................................................................................15 
1. Patients and samples ...............................................................................................15 
2. Analysis of germline and somatic variants ................................................................15 
2.1. Multiplex Custom-panel Sequencing ..................................................................15 
2.2. Clinical Classification of variants ........................................................................17 
2.3. Splicing prediction ..............................................................................................18 
3. Analysis of Promoter Methylation .............................................................................18 
4. RT-PCR and quantification of APC, CTHRC1 and β-Catenin mRNA expression ......21 
IV. Results and Discussion ..............................................................................................23 
1. Germline Landscape of Familial Intestinal Gastric Cancer Families..........................23 
2. Integration of Germline and Somatic Events of Familial Intestinal Gastric Cancer 
Families ........................................................................................................................28 
Detailed characterization of Families displaying co-occurrence of Germline Variants
 .................................................................................................................................28 
2.1. Family 1 .............................................................................................................28 
2.2. Family 4 .............................................................................................................34 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
iii 
Celina Beatriz Teixeira São José 
2.3. Family 7 .............................................................................................................38 
2.4. Family 8 .............................................................................................................44 
2.5. Family 11 ...........................................................................................................49 
2.6. Family 12 ...........................................................................................................54 
2.7. Family 13 ...........................................................................................................61 
2.8. Family 14 ...........................................................................................................65 
2.9. Family 16 ...........................................................................................................67 
2.10. Family 19 .........................................................................................................73 
Analysis of Families with single germline variants .....................................................77 
3. Somatic Landscape of Familial Intestinal Gastric Cancer .........................................84 
V. Conclusions .................................................................................................................90 
VI. Future Directions ........................................................................................................92 
VII. References ................................................................................................................93 
VIII. Supplementary Material .......................................................................................... 107 
 
  
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
iv 
Celina Beatriz Teixeira São José 
Figures Index 
Figure 1. Major factors that lead to intestinal GC, both environmental and molecular events, 
adapted from 50 ................................................................................................................ 5 
 
Figure 2. Bisulfite modification principle and Sanger sequencing ....................................19 
 
Figure 3. Pedigree and germline variants of Family 1. A: Pedigree of family 1. The proband 
is displayed by an arrow. B: Schematic representation of MSH6 protein, its domains, 
interacting molecules and germline variants found represented by green dots (missense 
variants). aa: amino acids. [57,58] C: Schematic representation of SDHD protein, its 
domains, interacting molecules and germline variant found represented by a green dot 
(missense variants) [57, 58] .............................................................................................29 
 
Figure 4. Somatic Events in Family 1. A: Somatic variants found in family 1 by multiplex 
custom-panel based sequencing. B: Schematic representation of MSH6 protein, its 
domains, interacting molecules and somatic variants found represented by green dots 
(missense variants). aa: amino acids [57,58]. C: MSH6 Promoter Methylation Analysis. 
Schematic representation of the CpG island located at the MSH6 promoter. Open circles 
represent a non-methylated CpG; Representative examples of sequences of each sample 
analyzed: HCT-116 cell line (negative control) and F1 tumor. D: SDHD Promoter 
Methylation Analysis. Schematic representation of the CpG island located at the SDHD 
promoter. Open circles represent a non-methylated CpG and yellow circles represent not 
accessed CpG sites; Representative examples of sequences of each sample analyzed: 
HCT-116 cell line (negative control) and F1 tumor. ..........................................................32 
Figure 4 (cont.). Somatic Events in Family 1. D: SDHD Promoter Methylation Analysis. 
Schematic representation of the CpG island located at the SDHD promoter. Open circles 
represent a non-methylated CpG and yellow circles represent not accessed CpG sites; 
Representative examples of sequences of each sample analyzed: HCT-116 cell line 
(negative control) and F1 tumor. ......................................................................................33 
 
Figure 5. Pedigree and germline variants of Family 4. A: Pedigree of family 4. The proband 
is displayed by an arrow. B: Schematic representation of SDHD protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense 
variants). aa: amino acids [57,58]. C: Schematic representation of MSH2 protein, its 
domains, interacting molecules and germline variant found represented by a purple dot 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
v 
Celina Beatriz Teixeira São José 
(splicing variants). D: Splicing prediction of variant Glu425Glu in MSH2. In bold is 
represented the variant alteration [57,58]. ........................................................................35 
 
Figure 6. Somatic Second Hit in Family 4. A: SDHD Promoter Methylation Analysis. 
Schematic representation of the CpG island located at the SDHD promoter. Open circles 
represent a non-methylated CpG and yellow circles represent not accessed CpG sites; 
Representative examples of sequences of each sample analyzed: HCT-116 cell line 
(negative control) and F4 tumor. B: MSH2 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the MSH2 promoter. Open circles represent a 
non-methylated CpG and yellow circles represent not accessed CpG sites; Representative 
examples of sequences of each sample analyzed: HCT-116 cell line (negative control) and 
F4 tumor. .........................................................................................................................37 
 
Figure 7. Germline variants of Family 7. A: Pedigree of family 7. The proband is displayed 
by an arrow. B: Schematic representation of MAP3K6 protein, its domains, interacting 
molecules and germline variant found represented by a green dot (missense variants). aa: 
amino acids [57,58]. C: Splicing prediction of variant c.-20+2dupT in BRCA1. In bold is 
represented the variant alteration.....................................................................................40 
 
Figure 8. Somatic events in Family 7. A: Somatic variants found in family 7 by multiplex 
custom-panel based sequencing. B: MAP3K6 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the MAP3K6 promoter. Open circles represent 
a non-methylated CpG and yellow circles represent not accessed CpG sites; 
Representative examples of sequences of each sample analyzed: MCF7 cell line (negative 
control) and F7 tumor. ......................................................................................................42 
 
Figure 9. Germline variants of Family 8. A: Pedigree of family 8. The proband is displayed 
by an arrow. B: Schematic representation of CASP10 protein, its domains, interacting 
molecules and germline variant found represented by a green dot (missense variants). aa: 
amino acids [57,58]. C: Splicing prediction of variant c.1256-2A>G in MAP3K6. In bold is 
represented the variant alteration.....................................................................................45 
 
Figure 10. Somatic Events in Family 8. A: Somatic variants found in family 8 by multiplex 
custom-panel based sequencing. B: MAP3K6 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the MAP3K6 promoter. Open circles represent 
a non-methylated CpG and yellow circles represent not accessed CpG sites; 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
vi 
Celina Beatriz Teixeira São José 
Representative examples of sequences of each sample analyzed: MCF7 cell line (negative 
control) and F8 tumor. ......................................................................................................47 
Figure 10 (cont.). Somatic Events in Family 8. C: MAP3K6 gene body Methylation Analysis. 
Schematic representation of the CpG island located at the MAP3K6 gene body. Open 
circles represent a non-methylated CpG; blue circles represent methylated CpG, white 
circles with blue risks represent hemi-methylated CpG and yellow circles represent not 
accessed CpG; Representative examples of sequences of each sample analyzed: MKN74 
cell line (negative control), F8 normal, F8 tumor and sample of bariatric surgery. ............48 
Figure 10 (cont.). Somatic Events in Family 8. D: CASP10 gene promoter Methylation 
Analysis. Schematic representation of the CpG island located at the CASP10 promoter. 
Open circles represent a non-methylated CpG; blue circles represent methylated CpG, 
white circles with blue risks represent hemi-methylated CpG and yellow circles represent 
not accessed CpG; Representative examples of sequences of each sample analyzed: HCT-
116 cell line (positive control), F8 normal, F8 tumor and sample of bariatric surgery........49 
 
Figure 11. Pedigree and germline variants of Family 11. A: Pedigree of family 11. The 
proband is displayed by an arrow. B: Schematic representation of MSH6 protein, its 
domains, interacting molecules and germline variant found represented by a green dot 
(missense variants). aa: amino acids [57,58]. C: Schematic representation of ATM protein, 
its domains, interacting molecules and germline variant found represented by a green dot 
(missense variants [57,58]). .............................................................................................51 
 
Figure 12. Somatic Events in Family 11. A: Somatic variants found in family 11 by multiplex 
custom-panel based sequencing. B: MSH6 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the MSH6 promoter. Open circles represent a 
non-methylated CpG and yellow circles represent not accessed CpG sites; Representative 
examples of sequences of each sample analyzed: HCT-116 cell line (negative control) and 
F11 tumor. C. ATM gene promoter Methylation Analysis. Schematic representation of the 
CpG island located at the ATM promoter. Open circles represent a non-methylated CpG 
and yellow circles represent not accessed CpG; Representative examples of sequences of 
each sample analyzed: HCT-116 cell line (positive control) and F11 tumor. ....................53 
 
Figure 13. DNA damage repair pathways – MRR and HR. Blue represents germline 
variants and yellow represents somatic variants. .............................................................54 
 
Figure 14. Pedigree and germline variants of Family 12. A: Pedigree of family 12. The 
proband is displayed by an arrow. B: Schematic representation of BRCA2 protein, its 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
vii 
Celina Beatriz Teixeira São José 
domains, interacting molecules and germline variants found represented by blue dots 
(missense variants). aa: amino acids [57,58]. C: Schematic representation of SDHD protein, 
its domains, interacting molecules and germline variant found represented by purple dots 
(frameshift variants [57,58]). ............................................................................................56 
 
Figure 15. Somatic Events in Family 12. A: Somatic variants found in family 12 by multiplex 
custom-panel based sequencing. B: BRCA2 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the BRCA2 promoter. Open circles represent a 
non-methylated CpG and yellow circles represent not accessed CpG sites; Representative 
examples of sequences of each sample analyzed: HCT-116 cell line (negative control) and 
F12 tumor. .......................................................................................................................59 
 
Figure 16. Somatic Events in Family 12, cont. A: CTHRC1 Promoter Methylation Analysis. 
Schematic representation of the CpG island located at the CTHRC1 promoter. Open circles 
represent a non-methylated CpG; blue circles represent methylated CpG, white circles with 
blue risks represent hemi-methylated CpG and yellow circles represent not accessed CpG; 
Representative examples of sequences of each sample analyzed: Hela and MKN74 cell 
lines (positive controls), F12 normal, F12 tumor and sample of bariatric surgery. B: UCSC 
genome browser, displaying promoter CpG island of CTHRC1. The blue rectangle 
represents the region amplified by the third set of primers in normal stomach and are 
represented in green, code for not methylated region. C: Expression of CTHRC1 (blue) in 
normal stomach, normal F12, tumor F12, cell line HCT-116 (positive control), normal breast 
(positive control) and MKN74 (negative control). D: Expression of APC (grey) and β-Catenin 
(yellow) in normal stomach, normal F12, tumor F12 and cell line HCT-116 (positive control).
 ........................................................................................................................................60 
 
Figure 17. Germline variants of Family 13. A: Pedigree of family 13. The proband is 
displayed by an arrow. B: Schematic representation of SDHB protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense 
variant). aa: amino acids [57,58]. C: Schematic representation of MTUS1 protein, its 
domains, interacting molecules and germline variant found represented by a green dot 
(missense variant) [57,58]. ...............................................................................................63 
 
Figure 18. Somatic Events in Family 13. A: SDHB Promoter Methylation Analysis. 
Schematic representation of the CpG island located at the SDHB promoter. Open circles 
represent a non-methylated CpG; Representative examples of sequences of each sample 
analyzed: Hela cell line (negative control) and F13 tumor. ...............................................64 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
viii 
Celina Beatriz Teixeira São José 
Figure 19. Germline variants of Family 14. A: Pedigree of family 14. The proband is 
displayed by an arrow. B: Schematic representation of ATM protein, its domains, interacting 
molecules and germline variant found represented by a green dot (missense variant). aa: 
amino acids [57,58]. C: Schematic representation of MTUS1 protein its domains, interacting 
molecules and germline variant found represented by a green dot (missense variant) 
[57,58]. ............................................................................................................................66 
 
Figure 20. Somatic Events in Family 14. A: ATM Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the ATM promoter. Open circles represent a 
non-methylated CpG and yellow circles represent not accessed CpG sites; Representative 
examples of sequences of each sample analyzed: HCT-116 cell line (negative control) and 
F14 tumor. .......................................................................................................................67 
 
Figure 21. Germline variants of Family 16. A: Pedigree of family 16. The proband is 
displayed by an arrow. B: Schematic representation of MSH2 protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense 
variant). aa: amino acids [57,58]. C: Schematic representation of TGFβRII protein, its 
domains, interacting molecules and germline variant found represented by a green dot 
(missense variant) [57,58]. C: Schematic representation of FAT4 protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense 
variant) [57,58]. ................................................................................................................69 
 
Figure 22. Somatic Events in Family 16. A: Somatic variants found in family 16 by multiplex 
custom-panel based sequencing. B: Schematic representation of FAT4 protein, its domains, 
interacting molecules and somatic variant found represented by a green dot (missense 
variant). aa: amino acids [57,58]. C: MSH2 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the MSH2 promoter. Open circles represent a 
non-methylated CpG; Representative examples of sequences of each sample analyzed: 
HCT-116 cell line (negative control) and F16 tumor. D: TGFβRII Promoter Methylation 
Analysis. Schematic representation of the CpG island located at the TGFβRII promoter. 
Open circles represent a non-methylated CpG and yellow circles represent not accessed 
CpG sites; Representative examples of sequences of each sample analyzed: MCF7 cell 
line (negative control) and F16 tumor. ..............................................................................72 
Figure 22 (cont.). Somatic Events in Family 16. E: FAT4 Promoter Methylation Analysis. 
Schematic representation of the CpG island located at the FAT4 promoter. Open circles 
represent a non-methylated CpG blue circles represent methylated CpG, white circles with 
blue risks represent hemi-methylated CpG and yellow circles represent not accessed CpG 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
ix 
Celina Beatriz Teixeira São José 
sites; Representative examples of sequences of each sample analyzed: NCI cell line 
(negative control), F16 normal, F16 tumor and an individual who underwent a bariatric 
surgery.............................................................................................................................72 
 
Figure 23. Pedigree and germline variants of Family 21. A: Pedigree of family 21. The 
proband is displayed by an arrow. B: Schematic representation of MAP3K6 protein, its 
domains, interacting molecules and germline variant found represented by a green dot 
(missense variant). aa: amino acids [57,58]. C: Schematic representation of MSR1 protein, 
its domains, interacting molecules and germline variant found represented by a green dot 
(missense variant) [57,58]. ...............................................................................................74 
 
Figure 24. Somatic Events in Family 19. A: Somatic variants found in family 19 by multiplex 
custom-panel based sequencing. B: MAP3K6 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the MAP3K6 promoter. Open circles represent 
a non-methylated CpG and yellow circles represent not accessed CpG sites; 
Representative examples of sequences of each sample analyzed: MCF7 cell line (negative 
control) and F19 tumor. C: MAP3K6 gene body Methylation Analysis. Schematic 
representation of the CpG island located at the MAP3K6 gene body. Open circles represent 
a non-methylated CpG; blue circles represent methylated CpG, white circles with blue risks 
represent hemi-methylated CpG and yellow circles represent not accessed CpG; 
Representative examples of sequences of each sample analyzed: MKN74 cell line 
(negative control), F19 normal, F19 tumor and sample of bariatric surgery. .....................75 
Figure 24 (cont.). Somatic Events in Family 19. C: MAP3K6 gene body Methylation 
Analysis. Schematic representation of the CpG island located at the MAP3K6 gene body. 
Open circles represent a non-methylated CpG; blue circles represent methylated CpG, 
white circles with blue risks represent hemi-methylated CpG and yellow circles represent 
not accessed CpG; Representative examples of sequences of each sample analyzed: 
MKN74 cell line (negative control), F19 normal, F19 tumor and sample of bariatric surgery.
 ........................................................................................................................................76 
 
Figure 25. Germline variant and somatic variants of F2. A: Schematic representation of 
SDHD protein, its domains, interacting molecules and germline variant found represented 
by a green dot (missense variant); B: Somatic variants in F2. ..........................................78 
 
Figure 26. Somatic variants found in F3. .........................................................................78 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
x 
Celina Beatriz Teixeira São José 
Figure 27. Schematic representation of ATM protein, its domains, interacting molecules 
and germline variant found represented by a green dot (missense variant). Somatic variants 
were not found. ................................................................................................................78 
 
Figure 28. Schematic representation of ITIH2 protein, its domains, interacting molecules 
and germline variant found represented by a green dot (missense variant). Somatic variants 
were not found. ................................................................................................................79 
 
Figure 29. Germline and somatic variants of F9. A: Schematic representation of MSH6 
protein, its domains, interacting molecules and germline variants found represented by a 
green dot (missense variant); B: Somatic variants in F9. .................................................79 
 
Figure 30. Germline and somatic variants of F10. A: Schematic representation of MSH6 
protein, its domains, interacting molecules and germline variant found represented by a 
green dot (missense variant); B: Somatic variants in F10. ...............................................79 
 
Figure 31. Germline and somatic variants of F18. A: Schematic representation of MSH6 
protein, its domains, interacting molecules and germline variant found represented by a 
green dot (missense variant); B: Somatic variants in F18. ...............................................80 
 
Figure 32. Germline and somatic variants of F20. A: Schematic representation of FAT4 
protein, its domains, interacting molecules and germline variant found represented by a 
green dot (missense variant); B: Somatic variants in F20. ...............................................80 
 
Figure 33. Germline and somatic variants of F21. A: Schematic representation of SDHD 
protein, its domains, interacting molecules and germline variant found represented by a 
green dot (missense variant); B: Somatic variants in F21. ...............................................80 
 
Figure 34. Germline and somatic variants of F22. A: Schematic representation of SDHB 
protein, its domains, interacting molecules and germline variant found represented by a 
green dot (missense variant); B: Somatic variants in F21. ...............................................81 
 
Figure 35. Schematic representation of MSR1 protein, its domains, interacting molecules 
and germline variant found represented by a green dot (missense variant). Somatic variants 
were not found .................................................................................................................81 
 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
xi 
Celina Beatriz Teixeira São José 
Figure 36. Oncoprint of somatic variants. Columns represent families that harbored somatic 
variants. Grey: somatic variant not found; 1/3 of the rectangle green: 1 somatic variant; 2/3 
of the rectangle green: 2 somatic variants; complete rectangle green: 3 somatic variants. % 
of variants in each gene/115. ...........................................................................................89 
 
 
  
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
xii 
Celina Beatriz Teixeira São José 
Tables Index 
Table 1. Hereditary cancer-predisposing syndromes associated with gastric cancer, the 
genetic cause identified, the inheritance pattern, the risk for developing GC and its histology, 
average age of appearance of polyps and respectively histology and initiation and intervals 
of endoscopic surveillance ...............................................................................................11 
Table 2. Panel of genes used in Multiplex Custom-panel Sequencing. ............................15 
Table 3. Bisulfite reaction components. ...........................................................................19 
Table 4. Thermal cycle protocol. ......................................................................................19 
Table 5. CpG island analyzed for each gene and respective primers. .............................20 
Table 6. PCR amplification program. ...............................................................................21 
Table 7. Sanger Sequencing components ………………………………………………….…21 
Table 8. Sanger Sequencing thermal cycle program…………………………………………21 
Table 9. Components of Reverse Transcriptase Mix. ......................................................22 
Table 10. Components of RT-PCR………………..……………………………………………22   
Table 11. Thermal cycle…………………………… ...........................................................22 
Table 12. Germline Variants identified in FIGC families by multiplex custom-panel based 
sequencing. .....................................................................................................................26 
Table 13. Characterization of germline variants found in each family. .............................27 
Table 14. Germline Variants identified in FIGC families with single germline variants by 
multiplex custom-panel based sequencing. ......................................................................82 
Table 15. Characterization of germline variants found in each family and somatic second 
hit found. ..........................................................................................................................82 
Table 16. Somatic Variants identified in FIGC families by multiplex custom-panel based 
sequencing. .....................................................................................................................86 
Table 17. Differences of somatic landscape between families with and without germline 
variants. ...........................................................................................................................89 
Table S1. Germline Variants identified in FIGC families by multiplex custom-panel based 
sequencing. ................................................................................................................... 107 
Table S2. Somatic Variants identified in FIGC families by multiplex custom-panel based 
sequencing………………………………………………………………………………………108 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
 
xiii 
Celina Beatriz Teixeira São José 
Abbreviations 
A  Adenine 
AKAP12 A-Kinase Anchoring Protein 12 
Ala  Alanine 
APC  Adenomatous Polyposis Coli 
Arg  Arginine 
ARID1A AT-Rich Interaction Domain 1A 
Asn  Asparagine 
Asp  Aspartic Acid 
ATM  Ataxia Telangiectasia Mutated 
BMPR1A Bone Morphogenetic Protein Receptor Type 1A 
BRCA1 Breast Cancer Type 1 Susceptibility Protein 
BRCA2 Breast Cancer Type 2 Susceptibility Protein 
C  Cytosine 
CASP10 Caspase 10 
CDH1  Cadherin 1 
CDKN2A Cyclin Dependent Kinase Inhibitor 2A 
CIN  Chromosomal Instability 
COSMIC Catalogue of Somatic Mutations in Cancer 
CTHRC1 Collagen Triple Helix Repeat Containing 1 
CTNNA1 Catenin Alpha 1 
Cys  Cysteine 
DNA  Deoxyribonucleic acid 
EPCAM Epithelial Cell Adhesion Molecule 
ERBB2 Erb-B2 Receptor Tyrosine Kinase 2 
ExAC  Exome Aggregation Consortium  
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
xiv 
Celina Beatriz Teixeira São José 
FAT4  FAT Atypical Cadherin 4 
FATHMM  Functional Analysis through Hidden Markov Models  
FIGC  Familial Intestinal Gastric Cancer  
G  Guanine 
GAPPS  Gastric and Proximal Polyposis of the Stomach  
GC  Gastric Cancer 
Gln  Glutamine 
Glu  Glutamic Acid 
Gly  Glycine 
HDGC  Hereditary Diffuse Gastric Cancer  
His  Histidine 
HR  Homologous Recombination  
HSPA5 Heat Shock Protein Family A (Hsp70) Member 5 
IDH2  Isocitrate Dehydrogenase (NADP(+)) 2 
IGCLC  International Gastric Cancer Linkage Consortium 
Ile  Isoleucine 
ITIH2  Inter-Alpha-Trypsin Inhibitor Heavy Chain 2 
JAK2  Janus Kinase 2 
KRAS  KRAS Proto-Oncogene 
Leu  Leucine 
LOH  Loss of Heterozygosity 
LRP1B LDL Receptor Related Protein 1B 
Lys  Lysine 
MAP3K6 Mitogen-Activated Protein Kinase Kinase Kinase 6 
MAPK  Mitogen-activated Protein kinase 
MCCC1 Methylcrotonoyl-CoA Carboxylase 1 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
xv 
Celina Beatriz Teixeira São José 
Met  Methionine 
MLH1  MutL Homolog 1 
MLH3  MutL Homolog 3 
MMR  Mismatch Repair 
mRNA  Messenger Ribonucleic acid 
MSH2  MutS Homolog 2 
MSH3  MutS Homolog 3 
MSH6  MutS Homolog 6 
MSI  Microsatellite Instability 
MSR1  Macrophage Scavenger Receptor 1 
MTUS1 Mitochondrial Tumor Suppressor Gene 1 
MYH  MutY Homolog 
PALB2 Partner And Localizer Of BRCA2 
PCLO  Piccolo Presynaptic Cytomatrix Protein 
PCP   Planar Cell Polarity 
PCR  Polymerase Chain Reaction 
PD-L1  Programmed death-ligand 1 
PD-L2  Programmed death-ligand 2 
Phe  Phenylalanine 
PI3K  Phosphoinositide-3-Kinase 
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha 
PMS1  PMS1 Homolog 1 
PMS2  PMS1 Homolog 2 
Pro  Proline 
PTEN  Phosphatase And Tensin Homolog 
RHOA  Ras Homolog Family Member A 
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SDHA  Succinate Dehydrogenase Complex Subunit A 
SDHB  Succinate Dehydrogenase Complex Subunit B 
SDHC  Succinate Dehydrogenase Complex Subunit C 
SDHD  Succinate Dehydrogenase Complex Subunit D 
Ser  Serine 
SMAD4 SMAD Family Member 4 
SNV  Single Nucleotide Variant 
STK11  Serine/Threonine Kinase 11 
SYNE1 Spectrin Repeat Containing Nuclear Envelope Protein 1 
T  Thymine 
TCGA  The Cancer Genome Atlas  
TGFβRII Transforming Growth Factor Beta Receptor 2 
Thr   Threonine 
TP53  Tumor Protein P53 
Trp  Tryptophan 
Tyr  Tyrosine 
U  Uracil 
Val  Valine 
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Abstract 
Gastric cancer is the fifth most common cancer and the third cause of cancer-related 
mortality worldwide. The majority of the cases have sporadic nature, nevertheless, 10% 
display familial aggregation. These may account for at least three syndromes: Hereditary 
Diffuse Gastric Cancer (HDGC), Gastric Adenocarcinoma and Proximal Polyposis of the 
Stomach (GAPPS) and Familial Intestinal Gastric Cancer (FIGC).  
FIGC has been thought of as an autosomal dominant inheritance pattern and is 
characterised by intestinal type adenocarcinoma without gastric polyposis, displaying 
common macroscopic features observed in sporadic intestinal gastric cancer. However, no 
underlying genetic defects have so far been described, and no genetic screening is 
available for FIGC families. Moreover, affected individuals generally display late onset 
intestinal gastric cancer and the pedigrees of FIGC families often exhibit generations 
without affected individuals. Underlying these characteristics may be the presence of low 
or moderate risk alleles that, when occurring in combination, may increase FIGC 
susceptibility. Therefore, the hypothesis of this master thesis was that co-occurrence of 
germline low or moderate risk alleles in one or more cancer-related genes may be the 
underlying genetic defect of FIGC. The general aim of this thesis was to identify genetic 
defects that could increase susceptibility to develop FIGC. 
To prove this hypothesis, normal and tumour DNA from 52 FIGC probands were screened 
for 67 candidate gastrointestinal cancer-associated genes with Illumina’s MiSeq platform, 
and classified using two distinct softwares: Illumina’s Variant Interpreter and our own 
Annotator57 software. Somatic second hits, such as second mutation and promoter 
methylation were searched for in FIGC tumours at potentially causative genes by PCR-
Sequencing. In addition, the mRNA expression of specific genes was evaluated, by 
quantitative real-time PCR, in order to determine the impact of germline and somatic 
variants found in one family. 
In the 52 FIGC families fulfilling IGCLC criteria, 36 germline variants were found in 24 FIGC 
families, affecting 17 genes. These variants include: one Likely Pathogenic, 11 Conflicting, 
three Likely Benign and 21 Variants of Unknown Significance according to Annotator57. 
Moreover, the most frequently mutated genes were MSH6 (17%), SDHD (11%), ATM (8%) 
and MTUS1 (8%).  
Interestingly, 10 out of the 24 FIGC families (42%) carried co-occurrence of germline 
variants, with potential impairment of specific pathways: Mismatch Repair, Homologous 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
xviii 
Celina Beatriz Teixeira São José 
Recombination, Mitogen-activated Protein kinase and Planar Cell Polarity. Of notice, DNA 
repair genes were frequently altered in co-occurrence with metabolism associated genes 
(e.g. MSH2 and SDHD).  
Further, only MSH6 and FAT4 genes were somatically inactivated, through a second 
mutation, in two families.  
The somatic landscape revealed 115 variants, affecting 23 genes, found in 36 families. 
These variants were classified as: Pathogenic (12), Likely Pathogenic (42), Conflicting (1) 
and Variants of Unknown Significance (60). The most frequently mutated genes were: TP53 
(18%), MSH3 (11%), ARID1A (10%), FAT4 (7%), APC (8%), MSH6 (7%), ATM (7%), 
BRCA2 (6%) and CTNNA1 (6%). In addition, the majority of families with germline variants 
(63%) harbored somatic variants in more than one gene, comparing with families without 
germline variants (35%). These results reflect the high frequency of MSI phenotype in 
families with germline variants. 
In conclusion, the work described in this thesis pinpointed FIGC as a likely polygenic rather 
than a monogenic disease in 42% of families, where co-occurrence of low or moderate risk 
alleles that interact with family history and other non-genetic factors (environmental) can 
affect the risk of cancer of each individual.   
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Resumo 
O cancro gástrico é o quinto cancro mais incidente e o terceiro cancro mais mortal no 
mundo. A maioria dos casos tem uma natureza esporádica, contudo, 10% demonstram 
agregação familiar. Estes últimos incluem, pelo menos, três síndromes: “Hereditary Diffuse 
Gastric Cancer”, “Gastric Adenocarcinoma and Proximal Polyposis of the Stomach” e 
“Familial Intestinal Gastric Cancer” (FIGC). 
FIGC tem sido considerado uma síndrome com padrão de hereditariedade autossómico 
dominante e é caracterizado por adenocarcinoma do tipo intestinal sem polipose gástrica, 
revelando características macroscópicas observadas em cancro gástrico esporádico do 
tipo intestinal. No entanto, até agora não são conhecidas alterações genéticas causais e 
nenhum rastreio está em vigor para famílias com FIGC. Para além destes factos, os 
indivíduos afetados apresentam, geralmente, cancro gástrico tardiamente e os pedigrees 
das famílias com FIGC exibem gerações sem indivíduos afetados. A presença de alelos de 
risco baixo ou moderado podem justificar estas características quando ocorrem em 
combinação, podendo aumentar a suscetibilidade para desenvolver FIGC. Desta forma, o 
estudo aqui desenvolvido, assenta na hipótese que a co-ocorrência de alelos de risco baixo 
ou moderado em genes associados a cancro pode ser o defeito genético subjacente ao 
FIGC. Assim, o objetivo desta tese foi identificar os defeitos genéticos que poderão 
aumentar a suscetibilidade para desenvolver FIGC. 
Para provar a nossa hipótese, DNA normal e tumoral de 52 probandos com FIGC foram 
sequenciados usando um painel de 67 genes, previamente associados a cancro 
gastrointestinal, e a plataforma MiSeq da Illumina. As variantes obtidas foram classificadas 
com dois softwares distintos: Illumina’s Variant Interpreter e um software desenvolvido no 
nosso grupo, designado Annotator57. Os tumores de probandos com FIGC foram também 
avaliados usando, PCR e sequenciação, para a presença de mecanismo somáticos de 
inactivação, tais como: segunda mutação e metilação do promotor, em genes 
potencialmente causadores. Adicionalmente, a expressão de mRNA de genes específicos 
foi avaliada por PCR quantitativo em tempo real, com o objetivo de determinar o impacto 
das variantes germinativas e somáticas numa família.  
Em 52 famílias que cumprem os critérios IGCLC, foram encontradas 36 variantes 
germinativas em 24 famílias, afetando 17 genes. Estas variantes incluem: uma “Likely 
Pathogenic”, onze “Conflicting”, três “Likely Benign” e 21 “Variants of Unknown 
Significance”, de acordo com o software Annotator57. Os genes mais frequentemente 
alterados foram: MSH6 (17%), SDHD (11%), ATM (8%) e MTUS1 (8%). 
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De especial interesse foi o facto de 10 das 24 famílias (42%) revelarem co-ocorrência de 
variantes germinativas, com potencial desregulação de vias específicas: “Mismatch 
Repair”, “Homologous Recombination”, “Mitogen-activated Protein kinase” e “Planar Cell 
Polarity”. De notar, que genes de reparação de DNA estavam frequentemente alterados 
em co-ocorrência com genes associados a metabolismo (por exemplo MSH2 e SDHD). 
Além disso, observamos que apenas os genes MSH6 e FAT4 foram inativados 
somaticamente, através de uma segunda mutação, em duas famílias. 
Ao nível somático, 115 variantes, foram encontradas em 36 famílias, afetando 23 genes. 
Estas variantes foram classificadas como: “Pathogenic” (12), “Likely Pathogenic” (42), 
“Conflicting” (1) e "Variants of Unknown Significance” (60). Os genes mais 
frequentemente mutados foram: TP53 (18%), MSH3 (11%), ARID1A (10%), FAT4 (7%), 
APC (8%), MSH6 (7%), ATM (7%), BRCA2 (6%) e CTNNA1 (6%). Por outro lado, 
observamos que a maioria das famílias com variantes germinativas (63%) continha 
variantes somáticas em mais de um gene, comparando com famílias sem variantes 
germinativas (35%). Estes resultados refletem a alta frequência do fenótipo de instabilidade 
de microssatélites em famílias com variantes germinativas. 
Em conclusão, o trabalho descrito nesta tese revelou que o FIGC é, possivelmente, uma 
doença poligénica em vez de uma doença monogénica em 42% das famílias, onde a co-
ocorrência de alelos de risco baixo ou moderado interagem com a história familiar e outros 
fatores não genéticos (ambientais), podendo afetar o risco de cancro de cada indivíduo. 
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I. Introduction 
1. Cancer 
Normal cells divide through mitosis to form new cells in a tightly controlled manner (1). 
When cells acquire genetic changes that disrupt proliferation and/or apoptosis pathways, 
cells start to grow and divide in an uncontrolled manner, and a tumor may arise (2-4).  
Tumors can be classified as benign and malignant (2). Benign tumors are characterized 
by a mass of cells that have a relatively slow rate of growth and are surrounded by a 
capsule or adjacent tissues. This mass of cells do not invade neighboring tissues or 
metastasize (5). Malignant tumors (or cancer), on the other hand, are characterized by 
the ability of cells to invade and infiltrate the surrounding tissues, and metastasize or 
travel to distant parts of the body. The growth rate of malignant tumors is erratic and 
atypical mitosis are commonly present (5).  
Cancer can thus result from the abnormal proliferation of different types of cells, affecting 
different tissues, such as stomach and colon (2). Indeed, cancer has been one of the 
major diseases of the 21st century. In 2012, there were 14.1 million new cancer cases, 
8.2 million deaths and 32.5 million people lived with cancer within 5 years of diagnosis, 
worldwide (6). 
 
1.1. Carcinogenesis 
The process of transformation of a normal cell into a cancer cell is named 
Carcinogenesis. This multi-step process is characterized by the accumulation of 
successive genetic and epigenetic changes that lead to an imbalance in proliferation and 
apoptosis, providing a selective advantage to cancer cells (7). 
The transformation process commonly requires the action of carcinogenic agents, which 
can be chemical, physical, and biological (e.g. alkylating agents (8), UV radiation (9),  
Helicobacter pylori (10), respectively  (2,3)). These carcinogenic agents act by inducing 
DNA damage and mutations in inductor genes (i.e. proto-oncogenes) and inhibitory 
genes (i.e. tumor suppressor genes) (2,11).  
Proto-oncogenes are normal cellular genes that participate in cell survival and 
proliferation pathways. These genes encode several types of proteins, such as: growth 
factors and their receptors (e.g. EGFR (12)), signal transducers (e.g. RAS (13)), 
transcription factors (e.g. MYC (14)) and cyclins and cyclin dependent kinases (e.g. CDKs 
(15)) (2). After DNA damage, proto-oncogenes are activated into oncogenes, and promote 
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cellular proliferation in an autonomous way (2,3). At least, three mechanisms have been 
described to explain oncogene activation (16): point mutations that leads to increased 
gene products (e.g. G12C mutation in K-RAS in 40% of lung cancer cases (17)), gene 
amplification that results in increased gene copy number (e.g. HER2 in breast cancer 
(18)) and chromosomal rearrangement in which a promoter of a gene expressed 
constitutively is rearranged to overproduce a normal protein, (e.g. Ig promoter, which is 
constitutively expressed, become rearranged with MYC, leading to its constitutive 
expression in Burkitt lymphoma (14) or the overproduction of a fusion protein as the case 
of BCR-ABL in chronic myeloid leukemia (19)). These gain-of-function alterations that 
convert proto-oncogenes into oncogenes are dominant (20). Therefore, a mutation in only 
one of the two alleles is sufficient to alter the cellular phenotype (one hit) and induce 
cancer, being this gene haplosufficient (2,20).  
Tumor suppressor genes encode proteins that inhibit cell survival and proliferation (11). 
These proteins can function as gatekeeper (e.g. TP53 (21,22)) which regulates cellular 
growth or apoptosis, or caretaker (e.g. MSH2 (23)) ensuring DNA fidelity, and participating 
in DNA repair and genomic stability processes  (2,3).  
Tumor suppressor genes generally encode cellular growth regulation factors (e.g. 
TGFβRII in colon cancer (24,25)), cellular adhesion proteins (e.g. CDH1 in Hereditary 
diffuse gastric cancer (26)), intracellular signal transducers (e.g. APC in colon cancer (27)), 
nuclear transcription factors (e.g. STAT3 in colon cancer (28)) and proteins involved in 
apoptosis (e.g. TP53 in Li-Fraumeni Syndrome (29)). Consequently, inactivation of these 
genes leads to uncontrolled apoptosis signaling pathways and defects in DNA damage 
repair (2,3). As a result, a proto-oncogene could be activated, due to the unsuccessful 
repair of DNA, leading to uncontrolled proliferation and cell survival (11). 
The loss-of-function alterations that inactivate Tumor suppressor genes act recessively 
(20). Thus, both alleles must be affected to alter the cellular phenotype (two hits) and 
enable tumor progression (20).  
Genomic alterations can occur at the germline and somatic levels. Germline alterations 
are present in the gametes, being inheritable and the underlying cause of hereditary 
syndromes. Somatic alterations are acquired during lifetime and are not transmitted to 
the offspring (2).  
In the context of hereditary syndromes, a germline alteration in a tumor suppressor gene 
is already present in all cells of the individual. When a somatic second hit appears in the 
wild-type allele, the expression of the gene is decreased or completely absent, leading 
ultimately to the formation of a tumor (20). This hypothesis is designated as “Two-hit 
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hypothesis”, from Knudson and was discovered in Retinoblastoma, which is caused by 
germline mutations in Rb gene (the first characterized tumor suppressor gene) (20). In 
fact, Hereditary Retinoblastoma commonly arises from de novo mutations in Rb and 
have an increased probability of suffering a second hit in the wild-type allele, such as 
loss of heterozygosity. Further, these cases are usually presented with bilateral 
retinoblastoma (20). In the case of sporadic Retinoblastoma, a germline mutation in Rb 
gene is not present. Thus, the individuals affected have a decreased probability of 
suffering two hits in both eyes, being, usually, presented as unilateral retinoblastoma (20). 
At least three mechanisms have been described to explain inactivation of the second, 
and wild-type allele at the somatic level: point mutation, loss of heterozygosity (LOH) and 
DNA promoter hypermethylation (16,30). Patients that already harbor a germline mutation, 
may acquire a second somatic mutation in the wild-type allele, that leads to complete 
loss of protein function, as observed in ta fraction of tumors with from Hereditary Diffuse 
Gastric Cancer patients bearing germline CDH1 mutations (31). LOH is a long deletion, 
resulting in partial or complete loss of a gene. In a heterozygous individual that carriers 
a germline mutation in one allele, LOH of the remaining wild-type allele leads to the 
complete loss of function. Indeed, both for somatic mutations and LOH, tumors become 
homozygously inactivated (32). LOH has been identified as a major second inactivation 
hit in several tumors types, being an example patients with Hereditary Retinobastoma 
(20). Further, promoters of genes frequently overlap CpG islands, which are regions that 
have a high content of CpG sites, dinucleotides of cytosine (C) and guanine (G). 
Methylation of cytosines at CpG sites (5-methylcytosine) inactivates the expression of 
genes (33), by preventing the binding of transcription factors (34). Methylation of CDH1 has 
been reported as a somatic second hit, for example in approximately 50% of the primary 
tumors from Hereditary Diffuse Gastric Cancer patients (35). 
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2. Gastric Cancer 
2.1. Clinical and Histological Features 
Gastric cancer (GC) is still the fifth most incident type of cancer, accounting for 7% 
(roughly 1 million) of all cancer cases (6), despite the recent improvements in diagnosis 
(36,37). According to Globocan, in 2012, the incidence of GC was higher in particular areas 
of the globe, such as Eastern Asia and Central and Eastern Europe, and higher among 
men than women (6,38). GC is also the third cause of cancer-related deaths, with 
approximately 0.7 million of deaths worldwide, in 2012 (6). Clinically, the absence of 
symptoms in an early stage of the disease restricts the initial diagnosis, reduces the 
chance of cure by surgery, and may explain the high mortality rate (37). In fact, the majority 
of cases are diagnosed at advance stages of the disease (III and IV), when symptoms 
and metastasis are already present, and when few therapeutic options are available (31,39-
41). These facts explain the GC patients’ poor 5-year survival rate of less than 25% (41,42).  
GC is a multifactorial disease with a variety of genetic and environmental factors that 
increase the susceptibility to develop cancer in the stomach (43). Helicobacter pylori 
infection, smoking and diet (e.g. salted food and smoked meat) play an important 
cumulative effect as key environmental factors (36,43,44). 
GC is an heterogenous disease commonly displayed as adenocarcinomas (i.e. a 
malignant neoplasia originated from epithelial tissue). According to Lauren, gastric 
adenocarcinomas can be histologically classified as diffuse or intestinal (45). Diffuse 
carcinomas are more prevalent in female younger individuals and are more aggressive 
than intestinal carcinomas (46). These tumors are characterized by isolated infiltrating 
neoplastic cells with absent or impaired expression of E-cadherin, an epithelial cell 
adhesion molecule (41). In addition, these cells do not form glandular structures and may 
have a signet ring morphology with high mucin content (47). Intestinal carcinomas tend 
to occur in male elderly individuals and in high risk areas  (43), such as Eastern Asia and 
Central and Eastern Europe (48). Intestinal-type tumours are highly associated with 
environmental factors, such as Helicobacter pylori infection (43). According to the Correa 
model (49), upon Helicobacter Pylori infection, a multistep process occurs in which normal 
gastric mucosa is transformed into an invasive carcinoma. In fact, long term infection 
leads to an inflammation process, termed gastritis (Figure 1). Subsequently, this gastritis 
can persist causing atrophy of the gastric mucosa, and a gradual replacement of gastric 
cells by intestinal cells (Goblet cells), usually absent in the stomach, in a process termed 
intestinal metaplasia (Figure 1). Intestinal metaplasia may progress to dysplasia and, 
ultimatly to GC (Figure 1). Thus, these tumors are characterized by solid masses of well-
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differentiated glandular structures with atrophic gastritis and peripheral intestinal 
metaplasia, in which intercellular adhesion is preserved (41).  
Diffuse and Intestinal tumours can have a sporadic nature or appear in a familial context. 
 
2.2. Sporadic Gastric Cancer 
The majority of GC cases (approximatelly 90%) are sporadic, and result from the 
complex interplay of genetic and environmental factors (Figure 1) (50). In fact, these 
factors affect different stages of the disease, from precancerous lesions to tumor 
initiation and progression. For instance, genetic polymorphisms in interleukin 1 beta (IL-
1B) gene have been associated with GC (51). In particular, individuals carrying the  
polymorphism IL-1B-511*T, have an increased susceptibility to the development of 
gastritis upon H pylori infection, and intestinal GC (52,53).  
 
 
Figure 1. Major factors that lead to intestinal GC, both environmental and molecular events, adapted from 
50 
 
Beyond genetically determined factors, other somatic genetic alterations have been 
recurrently found in GC (50). In fact, during the last decade, several studies (mostly based 
on next generation sequencing technologies) have been dissecting the molecular 
lansdcape of GC (54-56). For instance, The Cancer Genome Atlas (TCGA) project have 
proposed a molecular classification of GC into four subtypes: a) tumours positive for 
Epstein–Barr virus, which harbor recurrent PIK3CA mutations, extreme DNA 
hypermethylation (e.g. CDKN2A promoter) and amplification of JAK2, PD-L1, and PD-
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L2; b) microsatellite unstable tumours, which show an increased mutation rate and 
hypermethylation (including hypermethylation at the MLH1 promoter); c) genomically 
stable tumours, which are mainly of the diffuse histology and highly enriched for RHOA 
mutations; and d) tumors with chromosomal instability, which show an enrichment of 
TP53 mutations and focal amplification of oncogenes like ERBB2 (54).  
 
Among the recurrently found mutated genes in GC are: TP53 (50% of intestinal-type GC 
cases, ARID1A, (10%-15% of cases), KRAS (approximately 20%) and APC 
(approximately 20%) (56-58). 
MSI phenotype is observed in 15%-30% of GC cases, mainly of the intestinal-type and 
in older patients (43). MSI tumours are characterized by alterations in genes capable of 
reparing deletions or insertions in nucleotide repeats (microssatelite regions), known as 
mismatch repair genes (MMR) – MSH2, MSH3, MSH6, MLH1, PMS2 and others (59). 
Mutations and promoter methylation of MSH2 and MLH1, respectively, have been 
described in sporadic GC (50)(Figure 1). As a consequence, tumours harbour numerous 
mutations in microsatellite regions, specifically in non-coding regions, both in oncogenes 
and tumor suppressor genes (60). Genes that have microsatellite regions in the coding 
region, such as TGFβRII and MSH3, could likewise be mutated (39,61) , but hotspot coding 
mutations may also occur (KRAS and PI3KCA). 
CIN phenotype is observed in approximately 50% of GC cases of both histological types 
(62,63). CIN tumours are characterized by changes in chromossomal copy number, such 
as deletions, amplifications, LOH, and structural abnormalities (63,64). Targets of CIN 
include oncogenic pathways, such as amplification of HER2 (65,66). 
Promoter hypermethylation of tumor suppressor genes, such as CDH1 (41), RUNX3, p16 
and MLH1 can decrease the expression of the corresponding proteins (Figure 1), being 
MLH1 methylation a characteristic of MSI tumors (50). In fact, methylation is an early step 
in GC carcinogenesis and tendes to accumulate in a multistep pattern (Figure 1). 
Furthermore, H pylori infection can induce DNA methylation in the genome of stomach 
cells, due to infiltration of inflamatory cells (39,50,67). 
 
2.3. Familial Gastric Cancer 
Familial GC is characterized by an increased risk of GC development within families and 
occurs in approximately 10% of all GC cases (68). From these, at least three main 
syndromes, with primary predisposition to stomach cancer, have been described: 
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Hereditary Diffuse Gastric Cancer (HDGC), Gastric and Proximal Polyposis of the 
Stomach (GAPPS) and Familial Intestinal Gastric Cancer (FIGC) (46). 
Hereditary Diffuse Gastric Cancer (HDGC) was the first hereditary gastric cancer 
syndrome to be recognized, and follows an autosomal dominant inheritance pattern, in 
which a mutation occurs in only one copy of the gene (68). Inherited causative mutations 
and deletions in the E-cadherin gene (CDH1) explain roughly 45% of the cases, whilst 
5% are explained by mutations in CTNNA1, BRCA2, SDHB, PRSS1, PALB2, STK11, 
ATM and MSR1 (69). The remaining 50% of HDGC cases do not have so far an identified 
germline cause. Nevertheless, the importance of CDH1 gene in these cases is 
highlighted by the fact that 70% of HDGC individuals that do not harbor mutation in 
CDH1, display germline CDH1 monoallelic RNA downregulation (70). CDH1 gene 
encodes for E-cadherin protein, responsible for cell to cell adhesion and important for 
the maintenance of epithelial architecture (71). Somatic CDH1 promoter hypermethylation 
of the second allele is an early event in tumor development and leads to the inactivation 
of the gene in around 50% of HDGC tumors (35). Consequently, E-cadherin expression is 
reduced or absent, leading to loss of cell adhesion and, consequently, increased 
proliferation, invasion and metastasis (71). Lobular breast cancer is part of the tumor 
spectrum of HDGC families, as well as colon cancer (72). A similarity has been found 
between diffuse gastric cancer and lobular breast cancer, since high mucin content with 
associated signet ring features and the loss of E-cadherin expression are important 
characteristics of both cancers (73). In addition, CDH1 mutation carriers have a high 
lifetime risk (80% in both men and women) by the age of 80 years of developing diffuse 
GC (68,69), and women have 60% of probability of developing lobular breast cancer (68). 
To help diagnosing this syndrome, the International Gastric Cancer Linkage Consortium 
(IGCLC) established the following clinical criteria: 
1. Two or more cases of gastric cancer, one conﬁrmed case of diﬀuse gastric 
cancer in an individual younger than 50 years; 
2. Three or more conﬁrmed diﬀuse gastric cancer cases in first-degree or second-
degree relatives, independent of age of onset; 
3. Diﬀuse gastric cancer before age 40 years without a family history; 
4. Personal or family history of diﬀuse gastric cancer and lobular breast cancer, 
one of which must be diagnosed before age 50 years. (44,46,68,72,74,75) 
Genetic counseling is of capital importance in these families, so the individuals can make 
an informative decision in undertaking a genetic screening and considering the 
preventive measures available. The currently available genetic screening consists in 
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sequencing of CDH1 and CTNNA1 coding regions and perform multiplex ligation-
dependent probe ampliﬁcation to detect large CDH1 deletions (68). When positive for 
CDH1 or CTNNA1 mutations, individuals may undergo preventive measures, as 
prophylactic gastrectomy, and intensive surveillance with endoscopy (68). Endoscopy 
screening has, however, a poor diagnostic yield in these cases, since diffuse GC is 
commonly infiltrative and does not grow to the lumen of the stomach (73). 
 
Gastric and Proximal Polyposis of the Stomach (GAPPS) is a recently identified 
autosomal dominant inheritance syndrome, characterized by fundic gland polyposis, with 
areas of dysplasia and/or intestinal-type gastric adenocarcinoma, restricted to the 
proximal stomach (76). Before considering a diagnosis of GAPPS, other hereditary 
polyposis syndromes should be excluded, such as FAP, AFAP, MUTYH-associated 
polyposis and Peutz-Jeghers syndrome. GAPPS differs from FAP and AFAP, due to the 
tropism to the proximal stomach. Further, GAPPS differs from MUTYH-associated 
polyposis, an autosomal recessive inheritance syndrome, which is characterized by 
colorectal polyps. Additionally, whilst Peutz-Jeghers syndrome displays pigmentated 
gastric polyps, GAPPS is characterized by non-pigmentated polyps in the fundic region 
of the stomach (68). 
Recently, point mutations in the promoter of APC were found to be the cause of GAPPS 
in various families (77). However, genetic screening is not yet available for these families. 
Management of this disease includes endoscopic surveillance and prophylactic 
gastrectomy (68). Moreover, oesophagogastroduodenoscopy and a colonoscopy should 
be offered to first-degree relatives of families diagnosed with GAPPS carrying the 
disease-associated genotype (68). 
 
Familial Intestinal Gastric Cancer (FIGC) is generally characterized by an autosomal 
dominant inheritance pattern in many families with intestinal type adenocarcinomas 
without gastric polyposis (78). FIGC tumors display common macroscopic features with 
sporadic intestinal-type GC, such as well-differentiated glandular structures with atrophic 
gastritis and peripheral intestinal metaplasia, with preservation of intercellular adhesion 
(68). 
Epigenetic and/or genetic alterations in CDH1 have been reported in FIGC tumors (41). 
Particularly, 17% of FIGC tumors displayed CDH1 promoter hypermethylation, 9.4% 
showed loss of heterozygosity (LOH) and 3.8% harbored in concomitance CDH1 
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promoter hypermethylation and LOH (41). Importantly, somatic CDH1 LOH has been 
claimed as a poor prognosis factor in GC, and is particularly prevalent among FIGC 
cases (41). In addition, it has been demonstrated that intestinal tumors arising within FIGC 
families display similar frequencies of MSI phenotype comparing with sporadic intestinal 
GC (79,80). Nevertheless, the molecular characterization of FIGC remains scarce.  
In order to diagnose FIGC, three criteria have been described by the IGCLC, depending 
on the incidence of GC in each country: 
a) In countries with high incidence, such as Japan and Portugal: 
1. At least three relatives with intestinal GC and one should be a first degree 
relative of the other two; 
2. At least two successive generations should be affected; 
3. Gastric cancer should be diagnosed before the age of fifty in one relative. 
 
b) In countries with low incidence, such as UK: 
1. At least two ﬁrst or second-degree relatives affected by intestinal GC, being one 
diagnosed before the age of fifty, or, 
2. Three or more relatives with intestinal GC at any age (68,81-84). 
 
Management of this syndrome is still very controversial. According to Sereno, M., et al. 
(2011), periodic endoscopic surveillance in first degree relatives should begin 10 years 
before the youngest case in the family diagnosed with intestinal GC (83). Giovanni Corso, 
et al. (2013) proposed yearly endoscopic surveillance by gastroduodenoscopy beginning 
at the age of 40 years old, or 5 years before the youngest case diagnosed in the family. 
Moreover, FIGC families should be tested and eradicated for Helicobacter pylori and 
dietary habits should be taken in consideration (78). 
Contrary to other hereditary gastric cancer predisposing syndromes, no major genetic 
risk factor has been identified for this syndrome and, therefore, no genetic screening is 
available for FIGC families, thus reflecting their poor management.  
Understanding FIGC and its major risk factors is important to recognize families and 
individuals at high-risk of developing GC and refine clinical criteria, allowing an improved 
genetic counseling and management of patients and families.  
 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
10 
Celina Beatriz Teixeira São José 
2.4. Other Hereditary Cancer Susceptibility Syndromes Associated with Gastric 
Cancer Risk  
Over the past few decades, several other hereditary cancer-predisposing syndromes 
have been described in which GC is part of their tumor spectrum, such as Peutz-Jeghers 
Syndrome (PJS), Lynch Syndrome, Familial Adenomatous Polyposis (FAP), Juvenile 
Polyposis, and others (Table 1) (81,85). In addition, several genes have been implicated in 
those syndromes, like STK11 in Peutz-Jeghers Syndrome; APC in Familial 
Adenomatous Polyposis; MYH in MUTYH-associated polyposis.  
Peutz-Jeghers Syndrome (PJS) is an autosomal dominant inheritance syndrome, 
characterized by multiple polyps in the gastrointestinal tract with mucocutaneous 
pigmentation (95% of the cases), caused by mutations in STK11.  Gastric cancer has 
been described to develop at the mean age of 30 years old in 29% of the cases (86). 
Lynch Syndrome is caused by mutations in mismatch DNA repair genes (MSH2, MSH6, 
MSH3, MLH1, MLH3, PMS1, PMS2) (87). Lynch Syndrome is a disease with an autosomal 
dominant inheritance pattern, characterized by the appearance of polyps (adenomas) in 
the colorectal region. The estimated time of transformation of adenomas to carcinomas 
is 1-3 years with a ration 1:1, in comparison with sporadic individuals, which is 7-13 years 
with a ratio 30:1 (87). The risk of developing GC with intestinal histology was estimated to 
be 1-13% (81).  
Familial Adenomatous Polyposis (FAP) is an autosomal dominant syndrome caused by 
APC germline mutations and is defined by the development of more than 100 polyps in 
the colorectum. The lifetime risk of developing colorectal cancer is approximately 100% 
by the age of 80 years old (88), and the risk of developing intestinal-type GC is estimated 
to be 2 to 4% (81).  
Juvenile Polyposis Syndrome (JPS) is characterized by multiple juvenile polyps in the 
gastrointestinal tract with an increased risk to develop colorectal cancer (89). JPS follows 
an autosomal inheritance transmission of SMAD4 or BMPR1A mutations (89). In addition, 
patients with JPS affected by gastric polyps have a 21% risk of developing intestinal or 
diffuse GC (81).  
Hereditary Breast and Ovarian Cancer Syndrome follows an autosomal dominant 
inheritance transmission, characterized by germline mutations in BRCA1 and BRCA2. 
Carriers of BRCA1 or BRCA2 mutations display a 57–65% or 45–55% risk of developing 
breast cancer by age 70 years, and a lifetime risk of developing ovarian cancer of 39–
44% or 11–18%, respectively (90). The lifetime risk of developing GC is 5.5% and 2.6% 
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for BRCA1 and BRCA2, respectively. However, in families with family history of GC, the 
risk increases to 24% for BRCA1 carriers and 12% for BRCA2 carriers (81). 
Table 1. Hereditary cancer-predisposing syndromes associated with gastric cancer, the genetic cause 
identified, the inheritance pattern, the risk for developing GC and its histology, average age of appearance 
of polyps and respectively histology and initiation and intervals of endoscopic surveillance 
 
The inherited pattern of hereditary cancer-predisposing syndromes could be classified 
as Mendelian or non-Mendelian, if the disease follows the laws described by Gregor 
Mendel or not, respectively. Mendelian disorders are commonly monogenic and could 
follow a dominant or a recessive inheritance pattern (91). 
Individuals with an autosomal dominant syndrome, as FAP have a mutant allele in APC 
at the germline level that increases their risk to develop the disease (88). Later in life, 
these individuals may acquire a second mutant allele at the somatic level and develop 
cancer. The pedigrees of these families exhibit multiple successive generations affected 
Age Histology Initiation Interval
Peutz-Jeghers 
Syndrome
STK11
Autosomal 
dominant
29% Intestinal 16
Hamartomatous 
polyps
8 years
Based on 
the 
findings
Lynch 
Syndrome
MLH1, 
MSH2, 
MSH6, 
PMS2, 
MSH3
Autosomal 
dominant
13% Intestinal - -
30-35 
years
2-3 years
Familial 
Adenomatous 
Polyposis
APC
Autosomal 
dominant
2.1 – 4.2% Intestinal 8
Hamartomatous 
polyps
21-30 
years
3-5 years
Juvenile 
Polyposis
SMAD4, 
BMPR1A
Autosomal 
dominant
21%
Intestinal 
and 
Diffuse
41
Hamartomatous 
polyps
Midteens 
or when 
symptoms 
begin
3 years 
without 
polyps, 1 
year with
5.5%/24%
2.6/12%
MUTYH-
Associated 
Polyposis
MYH
Autosomal 
recessive
Very low - 14
Familial gastric 
polyposis and 
gastric adenoma
30-35 
years
3-5 years
Carney-
Stratakis 
Syndrome
SDHB, 
SDHC, 
SDHD
Autosomal 
dominant
77% by 
the age of 
50 years
- - -
Age of 
onset: <25 
years
3 years
Cowden 
Syndrome
PTEN
Autosomal 
dominant
Not well 
characteriz
ed
- -
Hamartomatous 
polyps with low 
malignancy 
potencial
- -
Endoscopic 
Surveillance Ref
Hereditary 
Breast and 
Ovarian Cancer 
Syndrome
BRCA1, 
BRCA2
Autosomal 
dominant
Diffuse - - - -
Syndrome Genes
Inheritance 
pattern
GC Risk
Histologic 
type
Polyposis
81, 85, 86 
81, 85, 87 
81, 85, 88 
81, 85, 89 
81, 85, 90 
81, 85, 92 
81, 85 
81, 85 
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(91). On the contrary, individuals with an autosomal recessive syndrome inherit mutant 
alleles from both parents, and both are needed to increase the susceptibility to develop 
cancer (91). This way, autosomal recessive syndromes, such as MUTYH-Associated 
Polyposis, with germline defects in MYH gene, are rare (92). In these syndromes, 
pedigrees tend to display skips in generations affected (91).  
The inheritance pattern of hereditary cancer-predisposing syndromes could be due to 
alterations in high or low penetrance genes (93). Penetrance is the percentage of 
individuals harboring a given mutation or genotype who exhibit an associated phenotype 
(93). Meaning that in a disease with 90% of penetrance, 90% of the individuals with the 
mutation will develop the disease and 10% will not. In syndromes with mutations in high 
penetrance genes, the majority of individuals with a mutation in the associated gene will 
display the phenotype and develop the disease during their lifetime (93). In fact, MSH2 
germline variants have been reported to be highly penetrant for Lynch Syndrome (87). On 
the contrary, in syndromes with mutations in moderate or low penetrance genes, the 
number of individuals with the associated genotype that do not have the disease is higher 
and the penetrance is lower (94). For example, variants in the ATM gene have been 
identified as moderate penetrance mutations in hereditary colorectal cancer (95). 
Additionally, moderate or low penetrance variants can be more prevalent in the general 
population, and in this setting represent high-risk alleles. For example, SNP rs2981582 
in FGFR2 gene is a high risk allele for breast cancer with a population frequency of 38% 
(96).  In addition, the penetrance can also be influenced by more than one affected gene, 
that together with environmental factors may be required to install the phenotype. 
Without the second factor (genetic or environmental), the phenotype may be either 
absent or less severe (93). In fact, hypogonadotrophic hypogonadism is derived from two 
different genes affected: FGFR1 and NELF, that in combination lead to a more severe 
phenotype (97). However, it is not clear yet for geneticists if a disease with an oligogenic 
inheritance pattern need both mutations to trigger the phenotype, or if the co-inheritance 
of two mutations is irrelevant, because only one of them is able to trigger the phenotype 
(98). A quite attractive possibility is a disorder, where the gene responsible for the 
phenotype is co-inherited with a variant in a modifier gene that also influence the 
phenotype (93). Therefore, with multiple possibilities, it is far more challenging for the 
geneticists to diagnose and manage multigenic diseases (99).  
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Next-Generation Sequencing (NGS) technologies, such as Whole-Genome Sequencing 
(WGS), Whole-Exome Sequencing (WES) and Multiplex Custom-panel Sequencing, 
have been used to dissect the genetic landscape of several diseases. In the particular 
case of HDGC, germline variants in PALB2, BRCA1, RAD51C, CTNNA1, BRCA2, 
STK11, SDHB, PRSS1, ATM and MSR1 have been described in CDH1 mutation 
negative carriers (69,100).  
In order to determine the relative relevance of each variant for a given disease, the data 
obtained from NGS technologies are submitted to bioinformatics analyses and variant 
classification. The American College of Medical Genetics and Genomics (ACMG) have 
described guidelines to help the classification of variants (101). To support the 
classification of variants it is fundamental to consult data deposited in databases such 
as UniProt, OMIM, ClinVar and COSMIC, as well as specific disease-associated 
databases, such as InSiGHT. 
UniProt is a repository of natural variants occurring in the protein sequence, including 
polymorphisms, variations between strands and others, and their association with the 
disease in human proteins. However, mutations such as frameshifts and other premature 
truncating mutations, that induce major protein changes, are not annotated (102,103). 
OMIM stands for Online Mendelian Inheritance in Man and displays information 
regarding the genotype and its association with each disease (104,105). 
ClinVar exhibits submissions concerning variants found in patients, both germline and 
somatic, and their clinical significance (106,107).   
The Catalogue of Somatic Mutations in Cancer, or COSMIC, is a repository of somatic 
mutations found in various types of cancer specimens, which were manually curated 
using literature data. Cosmic also displays a Functional Analysis through Hidden Markov 
Models (FATHMM) Prediction, predicting the functional consequences of coding Single 
Nucleotide Variants (SNVs)  (108).  
As one important factor to take into account in the evaluation of the pathogenicity of a 
variant is the frequency. dbSNP, Exome Aggregation Consortium (ExAC) and 
1000Genome Project are databases that provide the frequency of millions of variants in 
various populations (109-111). 
The information collected by all these databases, may help the geneticists to retrieve the 
clinical significance of each variant found by Next-Generation Sequencing technologies. 
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II. Rational and Objectives 
The majority of Gastric Cancer cases have a sporadic nature, however 10% display 
familial aggregation. These may account for at least three syndromes:  Hereditary Diffuse 
Gastric Cancer (HDGC), Gastric Adenocarcinoma and Proximal Polyposis of the 
Stomach (GAPPS) and Familial Intestinal Gastric Cancer (FIGC). 
Whilst germline defects at the CDH1 and APC genes have been found for HDGC and 
GAPPS families, respectively, FIGC families remain genetically unexplained. 
Consequently, there is no genetic screening available for these families and their clinical 
management is poor. Additionally, the pedigrees of FIGC families often display 
generations without affected individuals, as well as, late onset intestinal gastric cancer. 
These characteristics may indicate that increase cancer susceptibility in FIGC is 
determined by the presence of low or moderate risk alleles occurring in combination. 
Therefore, the hypothesis of this dissertation is that co-occurrence, in the germline, of 
low or moderate risk alleles in one or more cancer-related genes may be the underlying 
genetic defect of Familial Intestinal Gastric Cancer.  
Moreover, in other hereditary cancer susceptibility syndromes, such as Lynch syndrome, 
Hereditary Breast and Ovarian Cancer, or Ataxia-telangiectasia, among others, there is 
an unneglectable risk of developing gastric cancer. Therefore, genes causing hereditary 
cancer susceptibility syndromes, even if only remotely associated with gastric cancer 
susceptibility, would be good candidates to test as potential causal genes in FIGC 
families.   
The general objective of this dissertation was therefore to identify genetic defects that 
could increase susceptibility to develop Familial Intestinal Gastric Cancer. The specific 
aims of this dissertation were to:  
1. Identify the germline landscape of 52 FIGC families, by performing Multiplex 
Custom-panel sequencing;  
2. Classify the germline variants, using Illumina’s Variant Interpreter and Annotator 
platforms; 
3. Characterize somatic second-hits which may lead to the inactivation of genes 
with a pathogenic or co-occurring germline variant in FIGC tumors, using 
Multiplex Custom-panel Sequencing and methylation analysis; 
4. Identify and classify other somatic events in FIGC tumors, using Multiplex 
Custom-panel sequencing and Illumina’s Variant Interpreter and Annotator 
platforms.  
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III. Materials and Methods 
1. Patients and samples 
All 52 families diagnosed with FIGC that met at least one criteria from IGCLC (74) were 
admitted at the Division of General Surgery and Surgical Oncology, University of Siena, 
Italy. Informed consent was obtained from the 52 patients with hospital’s ethics 
committee approval. Tissue specimens of gastric cancer and matched normal samples 
were analyzed in this study. DNA and RNA were extracted from tumor (histologically 
verified to contain a minimum of 70% to 80% of neoplastic cells) and normal frozen 
tissues. 
 
2. Analysis of germline and somatic variants 
2.1. Multiplex Custom-panel Sequencing 
Multiplex custom-panel sequencing of 67 genes (table 2) was performed on normal and 
tumor DNA from 52 FIGC probands using Illumina’s TruSeq Custom Amplicon assay on 
the MiSeq platform (Illumina). All germline and somatic variants were validated by 
Sanger sequencing. 
Table 2. Panel of genes used in Multiplex Custom-panel Sequencing. 
 
 
 
 
 
 
Condition Gene Function
SDHB
SDHC
SDHD
PTEN AKT/PKB regulator
SDHB
SDHD
AKAP12 Activation of cAMP-Dependent PKA
CTHRC1 Noncanonical Wnt signaling pathway, PCP
FOXF1 Transcription factor
MSR1 Inflammation, LDL transport
Familial Adenomatous 
Polyposis
APC Wnt signaling pathway 
Familial Gastric Cancer MAP3K6 MAPK signalling pathway, regulation VEGF, Apoptosis
Kreb's cycle, respiratory eletron transport
Kreb's cycle, respiratory eletron transport
Carney-Stratakis Syndrome / 
Paraganglioma
Cowden Syndrome
Esophageal adenocarcinoma / 
Barret's esophagous
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Table 2 (cont). Panel of genes used in Multiplex Custom-panel Sequencing. 
 
 
 
 
 
 
Condition Gene Function
ARID1A Chromatin remodeling
ATM DNA double strand repair
BCL2L10
CASP10
CHEK2 DNA double strand repair
FAT4 Planar Cell Polarity
FHIT Purine metabolism
HSPA5 Regulation of proteins folding and degradation of misfolded proteins
IDH1
IDH2
PALB2 DNA double strand repair
PSCA Proteins metabolism
RUNX3 Transcription factor
TP53 Apoptosis
ITIH2 Cell adhesion to the matrix
MET Cell survival, migration and invasion
MTUS1 AT2 signalling pathway, p36 inhibition, apoptosis
BRCA1
BRCA2
ATM
BRCA2
CDH1
CTNNA1
MSR1 Inflammation, LDL transport
PALB2 DNA double strand repair
PRSS1 Degradation of the extracellular matrix,
SDHB Kreb's cycle, respiratory eletron transport
STK11 Cell metabolism, cell polarity, apoptosis and DNA damage response.
GREM1 Angiogenesis and Wnt, Hedgehog and Notch signalling pathways
SCG5 Chaperone
TGFBR2 Regulation of transcription of proliferating genes
BMPR1A
SMAD4
EPCAM
MLH1
MSH2
MSH3
MSH6
PMS1
PMS2
MUTYH Associated Polyposis MUTYH Oxidative DNA damage repair
AKR7A3 Detoxification of aldehydes and ketones
CDKN2A Cell cycle regulation
SPINK1 Anti-trypsin activity 
Peutz-Jeghers Syndrome STK11 Regulates cell polarity, G1 arrest
Mismatch Repair
DNA double strand repair
Apoptosis
Kreb's cycle
Regulation of transcription of proliferating genes
DNA double strand repair
Cell-cell adhesion
Gastric Cancer
Hereditary Breast and Ovarian 
Cancer
Hereditary Diffuse Gastric 
Cancer
Hereditary Mixed Polyposis 
Syndrome
Juvenile Polyposis, 
Pancreatic Cancer
Lynch Syndrome
Pancreas Adenocarcinoma
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Table 2 (cont). Panel of genes used in Multiplex Custom-panel Sequencing. 
 
 
2.2. Clinical Classification of variants 
Germline and somatic variants were classified using Illumina’s Variant Interpreter 
platform and re-classified using Annotator57 platform, which is a bioinformatics tool 
implemented by our group. Annotator57’s classification is based on three public 
databases: UniProt, OMIM and ClinVar. Additionally, all variants were manually curated 
using COSMIC data (not used for the integrated classification), as well as the frequency 
data for the population “Tuscany” available within the 1000Genome project. An 
integrated classification was defined using the following criteria:  
a) If UniProt, OMIM and ClinVar have the same information for a given variant, the 
integrated classification will correspond to such information, i.e. UniProt, OMIM 
and ClinVar all classify variant X as ‘Likely Pathogenic’, the classification of 
variant X will be ‘Likely Pathogenic’;  
b) If at least one of the three databases (UniProt, OMIM or ClinVar) classify a given 
variant as ‘Pathogenic’ or ‘Likely Pathogenic’ or ‘Likely Benign’, and information 
is missing for other databases, the integrated classification will be ‘Pathogenic’, 
‘Likely Pathogenic’ or ‘Likely Benign’, regardless of the frequency obtained from 
dbSNP or 1000Genome project; 
c) If one of the three databases (UniProt, OMIM or ClinVar) classify a given variant 
as ‘Pathogenic’ or ‘Likely Pathogenic’ and other database classify the variant as 
‘Uncertain Significance’ or ‘Likely Benign’, the integrated classification will be 
‘Conflicting’, regardless of the frequency obtained from dbSNP or 1000Genome 
project; 
Condition Gene Function
Others Colaborating Projects BAX Apoptosis
C12orf32 DNA double strand repair
CFTR Inflammation
FBXL4 Cell-cycle regulation
GAB2 Amplification of signal transduction growth factors, cytokines and antigen receptors
HIC1 Growth regulator
MCCC1 Leucine catabolism
NAT2 Activate and deactivate arylamine and hydrazine drugs and carcinogens
NEK1 Cel cicle regulation
PLAU Converts plasminogen into plasmin
PRR5 Regulates platelet-derived growth factor (PDGF) receptor beta expression
PXN Actin-membrane attachment at sites of cell adhesion to the extracellular matrix 
RNF43 Negatively regulate Wnt signaling
SCARF2 Degradation of acetylated low density lipoprotein
SCTR Secretin receptor
SLC22A4 Polyspecific organic cation transporter
TMEFF2 Tomoregulin family of transmembrane proteins
TNFRSF10B Apoptosis
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d) If there is no information in UniProt, OMIM and ClinVar, the variant will be 
classified as ´Variant of Unknown Significance’ (VUS).  
In addition, a potential risk allele was considered whenever a specific variant was more 
frequent in the FIGC cohort than in Global, or Europe or Tuscany populations.  For 
example, variant c.1256-2A>G in the MAP3K6 gene was considered a potential risk 
allele because it was more frequent in the FIGC cohort than in Tuscany (4% vs 0.47%, 
respectively), despite no information was available at UniProt, OMIM, and ClinVar 
databases. 
 
2.3. Splicing prediction 
The impact of germline variants, located in splice regions, on the function of the protein 
was evaluated using splicing prediction softwares, such as: Human Splicing Finder (112) 
and NetGen2 (113). These softwares displayed a score between 0 and 1 to demonstrate 
the probability of the splice donor or acceptor to occur in the region analyzed, revealing 
all splice donors and acceptors for the input sequence. A score of zero means a 
probability of 0% of the splicing occur in that region and a score of one displays a 
probability of 100% of the splicing occur. 
 
3. Analysis of Promoter Methylation  
Prediction of CpG islands in selected genes was performed using the bioinformatics tool, 
CpG Island Searcher, DBCAT (114) and sequence data retrieved from the Ensembl 
database v90 (115). For each gene, a CpG island was defined according to the following 
criteria: 
a) Genomic sequence length of CpG island with ≥200 bp; 
b) A percentage of GC content ≥55%; 
c) CpG dinucleotides observed/expected ratio ≥0.65. 
In order to evaluate the methylation status of each promoter, bisulfite modification 
followed by PCR and Sanger sequencing were performed. Bisulfite Modification consists 
in the deamination of unmethylated cytosines (C) into uracils (U), whereas methylated 
cytosines (5mC) are protected from deamination and are not converted, thus remaining 
a C upon treatment. Bisulfite treated DNA is further amplified by PCR using primers 
specifically designed for sequences without CpG sites. After Sanger Sequencing, the U 
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derived from deamination of unmethylated C is read as thymine (T) and the C derived 
5mC remained as a C, Figure 2 (116). 
 
 
Figure 2. Bisulfite modification principle and Sanger sequencing 
Approximately 200ng of DNA extracted from cell lines, tumor and normal tissues were 
treated with bisulfite, using EpiTeck Bisulfite kit (Qiagen, Hilden, Germany). Bisulfite 
conversion was performed using the reagents described in table 3 and the thermal cycle 
protocol described in table 4. The desulfonation and DNA purification was completed in 
an EpiTeck spin column membrane and the DNA was eluted in 20µl of UltraPure 
DNAse/RNAse-Free Water (Gibco, Invitrogen, Oregon, USA).  
 
 
 
 
 
 
Promoter methylation analysis was carried out in 13 genes, by amplifying bisulfite treated 
DNA using primers specifically designed for sequences without CpG sites (Table 5) and 
the PCR program depicted in Table 6 (the annealing temperatures of each set of primers 
can be found in Table 5). For the genes that a CpG island was not predicted based on 
the abovementioned criteria, primers were designed according to studies that had 
previously reported methylation analysis for those genes. Primers described in table 5 
were used for amplification and sequencing, with the exception of primers R4 and F5 in 
FAT4, which were only used for sequencing analysis.  Positive and negative controls are 
described in table 5.
Component Volume per reaction
DNA solution 200ng
Rnase-free water 40µl - VDNA solution µl
Bisulfite Mix 85 µl
DNA Protect Buffer 15 µl
Total Volume 140 µl
Step Time Temperature
Denaturation 5 min 95ºC
Incubation 25 min 60ºC
Denaturation 5 min 95ºC
Incubation 85 min 60ºC
Denaturation 5 min 95ºC
Incubation 175 min 60ºC
Hold Indefinitive 20ºC
Table 3. Bisulfite reaction components. Table 4. Thermal cycle protocol. 
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Gene CpG island
Region Analyzed                                                                                                                                            
hg38
Anealing 
Temperatures
Size  + Controls  - Controls
SDHB Not found 204bp upstream ATG (chr1: 17054019); 23 CpG sites F1: 5’- GGGGAAGTTAAATGGGTAT -3' R1: 5'- TCAACCCCACCCCTTAACC -3' 58ºC, 56ºC, 54ºC 176bp - Hela
BRCA2 Not found 1093bp upstream ATG (chr13:32316461); 27 CpG sites F1: 5'- GTTGGGATGTTTGATAAGGAAT -3' R1: 5'- ATCACAAATCTATCCCCTCA -3' 56ºC, 54ºC, 52ºC 224bp - HCT-116
F1: 5'- GGATTTTTTTTTGGATTTTAG -3' R1: 5'- AATCCTACCAACAACTACC -3' 55ºC, 53ºC, 51ºC 205bp
F2: 5'- GTAGTTGTTGGTAGGATT -3' R2: 5'- CCTCCCAAAACCCTAAATC -3' 57ºC, 55ºC, 53ºC 317bp
Gene body2474bp downstream of the ATG (chr1:27366597); 30 CpG sitesF3: 5'- GGTAGTTTGATTATGAGTATA -3' R3:  5'- AACCCAATCCACAAAACTC -3' 56ºC, 54ºC, 52ºC 239bp MKN74 -
F1: 5’- GAAGGTGAATTGTTGATTAAAG -3’ R1: 5’- CTAAACTCCCCTTCCCTCA -3’ 60ºC, 58ºC, 56ºC 252bp
F2: 5’- TGAGGGAAGGGGAGTTTAG -3’ R2: 5’- CCCAATAACCAATCAACAAAC -3’ 60ºC, 58ºC, 56ºC 162bp
F1: 5’- GAAAGGAGTTTTATTAAGGATG -3’ R1: 5’- CACACCCACTAAACTATTTCC -3’ 60ºC, 58ºC, 56ºC 200bp
F2: 5’- GGAAATAGTTTAGTGGGTGTG -3’ R2: 5’- CCTAAATCTTAAACACCTCC -3’ 58ºC, 56ºC, 54ºC 207bp
F3: 5’- GGAGGTGTTTAAGATTTAGG -3’ R3: 5’- CAATACATTAAAATACCTAACAC -3’ 58ºC, 56ºC, 54ºC 276bp
F1: 5’- GTAGTTTAGGTTGGAGTGTG -3’ R1: 5’- CCATATCCTAAACATCATTC -3’ 56ºC, 54ºC, 52ºC 264bp
F2: 5’- GGTTAAGGAGGGTGGATTAT -3’ R2: 5’- CCCTTTCTTATATCCACATAC -3’ 60ºC, 58ºC, 56ºC 188bp
F1: 5’- GGGAAAATTTTTGGTTTTAAAGG -3’ R1: 5’- CCTTATTATAATTCCTACTATA -3’ 56ºC, 54ºC, 52ºC 102bp
F2: 5’- TATAGTAGGAATTATAATAAGG -3’ R2: 5’- CTCTCACCCACCCTCTTC -3’ 56ºC, 54ºC, 52ºC 244bp
F3: 5’- GAAGAGGGTGGGTGAGAG -3’ R3: 5’- CCCCTACCACTACACTC -3’ 57ºC, 55ºC, 53ºC 347bp
F1: 5’- GTGTTTTTAAAATGTTTATTTAGG -3’ R1: 5’- CTCCCTCCCTTAATTCCTC -3’ 60ºC, 58ºC, 56ºC 237bp
F2: 5’- GAGGAATTAAGGGAGGGAG -3’ R2: 5’- CCTTTTACTTCCCCTTAAA -3’ 55ºC, 53ºC, 51ºC 232bp
F3: 5’- TTTAAGGGGAAGTAAAAGG -3’ R3: 5’- CTAAATTCCAAAACTCACTAC -3’ 55ºC, 53ºC, 51ºC 216bp
F1: 5’- GTTAGAGGTAAGTAGGAG -3’ R1: 5’- AAAACTCCACTCCAAC -3’ 49ºC, 47ºC, 45ºC 379bp
F2: 5’- GTTGGAGTGGAGTTTT -3’ R2: 5’- CCCTTTACACCACTAAC -3’ 49ºC, 47ºC, 45ºC 231bp
F3: 5’- GTTAGTGGTGTAAAGGG -3’ R3: 5’- CCTTTAACCCTCAACTTC -3’ 52ºC, 50ºC, 48ºC 186bp
F1: 5’- GGAATTTTTGAGTGGTGTGG -3’ R1: 5’- CTCACTCAACTTCAACTCAAC -3’ 60ºC, 58ºC, 56ºC 177bp
F2: 5’- GTTGAGTTGAAGTTGAGTGAG -3’ R2: 5’- CAAACCCCTAAACAACCCC -3’ 60ºC, 58ºC, 56ºC 293bp
F1: 5’- GGGAGGTTGAAGTGATTAG -3’ R1: 5’- CAACACTCAAAAACTTTACTC -3’ 58ºC, 56ºC, 54ºC 177bp
R4: 5’- CCCCTAACTCCCAATCC -3’ (seq) 121bp
F2: 5’- GGAGTTTTGGTTGTTGTTTG -3’ R2: 5’- CCTAAAATCCCCACTCCTC -3’ 58ºC, 56ºC, 54ºC 216bp
F5: 5’- GTTGTAGGAGGGGAAGG -3’ (seq) 152bp
F6: 5’- GTTTAGATTATTTGGATTTAAA -3’ R6: 5’- CCAACAAAAATTCAACTAAC -3’ 54ºC, 52ºC, 50ºC 211bp
MSR1 Promoter 80392bp upstream ATG (chr8:16177988); 9 CpG sites F1: 5’- GAGATGGAGATTTATTTTG -3’ R1: 5’- TAAAATAAAACTTCCAAACC -3’ 52ºC, 50ºC, 48ºC 230bp - -
SDHD Promoter 285bp upstream ATG (chr11:112086908); 23 CpG sites F1: 5'- GTATTTGTGTAGTAAATTG -3' R1: 5’- CTCAAAATCATCCACCAACCC -3’ 52ºC, 50ºC, 48ºC 218bp - HCT-116
-
-
NCI
MCF7-
MSH2 Promoter
263 base pairs upstream ATG (chr2:47403192); 76 CpG 
sites
Primer
HCT-116-
HCT-116-
Promoter
MAP3K6
165bp upstream ATG (chr1:27366597); 74 CpG sites
MSH6 Promoter 576bp upstream ATG (chr2:47783234); 59 CpG sites
45952bp upstream ATG (chr8:17755807); 108 CpG sites
TGFβRII Promoter 483bp upstream ATG (chr3:30606884); 54 CpG sites
CASP10 Promoter 4161bp upstream ATG (chr2:201185778); 18 CpG sites
CTHRC1 Promoter 389bp upstream ATG (chr8:103371657); 73 CpG sites
ATM Promoter 5204bp upstream ATG (chr11:108227625); 68 CpG sites
FAT4 Promoter 1605bp upstream ATG (chr4:125316412); 48 CpG sites
HCT-116-
- HCT-116
MKN74 -
- HCT-116
- MCF7
HCT-116
MTUS1 Promoter
CpG islands analyzed in the promoter region or in the gene body; the regions analyzed were described according to ATG position, indicated in parenthesis; F: primer forward, 
R: primer reverse. Annealing temperatures used in the touchdown PCR. Size: amplicon product size, bp: base pairs, + controls: positive controls, - controls: negative controls. 
Table 5. CpG island analyzed for each gene and respective primers. 
40,150
 
126 
31 
137 
142 
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Table 6. PCR amplification program. 
 
After amplification, PCR products were loaded in a 2% agarose gel with 1x loading buffer 
and purified using two distinct methods: ExoSap it Express (Affymetrix USB, USA), with an 
incubation of 4 minutes at 37ºC and 1 minute at 80ºC; or using a Gel Band Purification Kit 
(GE Healthcare, UK). Then, the purified DNA was submitted to Sanger Sequencing using 
primers listed in table 5, the reagents depicted in table 7, and the thermal cycle protocol 
described in table 8. The presence of a T peak revealed that cytosines were unmethylated, 
whereas the C peak revealed the presence of methylated cytosines. If a double T and C 
peaks were observed, the CpG site was considered hemi-methylated. Tumors displaying 
more than 25% of methylated or hemi-methylated CpG sites were considered methylated 
and hemi-methylated, respectively. 
 
 
 
4. RT-PCR and quantification of APC, CTHRC1 and β-Catenin mRNA 
expression  
A first-strand complementary DNA (cDNA) was obtained from 1µg of total RNA from HCT-
116 and MKN74 cell lines, commercial total RNAs from normal stomach and normal breast 
(Stratagene, Agilent Technologies, TX, USA), tumor and normal samples from the proband 
of family 12 using random hexamer primers (Invitrogen, Oregon, USA) and DNAse/RNAse-
Step Time Temperature Nº of Cycles
Denaturation 30 seg 94ºC
Annealing 90 seg 60ºC
Extension 90 seg 72ºC
Denaturation 30 seg 94ºC
Annealing 90 seg 58ºC
Extension 90 seg 72ºC
Denaturation 30 seg 94ºC
Annealing 90 seg 54ºC
Extension 90 seg 72ºC
Final Extension 10 min 72ºC 1
35
Initial denaturation and 
polymerate activation
15 min 95ºC 1
3
3
Component Volume per reaction/µl
Big Dye Buffer 1
Big Dye 0,5
Primer F/R 10µM 0,4
DNAse/RNAse-Free Water 2,1
Purified Sample 1
Step Time Temperature Nº of Cycles
Incubate 2 min 96ºC 1
Denature 30 seg 96ºC
Annealing 15 seg 54ºC
Extention 3 min 60ºC
Final Extension 10 min 60ºC 1
35
Table 7. Sanger Sequencing components. Table 8. Sanger Sequencing thermal cycle program. 
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free water in a final volume of 12µl. This mix was incubated at 70ºC for 10 minutes and then 
placed at 4ºC for 2 minutes. Then, the first-strand reaction was catalyzed by Superscript II 
Reverse Transcriptase (Invitrogen, Oregon, USA) at 37ºC for 60 minutes using the reagents 
described in table 9.  
 
 
Quantitative real time PCR was performed in triplicates for the target genes APC, CTHRC1, 
β-Catenin and 18s RNA (endogenous control) using as probes sets: Hs, PT.56a.3539689, 
Hs.PT.58.39259295, Hs00355045_m1 and Hs99999901_s1 (IDT and TaqMan), 
respectively, and an ABI Prism 7000 Sequence Detection System. Specifically, the qRT-
PCR reaction was performed using 50-100ng of cDNA and the KAPA probe fast enzyme 
(table 10) with a PCR program described in table 11.  Data was analyzed with the 
comparative Ct (2-ΔCt) method (117). 
 
Table 10. Components of RT-PCR.    Table 11. Thermal cycle. 
 
 
 
 
 
  
Component Volume/µl
Rox Low 1
cDNA 1
H2O 3,5
Probe 0,5
Total Volume 10
KAPA PROBE FAST 
qPCR Master mix
5
Component Volume/µl
Buffer 5x 4
DTT 0,1M 2
dNTPs 1
Rnasin 0,2
RT 0,75
H2O 0,75
Total volume 8,7
Table 9. Components of Reverse Transcriptase Mix. 
Time Temperature Nº of Cycles
2m 50ºC 1
10m 95ºC 1
15s 95ºC
1m 60ºC
45
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IV. Results and Discussion 
1. Germline Landscape of Familial Intestinal Gastric Cancer Families 
FIGC is characterized by the development of intestinal type adenocarcinomas without 
gastric polyposis, segregating within families. Contrary to HDGC and GAPPS, FIGC 
remains genetically unexplained. Hence, no genetic risk factor has been identified for this 
syndrome, and no genetic screening is available for FIGC patients (68). Therefore, the first 
two aims of this thesis were identifying and classifying germline variants that may increase 
susceptibility to develop FIGC.  
Probands of 52 FIGC families were screened for the presence of germline variants using a 
Multiplex Custom-panel of 67 gastrointestinal cancer-associated genes with Illumina’s 
MiSeq platform. Overall, 36 germline variants present in 17 genes were found in 24/52 
families analyzed (Table 12). Illumina’s software classified the 36 variants as: pathogenic 
(10 variants), likely pathogenic (3 variants), and variants of unknown significance (VUS) (23 
variants), Table 12.  
To refine the variant classification and improve the knowledge on VUS towards prioritization 
of families for further studies, the 36 variants were re-classified using a software developed 
in house. This software, named Annotator57, relies on criteria defined in section III, 2.2 of 
the Materials and Methods. 
The Annotator57 software allowed answering aim 2 of this thesis, and re-classify the 36 
variants as: Likely Pathogenic (1 variant), Conflicting (11 variants), Likely Benign (3 
variants) and VUS (21 variants). Furthermore, this software also collected the frequency of 
identified variants. Indeed, most of them were very rare (<1%: 19 variants) or rare (>1% 
and <5%: 9 variants), and eight variants were absent from the ExAC and the 1000Genome 
project, and were therefore novel (Table 12). Detailed information on the classification of 
germline variants is described in Supplementary Table 1. 
By comparing the performance of Illumina’s Variant Interpreter and Annotator57 for variant 
classification, 4/23 variants classified as VUS by the Illumina’s Variant Interpreter were 
reclassified into Conflicting (n=1) and Likely Benign (n=3). Annotator57 was not able to 
reclassify 19/23 variants that remained as VUS, due to lack of information deposited in the 
databases analyzed. In addition, the 10 Pathogenic variants classified with Illumina’s 
software were re-classified as Conflicting (10 variants). Additionally, one variant was 
classified as Likely Pathogenic by both softwares. All these findings, suggest that 
Annotator57 allowed an increased knowledge, particularly on variants of unknown 
significance (Table 12). Furthermore, 2 variants classified as Likely Pathogenic by Illumina’s 
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Variant Interpreter were re-classified as VUS, using Annotator57. These results may reflect 
an update in the databases analyzed, and highlighting the need of using constant online 
real time search. Further, Annotator57 discloses a classification based on clinical databases 
(e.g. ClinVar) and focused on the disorder in question, due to the use of Text Minning 
approaches. The frequency annotated by Annotator57 is focused on the population of the 
cohort, in this particular case, Tuscany. In fact, classification using Annotator 57 also relies 
on information retrieved from papers depicted in Pubmed and annotates using the last 
version of the genome, with up to date variants. Moreover, allows traceback of the 
classification, to confirm in which databases the information was found and which 
information. Therefore, the classification obtained with Annotator57 was used from this point 
onwards. 
Working under the hypothesis that FIGC is a syndrome that does not strictly follows 
Mendel’s laws, but rather presents as a polygenic disease with co-occurrence of low or 
moderate risk alleles as genetic risk factors. Under the same premise, it was assumed that 
variants with very rare or rare frequencies could present a cancer-predisposing effect, if co-
occurring in the same patient. Thus, if a very rare variant, in a relevant gene, is classified 
as benign and co-occurs with other variants classified as likely pathogenic, pathogenic or 
even VUS, the overall impact of those variants may also be considered cancer-
predisposing. In summary, for the study of susceptibility related to co-occurring variants, 
diverse types of variants were included, since association of two or more of these may have 
a cumulative effect for FIGC susceptibility. 
Subsequently, the 24 FIGC families that harbored germline variants were analyzed in detail. 
The most frequently mutated genes were MSH6 (17%, 6/36 variants), SDHD (11%, 4/36 
variants), MAP3K6 (11%, 4/36 variants), ATM (8%, 3/36 variants), and MTUS1 (8%, 3/36 
variants). Furthermore, 50% of the families harbored germline variants in DNA repair genes 
and 25% of the families carried germline variants in genes associated with metabolism. In 
addition, not only the same variant (e.g p.Val878Ala, MSH6) appeared in different families 
(F9, F10, F11, F18), but also that the same family often carried more than one variant (F1, 
F4, F7, F8, F11, F12, F13, F14, F16 and F19). In fact, 42% (10/24) of the families displayed 
co-occurrence of germline variants (Table 12 and 13). This finding supports our hypothesis 
and might indicate that FIGC is not a monogenic disease, but rather a polygenic disorder 
caused by a combination of moderate or low risk alleles (93). Moreover, DNA repair genes 
were frequently altered in co-occurrence with metabolism associated genes (F1, F4 and 
F11). In fact, the germline variants in metabolism genes (SDHB and SDHD) are very rare 
at a global scale, but present in similar frequencies in the Tuscany population and in our 
FIGC cohort. Despite this fact, we reasoned that these still rare variants when in co-
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occurrence with very rare variants in other important predisposing genes may still 
predispose to the development of FIGC, and therefore be classified as potential risk alleles.
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Description of germline variants, including both frequency in the cohort (freq cohort: % of mutated families), ExAC and 1000genomes and Clinical Significance classification from Illumina's Variant 
Interpreter, Annotator57 (in 3 databases) and integrated classification. Eur: Europe; Tusc: Tuscany; VUS: Variant of Unknown Significance; NA: Not available; Very Rare: <1%; Rare: >1, <5; Not 
Rare: >5. 
Table 12. Germline Variants identified in FIGC families by multiplex custom-panel based sequencing.  
 
 
 
 
 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Population Frequency Illumina's Classification Annotator57's Classification
Integrated 
Classification
Potential 
Risk Allele
MSH6 2 47799219 c.1236G>C p.Lys412Asn Missense 2% NA VUS NA VUS Yes
MSH6 2 47800241 c.2258C>T p.Ser753Phe Missense 2% NA VUS Uncertain Significance - 1 VUS Yes
SDHD 11 112086941 c.34G>A p.Gly12Ser Missense 4% Very Rare Global (1%), Rare Eur (2%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Uncertain Significance - 1 Conflicting Yes
2 SDHD 11 112086945 c.38C>T p.Ala13Val Missense 2% Very Rare Global (0,006%), Very Rare Eur (0%) VUS NA VUS Yes
3 MAP3K6 1 27362252 c.1256-2A>G - Splice acceptor 4% Very Rare Global (0,4%), Rare Eur (1,4%), Very Rare Tusc (0,9%) Likely Pathogenic NA VUS Yes
MSH2 2 47429940 c.1275A>G c.1275A>G(p.=) Splice region, Synonymous 2% Very Rare Global (0,02%), Very Rare Eur (0,05%) VUS Uncertain Significance - 1 VUS Yes
SDHD 11 112087953 c.149A>G p.His50Arg Missense 2% Rare Global (1,3%), Rare Eur (3,4%), Rare Tusc (2,8%) Pathogenic Likely Pathogenic - 2; Uncertain Significance - 1 Conflicting Yes
5 ATM 11 108329200 c.7269A>T p.Glu2423Asp Missense 2% NA VUS Uncertain Significance - 1 VUS Yes
6 ITIH2 10 7731989 c.1640C>T p.Ala547Val Missense 2% Very Rare Global (0,02%), Very Rare Eur (0,004%) VUS NA VUS Yes
MAP3K6 1 27358259 c.2837C>T p.Pro946Leu Missense 2% Very Rare Global (0,4%), Very Rare Eur (1%), Very Rare Tusc (0,9%) VUS NA VUS Yes
BRCA1 17 43125268 c.-20+2dupT - Splice region, Intron 2% NA VUS NA VUS Yes
MAP3K6 1 27362252 c.1256-2A>G - Splice acceptor 4% Very Rare Global (0,4%), Rare Eur (1,4%), Very Rare Tusc (0,9%) Likely Pathogenic NA VUS Yes
CASP10 2 201193048 c.506G>T p.Cys169Phe Missense 2% Very Rare Global (0,002%), Very Rare Eur (0,02%) VUS NA VUS Yes
9 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Likely Benign - 1 Conflicting Yes
10 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Likely Benign - 1 Conflicting Yes
MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Likely Benign - 1 Conflicting Yes
ATM 11 108289671 c.4306C>T p.His1436Tyr Missense 2% Very Rare Global (0,04%), Very Rare Eur (0,2%), Very Rare Tusc (0,9%) VUS Uncertain Significance - 1 VUS Yes
CTHRC1 8 103371707 c.57_62dupCCTGCT p.Leu20_Leu21dup Inframe insertion 2% NA VUS NA VUS Yes
BRCA2 13 32337163 c.2812_2815dupGCAA p.Thr939SerfsTer7 Frameshift Indels 2% NA Likely Pathogenic NA Likely Pathogenic Yes
SDHB 1 17027802 c.487T>C p.Ser163Pro Missense 4% Rare Global (1,9%), Rare Eur (3,4%), Rare Tusc (3,7%) Pathogenic Likely Pathogenic – 2; Uncertain Significance - 1 Conflicting Yes
MTUS1 8 17655975 c.2996A>G p.Glu999Gly Missense 2% Very Rare Global (0,6%), Rare Eur (2,6%), Rare Tusc (3,7%) VUS NA VUS Yes
MTUS1 8 17755177 c.631T>G p.Ser211Ala Missense 2% Very Rare Global (0,8%), Rare Eur (3,4%), Rare Tusc (3,7%) VUS NA VUS Yes
ATM 11 108267198 c.2494C>T p.Arg832Cys Missense 2% Very Rare Global (0,04%), Very Rare Eur (0%), Very Rare Tusc (0%) VUS Uncertain Significance - 1 VUS Yes
15 MTUS1 8 17684434 c.2732A>C p.Lys911Thr Missense 2% Very Rare Global (0,9%), Rare Eur (1,8%), Very Rare Tusc (0,9%) VUS Likely Benign - 1 Likely Benign Yes
MSH2 2 47475052 c.1787A>G p.Asn596Ser Missense 2% Very Rare Global (0,06%), Very Rare Eur (0,07%) VUS Likely Pathogenic – 2; Uncertain Significance - 1 Conflicting Yes
TGFBR2 3 30671751 c.643C>T p.Arg215Cys Missense 2% Very Rare Global (0,02%), Very Rare Eur (0%) VUS NA VUS Yes
FAT4 4 125316935 c.524G>T p.Arg175Leu Missense 2% Very Rare Global (0,2%), Very Rare Eur (1%) VUS Likely Benign - 1 Likely Benign Yes
17 APC 5 112839078 c.3484T>C p.Tyr1162His Missense 2% NA VUS NA VUS Yes
18 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Likely Benign - 1 Conflicting Yes
MAP3K6 1 27356633 c.3481C>G p.Pro1161Ala Missense 2% Very Rare Global (0,005%), Very Rare Eur (0,009%) VUS NA VUS Yes
MSR1 8 16155085 c.877C>T p.Arg293Ter Stop gained 2% Very Rare Global (1,1%), Rare Eur (2,4%), Rare Tusc (1,7%) Pathogenic Likely Pathogenic - 1; Uncertain Significance - 1 Conflicting Yes
20 FAT4 4 125451863 c.10847C>T p.Thr3616Met Missense 2% Very Rare Global (0,3%), Very Rare Eur (0,6%), Very Rare Tusc (0,9%) VUS Likely Benign - 1 Likely Benign Yes
21 SDHD 11 112086941 c.34G>A p.Gly12Ser Missense 4% Very Rare Global (1%), Rare Eur (2%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Uncertain Significance - 1 Conflicting Yes
22 SDHB 1 17027802 c.487T>C p.Ser163Pro Missense 4% Rare Global (1,9%), Rare Eur (3,4%), Rare Tusc (3,7%) Pathogenic Likely Pathogenic – 2; Uncertain Significance - 1 Conflicting Yes
23 CDH1 16 68813323 c.1148A>G p.Gln383Arg Missense 2% NA VUS NA VUS Yes
24 MSR1 8 16168606 c.482C>A p.Thr161Asn Missense 2% Very Rare Global (0,08%), Very Rare Eur (0,2%) Very Rare Tusc (0,9%) VUS NA VUS Yes
25-52 Germline variants were not found
13
14
16
19
1
4
7
8
11
12
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Gene Freq: Frequency of each gene’s variants in a total of 36 variants; Alt Freq: Frequency of each variant in a total of 36; Blue: Likely Pathogenic variant; Red: Conflicting Variant; Green: Likely 
Benign variant; Grey: Variant of Unknown Significance. * represents families with co-occurrence of germline variants. 
Table 13. Characterization of germline variants found in each family. 
 
Gene Gene Freq Alteration Alt Freq F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 F21 F22 F23 F24
p.Lys412Asn 3%
p.Val878Ala 11%
p.Ser753Phe 3%
p.Gly12Ser 6%
p.His50Arg 3%
p.Ala13Val 3%
p.Glu2423Asp 3%
p.His1436Tyr 3%
p.Arg832Cys 3%
c.1275A>G(p.=) 3%
p.Asn596Ser 3%
TGFBR2 3% p.Arg215Cys 3%
p.Arg175Leu 3%
p.Thr3616Met 3%
c.1256-2A>G 6%
p.Pro946Leu 3%
p.Pro1161Ala 3%
BRCA1 3% c.-20+2dupT 3%
CASP10 3% p.Cys169Phe 3%
p.Arg293Ter 3%
p.Thr161Asn 3%
p.Lys911Thr 3%
p.Glu999Gly 3%
p.Ser211Ala 3%
SDHB 6% p.Ser163Pro 6%
BRCA2 3% p.Thr939SerfsTer7 3%
CTHRC1 3% p.Leu20_Leu21dup 3%
ITIH2 3% p.Ala547Val 3%
APC 3% p.Tyr1162His 3%
CDH1 3% p.Gln383Arg 3%
MSR1
MTUS1
17%
11%
8%
6%
6%
11%
6%
8%
MSH6 
SDHD
ATM
MSH2
FAT4
MAP3K6 
* * * * * * * * * * 
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2. Integration of Germline and Somatic Events of Familial Intestinal 
Gastric Cancer Families 
Co-occurrence of variants in genes with low or moderate risk might explain some of the 
characteristics observed in FIGC families, such as late onset of gastric cancer and skipping 
of affected generations (93). These findings led us to prioritize the 10 FIGC families displaying 
co-occurrence of germline variants (F1, F4, F7, F8, F11, F12, F13, F14, F16 and F19), for 
further studies.  
Therefore, the somatic second hits (aim 3) was characterized at potentially causative genes 
that may lead to their inactivation in FIGC tumors, by integrating the germline and somatic 
sequencing data of each family and by performing promoter methylation analysis.   
 
Detailed characterization of Families displaying co-occurrence of Germline Variants  
2.1. Family 1 
Family 1 encloses a female proband (F1) of 78 years old with intestinal-type GC and vaginal 
cancer. By analyzing the pedigree of this family, it is observed that the brother of the 
proband had gastric cancer at the age of 71 (Figure 3, Panel A). 
 
2.1.1. Germline landscape 
F1 had three germline variants, two in the MSH6 gene, which belongs to the Mismatch 
Repair (MMR) pathway, and one in the SDHD gene that participates in the respiratory chain 
and Krebs cycle (Table 12).  
The two variants found in MSH6 gene were classified as VUS and their frequency at ExAC 
and 1000Genomes project is currently unknown. These variants, which are novel, were 
unique in this FIGC cohort (Table 12). Variant p.Lys412Asn is located in the MutSdomain I 
and variant p.Ser753Phe is located in the MutS domain III (Figure 3, Panel B). Since the 
MutSdomain I is essential for MSH2 binding and proper repair of mismatch errors in the 
DNA (118), the variant at this domain may hamper the binding of MSH2 and inhibit the 
function of both MSH6 and MSH2 proteins. MutS domain III is constituted of two 
subdomains that, alongside domain IV, suffer a large conformational change for the DNA 
to bind to domain I (119). It is possible that a single amino acid change at this position of the 
protein interferes with this conformational change, but that remains to be proved. The two 
germline variants found in MSH6 gene may increase FIGC susceptibility by: 1) be present 
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in different alleles and both contribute to increased susceptibility; 2) be present in the same 
allele and only one of them contributes to increased susceptibility; 3) be present in the same 
allele and both contribute to increased susceptibility; 4) be present in different alleles and 
still only one of them contributes to increased susceptibility.  
The variant found in the SDHD gene (p.Gly12Ser) was classified as conflicting, since 
classifications as likely benign, likely pathogenic and uncertain significance were found in 
the three databases analyzed (Table 12). In addition, this variant was found to be very rare 
in European population (0.9%) and slightly less rare in Tuscany population (2.34%). Further, 
this variant is not unique in this cohort since it was also present in F21, being enriched in 
this FIGC cohort (Table 12). The variant p.Gly12Ser was located in the transit peptide 
mitochondrion domain, which is responsible for the protein transport to the mitochondria 
and might impair the function of the protein due to the absent transport to the mitochondria 
and respective anchoring (Figure 3, Panel C). 
 
 
 
 
 
 
Figure 3. Pedigree and germline variants of Family 1. A: Pedigree of family 1. The proband is displayed by an 
arrow. B: Schematic representation of MSH6 protein, its domains, interacting molecules and germline variants 
found represented by green dots (missense variants). aa: amino acids. [57,58] C: Schematic representation of 
A 
B: MSH6
 
C: SDHD
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SDHD protein, its domains, interacting molecules and germline variant found represented by a green dot 
(missense variants) [57, 58] 
 
2.1.2 Somatic Landscape 
The sequencing data of F1 tumor revealed eight variants in genes ARID1A, MSH6, FAT4, 
AKAP12, ATM, BRCA2, IDH2 and PALB2 (Figure 4, Panel A). In addition, previous analysis 
of F1 tumor have also identified a KRAS mutation (G13D), hypermethylation of MLH1 
promoter and microsatellite instability (MSI) phenotype.  
The MSH6 germline variant located in the domain of interaction with MSH2 could explain 
the MSI phenotype, which is usually driven by MSH2 inactivation (120). Interestingly, the 
somatic variants presented at the AKAP12, ATM, BRCA2, IDH2 and PALB2, might be a 
consequence of the MSI phenotype, due to their location in microsatellite regions. Of notice, 
the MLH1 promoter was found to be methylated and TP53 variants were not found at the 
somatic level. These findings are also characteristic of the MSI phenotype (59). 
The Krebs Cycle pathway might be also impaired, since F1 harbored germline and somatic 
variants in SDHD and IDH2 genes, respectively (121). These findings may indicate that the 
occurrence of variants is important for the formation of the tumor, since SDHD and IDH2 
belong to the same pathway. 
Similarly, ATM, BRCA2 and PALB2 genes participate in the same pathway - Homologous 
Recombination (HR) (122). Therefore, somatic variants found in these genes may create an 
imbalance of repair of double strand breaks in the DNA molecule. Recognition of these 
errors might not occur, due to the impairment of ATM, as well as, the absent formation of 
the complex BRCA2-PALB2, important for the binding of DNA (122). 
 
2.1.3 Characterization of genetic and epigenetic second hits 
Family F1 harbored three germline variants, two in MSH6 and one in SDHD (Figure 3).  To 
understand whether these genes could be further inactivated at the somatic level, 
supporting their role as potential causative genes in this family, analysis of their coding 
sequence for somatic variants was performed, as well as, their CpG islands for traces of 
cancer-associated promoter methylation. 
A missense somatic variant in MSH6 (p.Ala1055Thr) was found in the tumor of F1 proband 
(Figure 4, Panel A; Table 15). This variant was located in MutS domain III, downstream of 
the MutS domain IV (Figure 4, Panel B) and was very rare globally (0,0008%). According 
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to the InSiGHT database (123,124), this variant has been found in a Lynch Syndrome patient, 
at the germline level, and was classified as a Class III variant (uncertain), due to insufficient 
evidence. Additionally, this variant has not been annotated nor curated in COSMIC 
database. Further, variants in the same region have been classified as likely pathogenic, in 
the particular case of codon 1055 (125). Thus, p.Ala1055Thr in MSH6 may lead to the somatic 
inactivation of the wild-type allele of MSH6. SDHD did not show the presence of somatic 
mutations in the tumor from F1. 
In parallel, the methylation status of the MSH6 and SDHD promoters was analyzed. Two 
sets of primers were designed to assess the CpG island of MSH6, according to Goodfellow, 
P. J. et al. (126). As shown in figure 4, Panel C, the CpG sites analyzed (1 to 59) of MSH6 
promoter were neither methylated in F1 tumor nor in HCT-116 cell line, used as negative 
control. A set of primers was used to screen the CpG island of SDHD promoter. Similarly to 
MSH6, the CpG sites of SDHD that were possible to analyze in F1 tumor (5 to 17) were not 
methylated, mimicking the result obtained for the negative control, HCT-116 (Figure 4, 
Panel D). 
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Figure 4. Somatic Events in Family 1. A: Somatic variants found in family 1 by multiplex custom-panel based 
sequencing. B: Schematic representation of MSH6 protein, its domains, interacting molecules and somatic 
variants found represented by green dots (missense variants). aa: amino acids [57,58]. C: MSH6 Promoter 
Methylation Analysis. Schematic representation of the CpG island located at the MSH6 promoter. Open circles 
represent a non-methylated CpG; Representative examples of sequences of each sample analyzed: HCT-116 
cell line (negative control) and F1 tumor. D: SDHD Promoter Methylation Analysis. Schematic representation of 
the CpG island located at the SDHD promoter. Open circles represent a non-methylated CpG and yellow circles 
represent not accessed CpG sites; Representative examples of sequences of each sample analyzed: HCT-116 
cell line (negative control) and F1 tumor. 
 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
ARID1A 1 26771139 c.3219G>A p.Trp1073Ter Stop gained 1
MSH6 2 47801146 c.3163G>A p.Ala1055Thr Missense 1
FAT4 4 125406935 c.5363G>A p.Arg1788His Missense 1
AKAP12 6 151351864 c.3479dupC p.Asp1161Ter Frameshift Indels 1
ATM 11 108229266 c.278delA p.Lys93ArgfsTer23 Frameshift Indels 1
BRCA2 13 32339422 c.5073delA p.Lys1691AsnfsTer15 Frameshift Indels 1
IDH2 15 90088686 c.435delG p.Thr146LeufsTer15 Frameshift Indels 1
PALB2 16 23635707 c.839delA p.Asn280ThrfsTer8 Frameshift Indels 1
A 
B: MSH6 
C: MSH6 
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Figure 5 (cont.). Somatic Events in Family 1. D: SDHD Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the SDHD promoter. Open circles represent a non-methylated CpG 
and yellow circles represent not accessed CpG sites; Representative examples of sequences of each sample 
analyzed: HCT-116 cell line (negative control) and F1 tumor. 
 
In summary, F1 harbored two novel germline variants in MSH6 classified as VUS, and a 
third MSH6 somatic variant also very rare, classified as VUS. These mutations may or not 
occur in the same allele, however their co-existence supports that MSH6 may be inactivated 
in this family, likely contributing to the disease phenotype. According to the International 
Society for Gastrointestinal Hereditary Tumors (InSiGHT) database (123,124) and  TCGA 
dataset of sporadic gastric adenocarcinomas (54,57,58), mutations in HNPCC are found 
throughout the MSH6 gene. In fact, both germline variants in MSH6 were not found in Lynch 
Syndrome patients (InSiGHT database (123,124)). Thus, these variants may be low or 
moderate risk alleles for FIGC, and likely not be sufficiently deleterious to cause Lynch 
Syndrome. Moreover, these alleles may contribute to increase the risk to develop FIGC 
when occurring in concomitance with other variants (in this particular case, variants at 
D: SDHD 
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SDHD, which pathway seems also to be impaired in the tumor due to presence of a somatic 
mutation in IDH2). 
 
2.2. Family 4 
Family 4 was represented by a male proband (F4) of 78 years old with intestinal-type GC. 
The pedigree showed that his sister had lung cancer at 84 years old and his son had kidney 
cancer at the age of 58. In addition, it is observed that the proband’s cousin had GC at 84 
years old and the grand daughter of his cousin had GC at the age of 60 (Figure 5, Panel A).  
 
2.2.1. Germline Events 
F4 had two germline variants in SDHD and MSH2 genes (Table 12). 
The variant found in SDHD gene (p.His50Arg) was rare both in Europe and in Tuscany 
populations (1.7% and 1.4%, respectively) and unique in the cohort (Table 12). This variant 
was enriched in this cohort and classified as conflicting, due to contradictory classifications 
(likely benign, likely pathogenic and uncertain significance) depicted in the three databases 
analyzed (Table 12). Further, it was located in the Succinate Dehydrogenase Cytochrome 
B Small Subunit domain (Figure 5, Panel B), membrane-anchoring subunit which is 
responsible for transferring electrons from succinate to ubiquinone and involved in complex 
II of the electron transport chain (127,128). 
The variant found in MSH2 gene, another member of MMR pathway, was very rare globally 
(0.009%) and unique in the cohort (2%), being enriched. Synonymous variant p.Glu424Glu 
was classified as VUS (Table 12) by Annotatorr57 and as a class III uncertain significance 
variant, due to insufficient evidence in the InSiGHT database (123,124). Furthermore, this 
variant was located in the splice region of exon 7 and 8 (Table 12). Therefore, in-silico tools 
(Human Splicing Finder and NetGene2) were used to better understand the effect of this 
variant on splicing defects. The wild-type codon AAG was predicted to have a score of 0.83 
(i.e a 83% probability of the splice donor to occur at this codon) as a splice donor (Figure 5, 
Panel D). In fact, in the mutant sequence exon 7 displays the same amino acid (Glu) as the 
Wild-type sequence, however the splice donor in the mutant allele occurs 47bp upstream 
in comparison with the wild-type allele, with a score of 0.5. Thus, the mutant allele has a 
decrease in 47bp in exon 7, which have an impact in the frame and could be deleterious, 
due to a premature stop codon, for example. 
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This variant was located in MutS domain III, which allows the heterodimer complex 
formation MSH2/MSH6 and MSH2/MSH3 (Figure 5, Panel C) (118) and may impact the 
heterodimer formation and, consequently, the repair in microsatellite regions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Pedigree and germline variants of Family 4. A: Pedigree of family 4. The proband is displayed by an 
arrow. B: Schematic representation of SDHD protein, its domains, interacting molecules and germline variant 
found represented by a green dot (missense variants). aa: amino acids [57,58]. C: Schematic representation of 
MSH2 protein, its domains, interacting molecules and germline variant found represented by a purple dot 
A 
B: SDHD 
C: MSH2 
D: 
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(splicing variants). D: Splicing prediction of variant Glu425Glu in MSH2. In bold is represented the variant 
alteration [57,58]. 
 
2.2.2 Somatic Landscape 
Somatic variants were not found in the panel of genes analyzed. However, previous 
analysis of this family, revealed that the tumor is microsatellite stable (MSS) and has loss 
of heterozygosity (LOH) at the CDH1 gene, which may lead to poor survival (41). 
 
2.2.3. Characterization of genetic and epigenetic second hits 
There were no somatic mutations affecting SDHD and MSH2. Therefore, methylation status 
of their promoters was assessed to check if promoter methylation could be the somatic 
second inactivation hit. 
Using the same strategy as in F1 family, it was observed that CpG island of SDHD was not 
methylated in F4 tumor (CpG sites 5 to 18) (Figure 6, Panel A). 
Three sets of primers were designed to assess the methylation status of the MSH2 CpG 
island. Figure 6, Panel B showed that the MSH2 CpG island was not methylated in the 
negative control (HCT-116, CpG sites 1 to 73), as well as, in the F4 tumor, CpG sites 1 to 
44 and 52 to 73. 
 
By combining the germline and somatic data, it can be inferred that the co-occurrence of 
germline variants at the MSH2 and SDHD genes was necessary to display the disease. In 
fact, the observed MSS phenotype of F4 tumor was also contradictory to a MSH2 driven 
tumor (120), reinforcing that this variant might not be sufficient to cause Lynch Syndrome, but 
may be important if co-occurring with a SDHD germline variant in the context of FIGC. 
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Figure 7. Somatic Second Hit in Family 4. A: SDHD Promoter Methylation Analysis. Schematic representation 
of the CpG island located at the SDHD promoter. Open circles represent a non-methylated CpG and yellow 
A: SDHD 
B: MSH2 
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circles represent not accessed CpG sites; Representative examples of sequences of each sample analyzed: 
HCT-116 cell line (negative control) and F4 tumor. B: MSH2 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the MSH2 promoter. Open circles represent a non-methylated CpG 
and yellow circles represent not accessed CpG sites; Representative examples of sequences of each sample 
analyzed: HCT-116 cell line (negative control) and F4 tumor. 
 
2.3. Family 7 
Family 7 was represented by a 66 years old male proband (F7) with intestinal-type GC. By 
analyzing the pedigree of family 7, it was observed that both grandparents of F7 were 
diagnosed with GC at 80 years old. From the 6 children that these individuals had, 5 had 
GC, including the mother of the proband, at 88 years old, two uncles at 70 and 60 years old 
and two aunts at 44 and 80 years old. Four cousins of the proband were also affected: one 
had leukemia at 22 years old, other had breast cancer at 24 years old, other had prostate 
cancer at 60 and a cousin with bladder cancer. A second degree cousin of the proband had 
brain cancer at 40 years old. The father of the proband had GC at 45 years old and his 
brother had an unidentified cancer at 80 years old, as well as, a proband’s cousin at 40 
years old. Two second degree uncles were diagnosed with GC at 79 years old and prostate 
cancer at 73 years old, respectively, and a second degree aunt was diagnosed with 
Gynaecological cancer. Two third degree cousins were affected, one was diagnosed with 
breast cancer and the other was diagnosed with osteosarcoma at 65 years old (Figure 7, 
Panel A). 
 
2.3.1. Germline Landscape 
F7 had two germline variants, one in MAP3K6 and one in BRCA1 genes (Table 12). 
MAP3K6 encodes for a serine/threonine kinase that participates in the regulation of vascular 
endothelial growth factor (VEGF) expression (129). The variant found in MAP3K6 
(p.Pro946Leu) was very rare both in European and Tuscany populations (0.5% and 0.47%, 
respectively) and was classified as VUS (Table 12). Further, this variant was unique in the 
cohort analyzed (2%) and enriched in comparison with European and Tuscany populations 
(Table 12) Moreover, p.Pro946Leu was not located in any known domain of the protein 
(Figure 7, Panel B). Interestingly, this variant was previously found in a familial gastric 
cancer cohort (31), increasing the likelihood of this variant being a susceptibility factor in the 
context of gastric cancer. 
The BRCA1 gene is involved in the HR pathway by repairing double strand errors in the 
DNA molecule (122). The variant c.-20+2dupT in BRCA1 was not yet described in the ExAC 
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and 1000Genome project database and was unique in the cohort. Further, was located in 
intron 1, specifically in a splice region, and was classified as VUS (Table 12).  
Splicing prediction revealed that the duplication of T did not affect this splice acceptor, being 
scored in 0.79 (a 79% probability of occurrence of splice acceptor) in both the wild-type and 
mutant sequence. The T nucleotide duplication leads to a frameshift mutation, however, 
since it occurred before the ATG, there is no alteration of the sequence frame (Figure 7, 
Panel C). Nevertheless, this region is associated with highest promoter activity, as well as, 
E2F transcription factor binding, important to induce BRCA1 activity (130). 
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Figure 8. Germline variants of Family 7. A: Pedigree of family 7. The proband is displayed by an arrow. B: 
Schematic representation of MAP3K6 protein, its domains, interacting molecules and germline variant found 
represented by a green dot (missense variants). aa: amino acids [57,58]. C: Splicing prediction of variant c.-
20+2dupT in BRCA1. In bold is represented the variant alteration. 
 
 
C: BRCA1 
A: 
B: MAP3K6 
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2.3.2 Somatic Landscape  
The F7 tumor is MSS (previous analysis) and had one somatic variant in the TP53 gene, 
p.His168Leu (Figure 8, Panel A). 
 
2.3.3 Characterization of genetic and epigenetic second hits 
MAP3K6 and BRCA1 were not found to be mutated at the somatic level. Therefore, 
promoter hypermethylation was tested to assessed the second inactivation hit of MAP3K6. 
Methylation status of the MAP3K6 promoter was evaluated using two sets of primers. As 
shown in Figure 8, Panel B, the MAP3K6 promoter (CpG sites 4 to 26) was not methylated 
in F7 tumor. Given that it was previously reported in a Familial Gastric Cancer (FGC) tumor, 
complete methylation of a CpG island within the MAP3K6 gene, in opposition to the normal 
counterpart, this CpG island (located in exon 15 of MAP3K6) was analyzed and predicted 
to harbor promoter associated features, by using the same strategy as in reference (31). 
As shown in Figure 8, Panel C, the CpG island located in gene body of MAP3K6 (CpG sites 
5 to 19) was hemi-methylated both in tumor and normal tissue of F7 proband. Due to the 
fact that the normal tissue was gastric mucosa adjacent to the tumor, it can be inferred that 
inflammation or other tumor-related phenomena could lead to methylation of the wild-type 
allele. Therefore, an unrelated normal gastric mucosa from a bariatric surgery was analyzed 
and found to be hemi-methylation.  
Additionally, to confirm these results, UCSC database (131) was analyzed to assess the 
methylation status of a normal stomach. The currently available information shows that the 
gene body CpG island of MAP3K6 is also hemi-methylated in a normal stomach (Figure 8, 
Panel D), which may suggest that neither second somatic mutation nor CpG island 
hypermethylation are the second inactivation hits in F7.  
In summary, F7 had two germline variants, in MAP3K6 and in BRCA1. The MAP3K6 
germline variant found in F7 has been previously identified in 2 unrelated families with 
aggregation of gastric cancer (31), supporting a potential role for this protein in gastric cancer. 
Additionally, the BRCA1 germline variant is located in a highest promoter activity region, to 
which E2F transcription factors binds. One possibility is that the variant c.-20+2dupT in 
BRCA1 may inhibit the binding of E2F, leading to decrease in BRCA1 protein expression. 
Furthermore, 3 familial members of F7 have been diagnosed with breast cancers, however, 
c.-20+2dupT has not been found in Breast and Ovarian Hereditary Syndrome. Thus, it can 
be inferred that this variant display a low or moderate risk allele. Interestingly, in a sporadic 
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cohort of GC (TCGA) (57,58), 2 individuals (approximately 1%) display co-occurrence of 
somatic variants in MAP3K6 and BRCA1. Thus, it could be inferred that co-occurrence of 
low or moderate risk alleles in MAP3K6 and BRCA1 may increase predisposition to FIGC.  
 
 
 
 
Figure 9. Somatic events in Family 7. A: Somatic variants found in family 7 by multiplex custom-panel based 
sequencing. B: MAP3K6 Promoter Methylation Analysis. Schematic representation of the CpG island located at 
the MAP3K6 promoter. Open circles represent a non-methylated CpG and yellow circles represent not accessed 
CpG sites; Representative examples of sequences of each sample analyzed: MCF7 cell line (negative control) 
and F7 tumor. 
 
 
 
 
 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
TP53 17 7675109 c.503A>T p.His168Leu Missense 1
A 
B: MAP3K6 
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C: MAP3K6 
D:  
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Figure 8 (cont.). Somatic events in Family 7. C: MAP3K6 gene body Methylation Analysis. Schematic 
representation of the CpG island located at the MAP3K6 gene body. Open circles represent a non-methylated 
CpG; blue circles represent methylated CpG, white circles with blue risks represent hemi-methylated CpG and 
yellow circles represent not accessed CpG; Representative examples of sequences of each sample analyzed: 
MKN74 cell line (negative control), F7 normal, F7 tumor and sample of bariatric surgery. D: UCSC genome 
browser, displaying gene body CpG island of MAP3K6. The blue rectangle represents the region amplified in 
normal stomach and are represented in yellow and orange, code for hemi-methylated region. 
 
2.4. Family 8 
Family 8 was represented by a 73 years old female proband (F8) with intestinal-type GC. 
By analyzing the pedigree, it was observed that a sister of the proband was diagnosed with 
gastric ulcer (Figure 9, Panel A). Furthermore, the father of the probands husband was 
diagnosed with GC at 40 years old. The proband had one daughter diagnosed with GC at 
49 years old and a granddaughter diagnosed with gastric ulcer at 21 years old (Figure 9, 
Panel A). 
 
2.4.1. Germline Landscape 
F8 had two germline variants in CASP10 and in MAP3K6 genes (Table 12).  
CASP10 belongs to the caspase family, playing a role similar to CASP8 in apoptosis (90). 
The missense variant p.Cys169Phe in CASP10 was very rare in the global population and 
was classified as VUS (Table 12). This variant was unique in the cohort analyzed (2%), 
being enriched in comparison with global population (0.0008%) and was located in the Dead 
Effector domain (Table 12, Figure 9, Panel B), which is described as a protein-protein 
interaction domain involved in apoptosis (132). It may be speculated that this very rare variant 
could hamper the protein-protein interaction and inhibit apoptosis. 
The MAP3K6 variant (c.1256-2A>G) was very rare in Europe and Tuscany populations 
(0.7% and 0.47%, respectively) and recurrently appeared in F3 and F8 from this cohort 
(4%), being enriched in comparison with European (0.7%) and Tuscany (0.47%) 
populations (Table 12). This variant was classified as VUS and was located in intron 8, 
between exon 8 and exon 9 and can give rise to splice defects (Table 12). In fact, splicing 
prediction of the missense alteration A>G revealed a decreased probability of occurring a 
splice acceptor (from 0.94-wild-type to 0.65-mutant) and a creation of a new splice acceptor. 
In this last scenario, a frameshift occurs, increasing two nucleotides in the beginning of exon 
5 (Figure 9, Panel C), which is predicted to lead to an alteration of the frame in exon 5 that 
could be deleterious, due to a premature stop codon, for example. 
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Figure 10. Germline variants of Family 8. A: Pedigree of family 8. The proband is displayed by an arrow. B: 
Schematic representation of CASP10 protein, its domains, interacting molecules and germline variant found 
represented by a green dot (missense variants). aa: amino acids [57,58]. C: Splicing prediction of variant c.1256-
2A>G in MAP3K6. In bold is represented the variant alteration. 
 
A:  
B: CASP10 
C: MAP3K6 
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2.4.2 Somatic Landscape 
At the somatic level, four variants were found in ARID1A, FAT4 and PTEN (Figure 10, Panel 
A). In addition, this tumor displayed an MSI phenotype and had methylation of MLH1 gene. 
The PTEN gene might be an MSI target gene, since the variant occurred at a microsatellite 
region. Interestingly, F8 does not exhibit a somatic variant in TP53 and is methylated in the 
promoter region of MLH1, characteristics of MSI tumors. 
 
2.4.3. Characterization of genetic and epigenetic second hits  
Somatic variants in CASP10 or MAP3K6 genes were not found in the F8 tumor, and do not 
constitute the second inactivation hit. Therefore, methylation status of both genes was 
analyzed. 
The methylation results obtained for the promoter and gene body of MAP3K6 were similar 
to those obtained for F7 (i.e the promoter was not methylated and the gene body was hemi-
methylated both in tumor and normal tissues) (Figure 10, Panel B and C). These findings 
suggested that a second mutation and methylation in the promoter and gene body regions 
of MAP3K6 might not be the second inactivation hits.  
To evaluate the methylation status of the CASP10 promoter, two sets of primers were 
designed. Figure 10, Panel D showed that CpG sites 1-10 were methylated and CpG sites 
11-18 were hemi-methylated both in F8 tumor and normal tissues, whereas all CpG sites 
were methylated in the HCT-116 cell line (the positive control). For the same reasons as 
describe above, tissue from a bariatric surgery was analyzed and the same pattern was 
observed. Further validation in the UCSC database could not be performed, since 
methylation in this region was not evaluated by microarrays. All these findings led us to 
hypothesize that promoter methylation may not be the second inactivation hit and do not 
control the expression of CASP10. However, further studies should be conducted.   
In summary, the co-occurrence of CASP10 and MAP3K6 germline variants might be the 
underlying cause of GC in this family. In fact, CASP10 and MAP3K6 somatic alterations 
appear, independently in each gene in approximately 4% of the sporadic GC cases depicted 
in the TCGA database, and co-occur in a single case (0.4%) (57,58). Furthermore, CASP10 
alterations had been associated with gastric cancer risk, highlighting the importance of this 
gene in gastric adenocarcinoma (133). Nevertheless, MAP3K6 has been identified as a 
genetic risk factor for FGC (31). Thus, by combining the germline and somatic data, it may 
be inferred that the co-occurrence of germline variants in moderate or low risk alleles 
(CASP10 and MAP3K6) could predispose to FIGC. 
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Figure 11. Somatic Events in Family 8. A: Somatic variants found in family 8 by multiplex custom-panel based 
sequencing. B: MAP3K6 Promoter Methylation Analysis. Schematic representation of the CpG island located at 
the MAP3K6 promoter. Open circles represent a non-methylated CpG and yellow circles represent not accessed 
CpG sites; Representative examples of sequences of each sample analyzed: MCF7 cell line (negative control) 
and F8 tumor.  
 
 
 
 
 
 
 
 
A 
B: MAP3K6 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
ARID1A 1 26773716 c.4003C>T p.Arg1335Ter Stop gained, Splice region 1
FAT4 4 125449221 c.8205A>C p.Lys2735Asn Missense 1
PTEN 10 87952216 c.595_597delATG p.Met199del Inframe deletion 1
PTEN 10 87958013 c.800delA p.Lys267ArgfsTer9 Frameshift Indels 1
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
48 
Celina Beatriz Teixeira São José 
 
Figure 12 (cont.). Somatic Events in Family 8. C: MAP3K6 gene body Methylation Analysis. Schematic 
representation of the CpG island located at the MAP3K6 gene body. Open circles represent a non-methylated 
CpG; blue circles represent methylated CpG, white circles with blue risks represent hemi-methylated CpG and 
yellow circles represent not accessed CpG; Representative examples of sequences of each sample analyzed: 
MKN74 cell line (negative control), F8 normal, F8 tumor and sample of bariatric surgery.  
 
 
C: MAP3K6 
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Figure 13 (cont.). Somatic Events in Family 8. D: CASP10 gene promoter Methylation Analysis. Schematic 
representation of the CpG island located at the CASP10 promoter. Open circles represent a non-methylated 
CpG; blue circles represent methylated CpG, white circles with blue risks represent hemi-methylated CpG and 
yellow circles represent not accessed CpG; Representative examples of sequences of each sample analyzed: 
HCT-116 cell line (positive control), F8 normal, F8 tumor and sample of bariatric surgery. 
 
2.5. Family 11 
Family 11 was represented by a 65 years old female proband (F11) with intestinal-type GC. 
The pedigree of this family showed that two brothers with disease: one had gastric ulcer at 
66 years old and the other had GC at 47 years old. In addition, the proband’s cousin had 
breast cancer at 44 years old (Figure 11, Panel A).  
D: CASP10 
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2.5.1. Germline Landscape 
F11 had two germline variants in MSH6 and ATM genes. The variant found in MSH6, 
(p.Val878Ala) was rare in Europe (1.3%) and Tuscany (2.34%) populations and was 
frequent in the cohort analyzed (8%) (Table 12). In addition, it was classified as conflicting 
by Annotator57, due to contradictory information regarding pathogenicity depicted in the 
databases (Table 12). This MSH6 variant has been recently described in a homozygous 
state in two individuals, but was not associated with Lynch Syndrome (data available from 
collaborators and not published). Therefore, it is likely that this specific variant is not 
associated with Lynch, but may contribute to increase FIGC susceptibility. This variant was 
present in MutS domain III (Figure 11, Panel B), that suffers a large conformational change 
for the DNA molecule to bind to domain I (119). It is possible that a single amino acid change 
at this position of the protein interferes with this conformational change, but that remains to 
be proved.  
ATM is a tumor suppressor gene that encodes for a cell cycle checkpoint kinase that 
regulates downstream proteins, such as TP53. The variant p.His1436Tyr in ATM is very 
rare in Europe (0.1%) and in Tuscany (0.47%) and was classified as VUS (Table 12). This 
variant was not located in any relevant domain of the ATM protein (Figure 11, Panel C). 
Furthermore, the cousin of the proband was diagnosed with breast cancer, which might be 
due to the presence of a germline variant in ATM (a moderate penetrance gene for 
hereditary breast cancer) (134). 
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Figure 14. Pedigree and germline variants of Family 11. A: Pedigree of family 11. The proband is displayed by 
an arrow. B: Schematic representation of MSH6 protein, its domains, interacting molecules and germline variant 
found represented by a green dot (missense variants). aa: amino acids [57,58]. C: Schematic representation of 
ATM protein, its domains, interacting molecules and germline variant found represented by a green dot 
(missense variants [57,58]). 
 
2.5.2 Somatic Landscape 
At the somatic level, two variants were found in CDH1 and TP53 (Figure 12, Panel A). In 
addition, this tumor displayed a phenotype of MSI and a characteristic methylation of MLH1 
promoter. However, a TP53 variant at the somatic level is not characteristic of MSI tumors. 
 
 
A 
B: MSH6 
C: ATM 
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2.5.3 Characterization of genetic and epigenetic second hits 
Somatic variants in MSH6 or ATM genes were not found in the F11 tumor and do not 
constitute the second inactivation hit. Therefore, the methylation status of both genes was 
assessed. 
The CpG island of MSH6 was analyzed as previously described and it was observed that 
CpG sites 1 to 59 were not methylated in the tumor of F11 (Figure 12, Panel B). 
Three sets of primers were designed to analyze the majority of the CpG island of ATM, 
according to Pal, R et al. (135). Similarly to MSH6, the CpG island of ATM (CpG sites 1 to 29 
and 33 to 63) was not methylated in the F11 tumor, as well as, the negative control, HCT-
116 (Figure 12, Panel C). These findings indicated that CpG island methylation was not the 
second inactivation hit in both genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
53 
Celina Beatriz Teixeira São José 
 
 
 
Figure 15. Somatic Events in Family 11. A: Somatic variants found in family 11 by multiplex custom-panel based 
sequencing. B: MSH6 Promoter Methylation Analysis. Schematic representation of the CpG island located at 
the MSH6 promoter. Open circles represent a non-methylated CpG and yellow circles represent not accessed 
A 
B: MSH6 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
CDH1 16 68819423 c.1709A>G p.Asn570Ser Missense, Splice region 1
TP53 17 7674947 c.584T>C p.Ile195Thr Missense 1
C: ATM 
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CpG sites; Representative examples of sequences of each sample analyzed: HCT-116 cell line (negative 
control) and F11 tumor. C. ATM gene promoter Methylation Analysis. Schematic representation of the CpG 
island located at the ATM promoter. Open circles represent a non-methylated CpG and yellow circles represent 
not accessed CpG; Representative examples of sequences of each sample analyzed: HCT-116 cell line 
(positive control) and F11 tumor. 
 
Notwithstanding, MSH6 is not usually a driver of the MSI phenotype (120), the association 
with ATM could be the underlying cause of FIGC in this family. Furthermore, F11 proband 
carried alterations in four genes that participate in DNA damage repair: MSH6 and ATM at 
the germline level (blue) and MLH1 and TP53 at the somatic level (yellow), that together 
could predispose to FIGC (Figure 13). According to the TCGA database (57,58), MSH6 and 
ATM somatic variants co-occur in 6 tumors (2%) with sporadic GC. Thus, it can be inferred 
that co-occurrence of germline low or moderate risk variants at MSH6 and ATM could 
predispose to FIGC in this family, by interfering with DNA repair pathways. 
 
 
Figure 16. DNA damage repair pathways – MRR and HR. Blue represents germline variants and yellow 
represents somatic variants. 
 
2.6. Family 12 
Family 12 was represented by a 71 years old male proband (F12) with intestinal-type GC. 
The pedigree of this family showed a proband’s brother with lung cancer, a sister with breast 
cancer and a cousin with GC (Figure 14, Panel A). 
 
2.6.1. Germline Landscape 
F12 had two germline variants in genes BRCA2 and CTHRC1 (Table 12).  
The variant found in BRCA2, p.Thr939SerfsTer7, is novel and is predicted to generate a 
premature termination codon 7 amino acids downstream of the frameshifted nucleotide. 
This BRCA2 truncating variant was classified as likely pathogenic since numerous likely 
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pathogenic variants were already described in the same region, particularly in the same 
codon, with similar consequences. The frequency of this variant was not described in ExAC 
and in the 1000Genome project and was unique in the FIGC cohort (Table 12). Additionally, 
this variant was not located in any known domain (Figure 14, Panel B). Interestingly, a sister 
of the proband had breast cancer (not tested for the variant so far), suggesting that this 
BRCA2 germline variant may represent a risk allele also for breast cancer. 
F12 also carried a novel germline in-frame duplication (p.Leu20_Leu21dup) at the CTHRC1 
gene that results in the insertion of two additional Leucine residues in the protein. This gene 
is involved in Planar Cell Polarity (PCP), through stabilization of the complex Wnt-Fzd-Ror2 
and activation of RhoA. Additionally, CTHRC1 is responsible for the preferential activation 
of PCP in alternative to the canonical WNT-signaling pathway (136). This unique variant was 
classified as VUS, since no information was not found, including frequency in ExAC and in 
the 1000Genomes project (Table 12). Only one domain has been identified in this gene 
(Collagen triple helix repeat) and variant p.Leu20_Leu21dup was not in the described 
domain (Figure 14, Panel C). However, residues 20 and 21 of CTHRC1 are part of a 
Leucine-rich domain which, is conserved at least in mouse, and is likely important for the 
function of this protein. Moreover, a close variant - Q44P -, has been associated with 
disruption of the protein’s ability to form secondary structure (137). 
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Figure 17. Pedigree and germline variants of Family 12. A: Pedigree of family 12. The proband is displayed by 
an arrow. B: Schematic representation of BRCA2 protein, its domains, interacting molecules and germline 
variants found represented by blue dots (missense variants). aa: amino acids [57,58]. C: Schematic 
representation of SDHD protein, its domains, interacting molecules and germline variant found represented by 
purple dots (frameshift variants [57,58]). 
 
2.6.2 Somatic Landscape 
At the somatic level, one variant was found in APC, a tumor suppressor gene associated 
with cell polarity and proliferation – WNT-signaling pathway (Figure 15, Panel A). From 
previous analysis of this family, the tumor has LOH of CDH1 and displayed a phenotype of 
MSI.  
 
 
A 
B: BRCA2 
C: CTHRC1 
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2.6.3. Characterization of genetic and epigenetic second hits 
Somatic variants in BRCA2 and CTHRC1 were not found, therefore the following step was 
to evaluate promoter methylation of these genes to determine if promoter methylation could 
be the somatic second inactivation hit. 
In order to evaluate promoter methylation status in BRCA2, a pair of primers were designed 
according to Price RJ, et al. (138). Tumor of F12 was not methylated in the CpG sites analyzed 
(1-26), as well as, the negative control, HCT-116 (Figure 15, Panel B).  
For the analysis of CTHRC1 CpG island, 3 sets of primers were designed to analyze the 
entire island. Since Hela cells (positive control), were not methylated in the regions analyzed 
with the first and second sets of primers, the third region was prioritized. In fact, CTHRC1 
was hemi-methylated (CpG sites 59-73) in Hela cells and was fully methylated in MKN74 
cells (CpG sites 57-73). Both tumor and normal tissue of F12 were hemi-methylated (59-72 
and 57-73, respectively). Since normal tissue derived from tumor adjacent mucosa could 
be affected by the tumor, methylation status from a normal patient who underwent a bariatric 
surgery was analyzed. This tissue was also hemi-methylated (CpG sites 57-72), Figure 16, 
Panel A. In addition, UCSC database (131) was used to evaluate the methylation status of 
normal stomach and found that the region amplified by the third set of primers was not 
methylated, using microarrays (Figure 16, Panel B). In fact, it can be speculated that the 
gastric mucosa of the normal individual could be affected by environmental factors, such as 
H. pylori infection or ingestion of salted food, leading to inflammation or other tumor-related 
phenomena. Nevertheless, the possibility that different techniques might also influence the 
methylation status evaluation could not be excluded. 
 
2.6.4. RNA Expression 
Then, quantitative real-time PCR was performed, to evaluate the impact of germline and 
somatic variants found at CTHRC1 and APC genes, respectively. Expression of β-Catenin 
was also quantified since it is a downstream target of APC. Of notice, RNAs from a 
commercial normal stomach, commercial normal breast and HCT-116 cell line were used 
as positive controls and MKN74 as negative control. 
Observing the results, F12 tumor did not express APC, but expressed CTHRC1 and β-
Catenin and the normal counterpart did not express APC and CTHRC1, but expressed β-
Catenin (Figure 16, Panel C). Since APC is essential for the embryonic development (139), 
the absence of its expression in F12 normal tissue may be explained by the poor quality of 
the RNA. This assumption is based on the fact that the endogenous control (18S) was 
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amplified very late. Therefore, commercial normal stomach was used as a control, instead 
of the normal counterpart of tumor F12. 
CTHRC1 is not expressed in normal stomach and is hemi-methylated in the region analyzed 
(Figure 16, Panel B and C). It can be inferred that repressors might bind to this region in 
order to suppress the expression of the RNA, that alongside with hemi-methylation of the 
other allele might explain absent RNA expression (Figure 16, Panel B and C). In F12 tumor, 
hemi-methylation is conserved and CTHRC1 RNA expression is increased (Figure 16, 
Panel A and C). This may be due to the absence of repressors in the unmethylated allele 
that is sufficient to increase RNA expression. Furthermore, MKN74 cell line is methylated 
and CTHRC1 RNA is not expressed, revealing that the action of CTHRC1 repressors might 
not act in this context, or could act synergically with promoter methylation (Figure 16, Panel 
B and C). Moreover, expression of CTHRC1 is decreased in comparison with positive 
control, normal breast tissue. According to Wang et al (140), protein expression of CTHRC1 
was absent in gastric normal mucosa and was progressively increased with stage of gastric 
adenocarcinoma (140), which was in accordance with our RNA expression results. However, 
Wang et al. (140) also stated that promoter demethylation is responsible for increased protein 
expression.  It can be inferred that, in tumor context, repressors that inactivate CTHRC1 in 
the stomach might be absent and methylation might not be sufficient to decrease RNA 
expression. Thus, it can also be inferred that CTHRC1 could act as a pro-tumorous gene 
and is activated with a germline variant p.Leu20_Leu21dup. In summary, since CTHRC1 is 
not expressed in the stomach, an activating mutation might not impact protein expression 
in this tissue. In gastric tumor context, repression of this gene is inhibited and CTHRC1 is 
expressed. 
The absence of APC mRNA expression in the tumor may be due to the presence of a 
somatic mutation at the APC gene. In addition, mRNA expression levels of β-Catenin of 
F12 tumor were decreased in comparison with commercial normal stomach. These findings 
are in accordance with CTHRC1 being responsible for the preferential activation of PCP in 
alternative to the canonical WNT-signaling pathway (136), decreasing expression of β-
Catenin, a key protein in WNT-signaling pathway. 
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Figure 18. Somatic Events in Family 12. A: Somatic variants found in family 12 by multiplex custom-panel based 
sequencing. B: BRCA2 Promoter Methylation Analysis. Schematic representation of the CpG island located at 
the BRCA2 promoter. Open circles represent a non-methylated CpG and yellow circles represent not accessed 
CpG sites; Representative examples of sequences of each sample analyzed: HCT-116 cell line (negative 
control) and F12 tumor. 
 
 
 
 
 
 
 
 
A 
B: BRCA2 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
12 APC 5 112842961 c.7367T>A p.Leu2456Ter Stop gained 1
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Figure 19. Somatic Events in Family 12, cont. A: CTHRC1 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the CTHRC1 promoter. Open circles represent a non-methylated 
CpG; blue circles represent methylated CpG, white circles with blue risks represent hemi-methylated CpG and 
yellow circles represent not accessed CpG; Representative examples of sequences of each sample analyzed: 
Hela and MKN74 cell lines (positive controls), F12 normal, F12 tumor and sample of bariatric surgery. B: UCSC 
genome browser, displaying promoter CpG island of CTHRC1. The blue rectangle represents the region 
amplified by the third set of primers in normal stomach and are represented in green, code for not methylated 
A: CTHRC1 
B 
C 
D 
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region. C: Expression of CTHRC1 (blue) in normal stomach, normal F12, tumor F12, cell line HCT-116 (positive 
control), normal breast (positive control) and MKN74 (negative control). D: Expression of APC (grey) and β-
Catenin (yellow) in normal stomach, normal F12, tumor F12 and cell line HCT-116 (positive control). 
 
In summary, two germline variants were found in CTHRC1 and BRCA2 and one somatic 
variant in APC. In fact, CTHRC1 and APC are involved in WNT signaling pathway, non-
canonical (PCP) and canonical, respectively (136). CTHRC1 enhances the formation of Wnt-
Fzd-Ror2 complex and activates RhoA (136). Furthermore, CTHRC1 selectively activates 
PCP signaling pathway, alternatively to the canonical WNT-signaling pathway (136). In 
normal stomach, CTHRC1 is not expressed, thus, PCP is not the preferential signaling 
pathway and stabilization of Wnt-Fzd-Ror2 and activation of RhoA is not completed, 
impairing this pathway. At the somatic level, APC variant leads to an imbalance of the 
canonical WNT-signaling pathway and CTHRC1 is expressed, leading to a preferential 
activation of PCP signaling pathway. Additionally, expression of APC is absent in tumor F12 
and expression of CTHRC1 is increased in comparison with commercial RNA derived from 
normal stomach. The importance of BRCA2 germline variant could not be excluded, due to 
the affected sister with breast cancer. In fact, the co-occurrence of both germline variants 
might predispose to breast cancer as well, since CTHRC1 is expressed in normal breast. 
According to the TCGA database (57,58), 4 (1.4%) tumors displayed sporadic GC and co-
occurring of somatic variants in CTHRC1 and BRCA2. Thus, co-occurrence with BRCA2 
could lead to an impairment of two important signaling pathways: WNT and HR, 
predisposing this family to FIGC. 
 
2.7. Family 13 
Family 13 was represented by a male proband (F13) with 64 years old and intestinal-type 
GC. By analyzing the pedigree, it was observed that both parents of the proband were 
affected, the father with GC at 66 years old and the mother with laryngotracheal cancer at 
62 years old. Two cousins from different parental lines were also affected, an uncle from 
the mother side with gastric ulcer at 68 years old and an aunt diagnosed with hepatobiliary 
cancer at 70 years old. A cousin of the proband was diagnosed with laryngotracheal cancer 
at 58 years old. A nephew and a niece of the proband were also affected, being diagnosed 
with a gastric ulcer at 61 years old and a gynaecological cancer at 54 years old, respectively. 
 
2.7.1. Germline Landscape 
F13 has two germline variants, in SDHB and MTUS1 (Table 12). 
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SDHB is a subunit of Succinate Dehydrogenase Complex, responsible for the oxidation of 
succinate. Variant p.Ser163Pro in SDHB was rare in both Europe (1.7%) and Tuscany 
(1.87%) and was classified as conflicting, since contradictory information was found in the 
three databases analyzed (Table 12). Additionally, this variant recurrently appeared in F22, 
being enriched in this FIGC cohort (4%) (Table 12). A recent study revealed that this variant 
was present in one case of HDGC, being associated with AKT and MAPKT pathways 
increased activity (141). As represented in Figure 17, Panel A, this variant was not located in 
any known domain. 
MTUS1 encodes for a variety of proteins, such as ATIP1 and ATIP2, involved in AT2 
signaling pathway, responsible for cell proliferation inhibition, via MAPK inhibition (142). The 
variant in MTUS1 (p.Glu999Gly) was rare in both Europe (1.3%) and Tuscany (1.87%), and 
was unique in the FIGC cohort (Table 12). This variant was classified as VUS and located 
in a coiled-coil domain, responsible for dimerization of MTUS1 (Figure 17, Panel B) with 
AT2R, a pró-apoptotic and anti-proliferative receptor (143). It is possible that dimerization of 
MTUS1 with AT2 receptor could not occur in F13 tumor, inhibiting AT1 intercellular 
response and leading to activation of AT2R pathway independent of ligand/AT2 receptor 
interaction (143) and, consequently, to activation of MAPK pathway and increased 
proliferation (Figure 17, Panel A). 
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Figure 20. Germline variants of Family 13. A: Pedigree of family 13. The proband is displayed by an arrow. B: 
Schematic representation of SDHB protein, its domains, interacting molecules and germline variant found 
represented by a green dot (missense variant). aa: amino acids [57,58]. C: Schematic representation of MTUS1 
protein, its domains, interacting molecules and germline variant found represented by a green dot (missense 
variant) [57,58]. 
 
2.7.2 Somatic Landscape 
Somatic variants were not found in the panel of genes analyzed. However, previous 
analysis of this family, revealed that the tumor is MSS. 
 
2.7.3. Characterization of genetic and epigenetic second hits 
Somatic variants were not found in either SDHB or MTUS1 and did not constitute the second 
inactivation hit. Therefore, methylation analysis in the promoter of SDHB was performed. 
Although, in the Ensembl genome browser, a CpG island in the SDHB was not annotated, 
primers were designed to cover the CpG island as described in Westermeier, F. et al. (144), 
A:  
B: SDHB 
C: MTUS1 
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analyzing almost the entire CpG island. As shown in Figure 18, Panel A, the F13 tumor was 
not methylated in all CpG sites (23), as well as, the negative control (Hela). 
Regarding MTUS1 promoter methylation, technical issues did not allow the analysis of the 
methylation status in the CpG island of this gene. 
 
 
Figure 21. Somatic Events in Family 13. A: SDHB Promoter Methylation Analysis. Schematic representation of 
the CpG island located at the SDHB promoter. Open circles represent a non-methylated CpG; Representative 
examples of sequences of each sample analyzed: Hela cell line (negative control) and F13 tumor. 
 
MTUS1 was found to be altered in 9% of sporadic GC (57,58). Additionally, downregulation 
and association with proliferation and metastasis in gastric cancer cells have been 
described (145), revealing the importance of this gene in GC. In fact, SDHB was found to be 
mutated in patients with HDGC and associated with AKT and MAPK pathways increased 
activity. AKT and MAPK pathways have been linked with cell growth, proliferation and 
A: SDHB 
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survival (146), important hallmarks of cancer (147). In fact, MTUS1 and SDHB were found to 
be somatically mutated in co-occurrence, in only one tumor of a subset of sporadic GCs 
(0.3% - TCGA data (57,58)). Variant p.Ser163Pro in SDHB may be a low or moderate risk 
allele that predisposes to familial gastric cancer that in association with MTUS1 variant 
increases the risk for intestinal type gastric cancer (FIGC).  
 
2.8. Family 14 
Family 14 was represented by a female proband (F14) of 74 years old with intestinal-type 
GC. By analyzing the pedigree of this family, it was observed that the mother of the proband 
was diagnosed with GC at 52 years old, as well as, an uncle from the mother side, who was 
diagnosed with GC at 80 years old (Figure 19, Panel A) 
 
2.8.1. Germline Landscape 
The F14 harbored two germline variants, in ATM and MTUS1 (Table 12).  
The ATM variant, p.Arg832Cys, was absent in both Europe and Tuscany populations and 
unique in this FIGC cohort (2%), being enriched (Table 12). Furthermore, p.Arg832Cys was 
classified as VUS and was not located in any known domain of the ATM gene (Figure 19, 
Panel A). 
Variant p.Ser211Ala in MTUS1 was classified as VUS and was rare in both Europe (1.7%) 
and Tuscany (1.87%) (Table 12). Further, this variant was unique in the FIGC cohort (2%) 
and was not located in any domain discovered so far (Table 12, Figure 19, Panel A). 
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Figure 22. Germline variants of Family 14. A: Pedigree of family 14. The proband is displayed by an arrow. B: 
Schematic representation of ATM protein, its domains, interacting molecules and germline variant found 
represented by a green dot (missense variant). aa: amino acids [57,58]. C: Schematic representation of MTUS1 
protein its domains, interacting molecules and germline variant found represented by a green dot (missense 
variant) [57,58]. 
 
2.8.2 Somatic Landscape 
At the somatic level, variants were not found in the panel of genes analyzed. However, 
previous analysis classified this tumor as MSS. 
 
2.8.3. Characterization of genetic and epigenetic second hits 
ATM and MTUS1 were not found to be mutated in the tumor of F14. Therefore, methylation 
in the promoter of ATM was analyzed to determine if methylation could be the somatic 
second hit. Using the same strategy as in F11, tumor of F14 was not methylated, CpG sites 
1 to 27 (Figure 20, Panel A). 
A:  
B: ATM 
C: MTUS1 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
67 
Celina Beatriz Teixeira São José 
 
 
Figure 23. Somatic Events in Family 14. A: ATM Promoter Methylation Analysis. Schematic representation of 
the CpG island located at the ATM promoter. Open circles represent a non-methylated CpG and yellow circles 
represent not accessed CpG sites; Representative examples of sequences of each sample analyzed: HCT-116 
cell line (negative control) and F14 tumor. 
 
ATM and MTUS1 have been reported to be frequently altered in sporadic GC, being 16% 
and 9%, respectively (57,58). Furthermore, according to TCGA database (57,58), 7 (2.4%) 
sporadic GC tumors had co-occurrence of mutations in ATM and MTUS1. In fact, MTUS1 
downregulation has been associated with proliferation and metastasis in solid tumors, such 
as gastric cancer (145). In co-occurrence with ATM variant, important gene in repairing double 
strand breaks, MTUS1 could predispose to FIGC in this family. 
 
2.9. Family 16 
Family 16 was represented by a proband (F16) of the male sex with 78 years old and 
intestinal-type GC. It was observed that the proband’s brother was diagnosed with GC at 
97 years old. The wife of the proband had GC at 55 years old, as well as, the wife’s sister 
of the proband, at 70 years old. 
 
 
A: ATM 
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2.9.1. Germline Landscape  
F16 had three germline variants in MSH2, TGFβR2 and FAT4 (Table 12).  
Variant Asn596Ser in MSH2 was very rare globally (0.02%) and classified as Conflicting, 
since contradictory information was found in the three databases analyzed (Table 12). 
According to InSiGHT database (123,124), this variant was classified as a class III variant with 
uncertain significance, due to insufficient evidence. MSH2 protein expression was 
evaluated in Lynch Syndrome patients with p.Asn596Ser germline variant and revealed to 
be absent in 2 tumors (148) and present in 1 (149). Therefore, it is not clear if variant 
p.Asn596Ser has an impact in protein expression. Furthermore, this variant was unique in 
the FIGC cohort and located in the MutS domain III, region responsible for the interaction 
with MSH6 and MSH3 (118), and may impact the heterodimer formation and, consequently, 
the repair in microsatellite regions (Table 12, Figure 21, Panel A) 
TGFβR2 encodes for a serine/threonine protein kinase that forms a complex with TGFβR1 
and, upon TGFβ binding is able to regulate the transcription of genes associated with cell 
proliferation, through a signaling pathway (150). Variant p.Arg215Cys was unique in the FIGC 
cohort and very rare globally (0.0008%), being classified as VUS (Table 12). Additionally, 
this variant was not located in any known domain, although present in the cytoplasmatic 
region of the protein (Figure 21, Panel B). 
FAT4 belongs to the proto-cadherin family, responsible for adhesion and may regulate 
planar cell polarity (PCP), as well as, hippo signaling pathway (151). Variant in FAT4 was 
very rare in Europe (0.5%) and was classified as Likely Benign (Table 12). Variant 
p.Arg175Leu was unique in this cohort and located in the first cadherin domain (Table 12, 
Figure 21, Panel C) 
 
 
 
 
 
 
 
 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
69 
Celina Beatriz Teixeira São José 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Germline variants of Family 16. A: Pedigree of family 16. The proband is displayed by an arrow. B: 
Schematic representation of MSH2 protein, its domains, interacting molecules and germline variant found 
represented by a green dot (missense variant). aa: amino acids [57,58]. C: Schematic representation of TGFβRII 
protein, its domains, interacting molecules and germline variant found represented by a green dot (missense 
variant) [57,58]. C: Schematic representation of FAT4 protein, its domains, interacting molecules and germline 
variant found represented by a green dot (missense variant) [57,58]. 
 
2.9.2. Somatic Landscape 
At the somatic level, six variants were found in ARID1A, FAT4, MSH3, ATM and two variants 
in PTEN (Figure 22, Panel A). Additionally, promoter of MLH1 and CDH1 was methylated 
and the MSI phenotype was present in this tumor. ARID1A, MSH3 and a PTEN variant were 
A:  
C: TGFβRII 
C: FAT4 
B: MSH2 
C: TGFβRII 
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targets of the MSI phenotype, being located in microsatellite regions. In fact, MSI tumors do 
not usually carry TP53 somatic mutations, as observed in this case. 
 
2.9.3. Characterization of genetic and epigenetic second hits 
According to section 2.9.2, a second mutation was found in FAT4, p.Thr3616Met (Figure 
22, Panel A). This variant, which is novel, was located immediately after the last cadherin 
domain. Due to the lack of information, it may only be speculated that this somatic variant 
may work as a second hit (Figure 22, Panel B). 
Despite this finding, methylation status was assessed in MSH2, TGFβR2 and FAT4. 
Methylation in the promoter of MSH2 was performed as described above. It was observed 
that F16 tumor was not methylated before and after ATG (CpG sites 1 to 51 and 53 to 66), 
Figure 22, Panel C. 
Promoter methylation of TGFβR2 was assessed through the design of two sets of primers. 
F16 tumor, CpG sites 1 to 9 and 20 to 40 is not methylated in the region analyzed, as well 
as, MCF7 cell line, negative control (Figure 22, Panel D). 
Regarding FAT4 promoter methylation, three sets of primers were designed based on 
Yoshida S et al and Pilehchian Langroudi M et al (40,152). In the first set of primers, NCI-N87 
cell line was not methylated. In fact, there was a difference between normal and tumor 
tissue, being the first not methylated and the second hemi-methylated. To compare with 
normal stomach, methylation status was analyzed in an individual who underwent bariatric 
surgery, being not methylated, as well. Regarding the second set of primers, NCI-N87 was 
methylated and no differences in methylation was observed between normal, F16 tumor 
and bariatric surgery, being hemi-methylated. The same was observed in the third set of 
primers (Figure 22, Panel E). However, FAT4 promoter hypermethylation was found in 
sporadic gastric cancer for the same region (40), in accordance to the methylation pattern 
disclosed by the first set of primers. 
In fact, differences between normal and tumor tissue has only been observed in FAT4 CpG 
island region amplified by the first set of primers. However, NCI-87, F16 normal tissue and 
bariatric surgery sequencing was controversial. Sequencing with primer forward revealed 
to be hemi-methylated and with primer reverse were not methylated. Nevertheless, F16 
tumor was hemi-methylated with both primers. This suggests that methylation analysis of 
FAT4 CpG island is contradictory for this region, therefore, second mutation might be the 
second inactivation hit in F16. 
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A 
B: FAT4 
C: MSH2 
D: TFGβRII 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
ARID1A 1 26771131 c.3216delA p.Lys1072AsnfsTer21 Frameshift Indels 1
FAT4 4 125451167 c.10151C>T p.Ala3384Val Missense 1
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 13
PTEN 10 87933147 c.388C>T p.Arg130Ter Stop gained 1
PTEN 10 87961042 c.955_958delACTT p.Thr319Ter Frameshift Indels 1
ATM 11 108244846 c.721A>T p.Lys241Ter Stop gained 1
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Figure 25. Somatic Events in Family 16. A: Somatic variants found in family 16 by multiplex custom-panel based 
sequencing. B: Schematic representation of FAT4 protein, its domains, interacting molecules and somatic 
variant found represented by a green dot (missense variant). aa: amino acids [57,58]. C: MSH2 Promoter 
Methylation Analysis. Schematic representation of the CpG island located at the MSH2 promoter. Open circles 
represent a non-methylated CpG; Representative examples of sequences of each sample analyzed: HCT-116 
cell line (negative control) and F16 tumor. D: TGFβRII Promoter Methylation Analysis. Schematic representation 
of the CpG island located at the TGFβRII promoter. Open circles represent a non-methylated CpG and yellow 
circles represent not accessed CpG sites; Representative examples of sequences of each sample analyzed: 
MCF7 cell line (negative control) and F16 tumor.  
 
 
Figure 26 (cont.). Somatic Events in Family 16. E: FAT4 Promoter Methylation Analysis. Schematic 
representation of the CpG island located at the FAT4 promoter. Open circles represent a non-methylated CpG 
blue circles represent methylated CpG, white circles with blue risks represent hemi-methylated CpG and yellow 
circles represent not accessed CpG sites; Representative examples of sequences of each sample analyzed: 
NCI cell line (negative control), F16 normal, F16 tumor and an individual who underwent a bariatric surgery.  
 
E: FAT4 
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In summary, this family harbored a germline and a somatic variant in FAT4, suggesting that 
both variants could lead to a certain level of inactivation of the FAT4 protein. In fact, recent 
exome studies in sporadic GC (55) revealed FAT4 mutations throughout the gene, 
particularly in the EGF domain. These results were confirmed by TCGA sporadic GC (57,58), 
in which FAT4 is altered in 24% of the cases in the complete gene. Furthermore, according 
to the TCGA database (57,58), TGFβRII is altered in 7% of individuals with sporadic GC and 
in 8 individuals (3%) with co-occurring variants in MSH2. Moreover, a germline variant in 
MSH2 was found in the binding domain of MSH3 and MSH6 and a somatic variant was 
present in its partner MSH3, which could lead to an impairment of the pathway, explaining 
the MSI phenotype. In fact, MSH2 is altered in 2.4% of sporadic TCGA GC cases, in which 
2 individuals (approximately 1%) display co-occurrence of mutations in FAT4 and MSH2 
(57,58). Overall, these results suggest that the co-occurrence of germline variants in FAT4, 
MSH2 and TGFβRII might predispose this family to the development of FIGC. 
 
2.10. Family 19 
Family 19 was represented by a proband (F19) of 82 years old and male sex with intestinal-
type GC and colon cancer. Analyzing the pedigree, it was observed that one of his sisters 
had colorectal cancer at the age of 70 and other had GC at 39 years old (Figure 23, Panel 
A). 
 
2.10.1. Germline Landscape 
At the germline level, two variants were found in F19 in genes MAP3K6 and MSR1 (Table 
12). 
Variant p.Pro1161Ala in MAP3K6 was classified as VUS and was very rare globally 
(0.002%). This variant was unique in this FIGC cohort (2%), being enriched and located 
immediately before the second coiled-coil domain (Table 12, Figure 23, Panel B). 
MSR1 gene encodes for a receptor that mediates inflammation (137). The variant in MSR1 
(p.Arg293X) originates a premature stop codon, was very rare in Tuscany (0.93%), unique 
in the FIGC cohort (2%), being enriched and classified as conflicting (Table 12). In fact, this 
variant was located in the highly conserved Collagen Triple Helix Repeat domain (Figure 
23, Panel C), being expected to disrupt the function of the protein (69,137). Additionally, this 
variant was described previously in four individuals with HDGC (69).  
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Figure 27. Pedigree and germline variants of Family 21. A: Pedigree of family 21. The proband is displayed by 
an arrow. B: Schematic representation of MAP3K6 protein, its domains, interacting molecules and germline 
variant found represented by a green dot (missense variant). aa: amino acids [57,58]. C: Schematic 
representation of MSR1 protein, its domains, interacting molecules and germline variant found represented by 
a green dot (missense variant) [57,58]. 
 
2.10.2 Somatic Landscape 
The tumor of this family had three variants in ARID1A, MSH6 and MSH3 (Figure 24, Panel 
A). Additionally, this tumor presented a MSI phenotype and methylation of MLH1. Promoter 
methylation of MLH1 and the absence of TP53 mutation in F19 tumor are characteristic of 
MSI tumors. In fact, MSH6 and MSH3 variants are targets of MSI phenotype, due to the 
microsatellite regions in which the variants are contained. 
 
 
A 
B: MAP3K6 
C: MSR1 
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2.10.3. Characterization of genetic and epigenetic second hits 
Somatic variants in MAP3K6 and MSR1 were not found, therefore, promoter methylation of 
these genes was assessed to determine if methylation of the wild-type allele could be the 
somatic second inactivation hit. 
The methylation results obtained for the promoter and gene body of MAP3K6 were similar 
to those obtained for F7 and F8 (i.e the promoter was not methylated and the gene body 
was hemi-methylated both in tumor and normal tissues; Figure 23, Panel B and C). These 
findings suggest that second mutation and methylation of the promoter and gene body 
regions of MAP3K6 might not be the second inactivation hit.  
Regarding MSR1 promoter methylation, technical difficulties did not allow the analysis of 
the methylation status, since no CpG island was found to regulate this gene. 
 
 
 
Figure 28. Somatic Events in Family 19. A: Somatic variants found in family 19 by multiplex custom-panel based 
sequencing. B: MAP3K6 Promoter Methylation Analysis. Schematic representation of the CpG island located at 
the MAP3K6 promoter. Open circles represent a non-methylated CpG and yellow circles represent not accessed 
CpG sites; Representative examples of sequences of each sample analyzed: MCF7 cell line (negative control) 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
ARID1A 1 26779533 c.5635C>T p.Arg1879Trp Missense 1
MSH6 2 47803500 c.3261dupC p.Phe1088LeufsTer5 Frameshift Indels 2
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 13
A 
B: MAP3K6 
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and F19 tumor. C: MAP3K6 gene body Methylation Analysis. Schematic representation of the CpG island 
located at the MAP3K6 gene body. Open circles represent a non-methylated CpG; blue circles represent 
methylated CpG, white circles with blue risks represent hemi-methylated CpG and yellow circles represent not 
accessed CpG; Representative examples of sequences of each sample analyzed: MKN74 cell line (negative 
control), F19 normal, F19 tumor and sample of bariatric surgery. 
 
 
Figure 29 (cont.). Somatic Events in Family 19. C: MAP3K6 gene body Methylation Analysis. Schematic 
representation of the CpG island located at the MAP3K6 gene body. Open circles represent a non-methylated 
C: MAP3K6 
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CpG; blue circles represent methylated CpG, white circles with blue risks represent hemi-methylated CpG and 
yellow circles represent not accessed CpG; Representative examples of sequences of each sample analyzed: 
MKN74 cell line (negative control), F19 normal, F19 tumor and sample of bariatric surgery. 
 
MSR1 variant R293X has been identified in patients with HDGC (69) and Barrett Esophagus 
and Esophageal Adenocarcinoma (137), suggesting a correlation with the presence of this 
variant and susceptibility to gastrointestinal tract cancers. In fact, MSR1, as a macrophage 
scavenger receptor, has been associated with inflammation (137), a hallmark of Intestinal GC 
(50). Furthermore, MSR1 is altered in 9% of sporadic GC individuals depicted in the TCGA 
database, with co-occurrence with MAP3K6 in 2 individuals (approximately 1%) (57,58). Thus, 
suggesting that co-occurrence of germline variants in MSR1 and MAP3K6, a gene 
associated with familial gastric cancer (31), could predispose to FIGC in this family. 
 
After a detailed analysis of FIGC families carrying more than one germline variant, 
characterization of FIGC families that harbored single germline variants was performed. It 
is important to state that the possibility of occurrence of other germline variants affecting 
genes that were not included in the custom-panel could not be excluded. 
 
Analysis of Families with single germline variants  
It was observed that 14 out of the 24 families carrying germline variants, displayed a single 
variant (i.e. one variant in a single gene). These 14 germline variants were re-classified as: 
conflicting (5), likely benign (2), and VUS (7), using the Annotator57’s software (Table 14). 
The most frequently mutated gene was MSH6 (in 3 families). Interestingly, these families 
(F9, 10 and 18) harbored exactly the same variant - p.Val878Ala -, which was located in 
MutS domain III and already detected and classified in F11 (section 2.5.1.). In addition, F9, 
F10 and F18 families displayed a similar somatic landscape, carrying variants in TP53 (F9 
and F10) and ARID1A (F10 and F18). Interestingly, F18 also carried a somatic mutation in 
MSH3 gene, which may indicate a defect on the MMR pathway, since both MSH6 and 
MSH3 bind to MSH2 (Table 14, Figure 28, 29, 30). 
Other families were found to display single germline variants, such as: SDHD p.Ala13Val in 
family 3 (F3) and SDHD p.Gly12Ser in family 21 (F21); ITIH2 p.Ala547Val in family 6 (F6); 
SDHB p.Ser163Pro in family 22 (F22); and MSR1 p.Thr161Asn in family 24 (F24).  The 
somatic landscape of these families revealed variants in TP53 (F2, F3, F21 and F22), in 
BRCA2 (F3), and in FAT4 (F22) (Table 14, Figure 25, 26, 27, 31, 32, 33).  
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
78 
Celina Beatriz Teixeira São José 
Focusing on the somatic second hit, second mutation and promoter methylation was not 
found in these families. 
      
F2 
 
 
 
  
Figure 30. Germline variant and somatic variants of F2. A: Schematic representation of SDHD protein, its 
domains, interacting molecules and germline variant found represented by a green dot (missense variant); B: 
Somatic variants in F2. 
 
F3     
   MAP3K6 splice acceptor  
 
 
 
Figure 31. Somatic variants found in F3. 
 
F5 
 
 
 
     - 
 
Figure 32. Schematic representation of ATM protein, its domains, interacting molecules and germline variant 
found represented by a green dot (missense variant). Somatic variants were not found. 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
TP53 17 7674953 c.578A>T p.His193Leu Missense 1
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
BRCA2 13 32332779 c.1310_1313delAAGA p.Lys437IlefsTer22 Frameshift Indels 1
TP53 17 7673764 c.856G>T p.Glu286Ter Stop gained 1
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F6      
  
   
 
     - 
 
Figure 33. Schematic representation of ITIH2 protein, its domains, interacting molecules and germline variant 
found represented by a green dot (missense variant). Somatic variants were not found. 
 
F9 
 
 
 
 
 
Figure 34. Germline and somatic variants of F9. A: Schematic representation of MSH6 protein, its domains, 
interacting molecules and germline variants found represented by a green dot (missense variant); B: Somatic 
variants in F9. 
 
F10 
 
 
 
 
 
Figure 35. Germline and somatic variants of F10. A: Schematic representation of MSH6 protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense variant); B: Somatic 
variants in F10. 
 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
TP53 17 7674238 c.725G>T p.Cys242Phe Missense 1
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
ARID1A 1 26780111 c.6214delG p.Asp2072ThrfsTer63 Frameshift Indels 1
CTNNA1 5 138824612 c.671delC p.Ala224AspfsTer20 Frameshift Indels 1
TP53 17 7674221 c.742C>T p.Arg248Trp Missense 2
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F18 
 
 
 
 
 
Figure 36. Germline and somatic variants of F18. A: Schematic representation of MSH6 protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense variant); B: Somatic 
variants in F18. 
 
F20 
 
 
 
 
 
Figure 37. Germline and somatic variants of F20. A: Schematic representation of FAT4 protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense variant); B: Somatic 
variants in F20. 
 
F21 
 
 
 
 
 
Figure 38. Germline and somatic variants of F21. A: Schematic representation of SDHD protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense variant); B: Somatic 
variants in F21. 
 
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
ARID1A 1 26774926 c.4703delC p.Pro1568LeufsTer44 Frameshift Indels 1
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 13
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
TP53 17 7674250 c.713G>T p.Cys238Phe Missense 1
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Gene Chr Position GRCh38 cDNA Protein Consequence
TP53 17 7675228 c.380_384delCCCCT p.Ser127CysfsTer20 Frameshift Indels
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F22 
 
 
 
 
Figure 39. Germline and somatic variants of F22. A: Schematic representation of SDHB protein, its domains, 
interacting molecules and germline variant found represented by a green dot (missense variant); B: Somatic 
variants in F21. 
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Figure 40. Schematic representation of MSR1 protein, its domains, interacting molecules and germline variant 
found represented by a green dot (missense variant). Somatic variants were not found
Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort
FAT4 4 125450920 c.9904C>A p.Leu3302Ile Missense 1
TP53 17 7674208 c.743_755delGGAGGCCCATCCT p.Arg248ProfsTer93 Frameshift Indels 1
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Table 14. Germline Variants identified in FIGC families with single germline variants by multiplex custom-panel based sequencing. 
 
Description of germline variants, including both frequency in the cohort (freq cohort: % of mutated families), ExAC and 1000genomes and Clinical Significance classification from 
Illumina's Variant Interpreter, Annotator (in 3 databases) and integrated classification. Eur: Europe; Tusc: Tuscany; VUS: Variant of Unknown Significance; NA: Not available; 
Very Rare: <1%; Rare: >1, <5; Not Rare: >5. 
 
Table 15 represents a characterization of germline variants and corresponding potential somatic second hits. 
 
 
 
 
 
 
 Table 15. Characterization of germline variants found in each family and somatic second hit found. 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Population Frequency Illumina's Classification Annotator57's Classification
Integrated 
Classification
Potential 
Risk Allele
2 SDHD 11 112086945 c.38C>T p.Ala13Val Missense 2% Very Rare Global (0,006%), Very Rare Eur (0%) VUS NA VUS Yes
3 MAP3K6 1 27362252 c.1256-2A>G - Splice acceptor 4% Very Rare Global (0,4%), Rare Eur (1,4%), Very Rare Tusc (0,9%) Likely Pathogenic NA VUS Yes
5 ATM 11 108329200 c.7269A>T p.Glu2423Asp Missense 2% NA VUS Uncertain Significance - 1 VUS Yes
6 ITIH2 10 7731989 c.1640C>T p.Ala547Val Missense 2% Very Rare Global (0,02%), Very Rare Eur (0,004%) VUS NA VUS Yes
9 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Likely Benign - 1 Conflicting Yes
10 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Likely Benign - 1 Conflicting Yes
15 MTUS1 8 17684434 c.2732A>C p.Lys911Thr Missense 2% Very Rare Global (0,9%), Rare Eur (1,8%), Very Rare Tusc (0,9%) VUS Likely Benign - 1 Likely Benign Yes
17 APC 5 112839078 c.3484T>C p.Tyr1162His Missense 2% NA VUS NA VUS Yes
18 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Likely Benign - 1 Conflicting Yes
20 FAT4 4 125451863 c.10847C>T p.Thr3616Met Missense 2% Very Rare Global (0,3%), Very Rare Eur (0,6%), Very Rare Tusc (0,9%) VUS Likely Benign - 1 Likely Benign Yes
21 SDHD 11 112086941 c.34G>A p.Gly12Ser Missense 4% Very Rare Global (1%), Rare Eur (2%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic - 2; Uncertain Significance - 1 Conflicting Yes
22 SDHB 1 17027802 c.487T>C p.Ser163Pro Missense 4% Rare Global (1,9%), Rare Eur (3,4%), Rare Tusc (3,7%) Pathogenic Likely Pathogenic – 2; Uncertain Significance - 1 Conflicting Yes
23 CDH1 16 68813323 c.1148A>G p.Gln383Arg Missense 2% NA VUS NA VUS Yes
24 MSR1 8 16168606 c.482C>A p.Thr161Asn Missense 2% Very Rare Global (0,08%), Very Rare Eur (0,2%) Very Rare Tusc (0,9%) VUS NA VUS Yes
25-52 Germline variants were not found
* * * * * * * * * * 
 The Germline and Somatic Landscape of Familial Intestinal Gastric Cancer: Search for a Cause  
83 
Celina Beatriz Teixeira São José 
Gene Freq: Frequency of each gene’s variants in a total of 36 variants; Alt Freq: Frequency of each variant in a total of 36; Blue: Likely Pathogenic variant; Red: Conflicting Variant; Green: Likely 
Benign variant; Grey: Variant of Unknown Significance. * represents families with co-occurrence of germline variants.# represents potential second mutation as second inactivating hit.  
 
Gene Gene Freq Alteration Alt Freq F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 F21 F22 F23 F24
p.Lys412Asn 3%
p.Val878Ala 11%
p.Ser753Phe 3%
p.Gly12Ser 6%
p.His50Arg 3%
p.Ala13Val 3%
p.Glu2423Asp 3%
p.His1436Tyr 3%
p.Arg832Cys 3%
c.1275A>G(p.=) 3%
p.Asn596Ser 3%
TGFBR2 3% p.Arg215Cys 3%
p.Arg175Leu 3%
p.Thr3616Met 3%
c.1256-2A>G 6%
p.Pro946Leu 3%
p.Pro1161Ala 3%
BRCA1 3% c.-20+2dupT 3%
CASP10 3% p.Cys169Phe 3%
p.Arg293Ter 3%
p.Thr161Asn 3%
p.Lys911Thr 3%
p.Glu999Gly 3%
p.Ser211Ala 3%
SDHB 6% p.Ser163Pro 6%
BRCA2 3% p.Thr939SerfsTer7 3%
CTHRC1 3% p.Leu20_Leu21dup 3%
ITIH2 3% p.Ala547Val 3%
APC 3% p.Tyr1162His 3%
CDH1 3% p.Gln383Arg 3%
MSR1
MTUS1
17%
11%
8%
6%
6%
11%
6%
8%
MSH6 
SDHD
ATM
MSH2
FAT4
MAP3K6 
# 
# 
# 
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3. Somatic Landscape of Familial Intestinal Gastric Cancer 
Despite the already described similarities between FIGC and Sporadic GC, such as the MSI 
phenotype and their target genes (59), very little is known concerning the somatic landscape 
of FIGC tumors. Therefore, the fourth aim of this thesis was to identify other somatic events 
in FIGC tumors by using a panel-based sequencing approach.  
Sequencing data from the tumors of the 52 FIGC families revealed the presence of 115 
somatic variants, affecting 23 genes in 36 families (table 16). These 115 somatic variants 
were classified by the Illumina´s software as: pathogenic (21 variants), likely pathogenic (52 
variants), and variants of unknown significance (42 variants) (Table 16). Using Annotator57, 
following re-classification was obtained: Pathogenic (12 variants), Likely Pathogenic (42 
variants), Conflicting (1) and VUS (60 variants) (table 16). Furthermore, 22 out of the 115 
variants were very rare in the global population and one very rare variant in the Tuscany 
population (Table 16). For the remaining 92 information regarding frequency was not found 
(Table 16). Detailed information on the classification of variants is described in 
Supplementary Table 2. 
Considering the Illumina’s Variant Interpreter, 42 variants were classified as VUS. From 
these, Annotator57 re-classified eight as Likely Pathogenic, one as Conflicting and 33 as 
VUS, allowing an increased knowledge of the pathogenicity of these variants. Concerning 
the 52 variants classified with Illumina’s Variant Interpreter as Likely Pathogenic, 22 were 
re-classified as Likely Pathogenic, three as Pathogenic and 27 as VUS. This may be due to 
the actualization of the databases. Additionally, 21 variants were classified with Illumina’s 
Variant Interpreter as Pathogenic and 9 were re-classified with Annotator57 as Pathogenic 
and 12 as Likely pathogenic (Table 16). 
In Figure 34 is represented an oncoprint, with all the genes somatically altered in each 
family. In fact, tumor suppressor genes were the most frequently mutated genes, including 
TP53 (18%), MSH3 (11%), ARID1A (10%), FAT4 (7%), APC (8%), MSH6 (7%), ATM (7%), 
BRCA2 (6%) and CTNNA1 (6%). 
Interestingly, the TCGA research network had published a comprehensive molecular 
characterization of gastric adenocarcinoma (54), showing that the most frequently mutated 
genes in intestinal type sporadic GC were TP53 (54%), LRP1B (33%), SYNE1 (31%), 
ARID1A (30%), PCLO (29%) and FAT4 (28%) (54,57,58). However, the LRP1B, SYNE1 and 
PCLO genes were not included in the custom-panel, which could explain their absence in 
this cohort. In addition, other studies based on next generation sequencing have also 
showed FAT4 and ARID1A mutations in sporadic GC (55). Of notice, variants in the common 
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genes between FIGC cohort and the TCGA sporadic GC cohort (TP53, ARID1A, FAT4) are 
more frequent in the sporadic intestinal type GC subset, in comparison with the intestinal 
familial subset. This may be another argument that FIGC is an independent entity with clear 
differences from sporadic intestinal type GC.   
A similar somatic landscape was observed between FIGC families with and without 
germline variants (Table 17).  In fact, TP53 was the most frequently mutated gene in both 
type of families (18%), which is not in accordance with frequency of TP53 mutations found 
in the sporadic setting (54%) (57,58). In addition, ARID1A (10%) and APC (8%) were the 
second most frequently mutated genes in families with and without germline variants, 
respectively). Interestingly, ARID1A mutations have been described in gastric 
adenocarcinoma, predominantly intestinal type. Additionally, the majority of families 
carrying germline variants (63%) harbored more frequently somatic variants in more than 
one gene in comparison with families without germline variants (35%). This may be due to 
the fact that the MSI phenotype is more frequent in families with germline variants (50%), 
than without (32%), Table 16. According to the TCGA database (57,58), in sporadic intestinal-
type GC, MSI phenotype is present in 25% of the cases, a reduced number in comparison 
to our results (MSI is present in 22/52 (42%) families). Thus, the MSI phenotype is more 
frequent in FIGC tumors than in sporadic intestinal-type GC tumors, not in accordance with 
previous studies (79,80). 
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Table 16. Somatic Variants identified in FIGC families by multiplex custom-panel based sequencing.
 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Frequency Illumina's Classification Annotator's Classification
Integrated 
Classification
ARID1A 1 26771139 c.3219G>A p.Trp1073Ter Stop gained 2% - Likely Pathogenic NA VUS
MSH6 2 47801146 c.3163G>A p.Ala1055Thr Missense 2% Very Rare Global (0,002%) VUS Uncertain Significance - 1 VUS
FAT4 4 125406935 c.5363G>A p.Arg1788His Missense 2% - VUS NA VUS
AKAP12 6 151351864 c.3479dupC p.Asp1161Ter Frameshift Indels 2% - Likely Pathogenic NA VUS
ATM 11 108229266 c.278delA p.Lys93ArgfsTer23 Frameshift Indels 2% - Likely Pathogenic NA VUS
BRCA2 13 32339422 c.5073delA p.Lys1691AsnfsTer15 Frameshift Indels 2% - Pathogenic Likely Pathogenic - 1 Likely Pathogenic
IDH2 15 90088686 c.435delG p.Thr146LeufsTer15 Frameshift Indels 2% - Likely Pathogenic NA VUS
PALB2 16 23635707 c.839delA p.Asn280ThrfsTer8 Frameshift Indels 2% - Likely Pathogenic NA VUS
2 TP53 17 7674953 c.578A>T p.His193Leu Missense 2% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
BRCA2 13 32332779 c.1310_1313delAAGA p.Lys437IlefsTer22 Frameshift Indels 2% Very Rare Global (0,002%) Likely Pathogenic Likely Pathogenic - 1 Likely Pathogenic
TP53 17 7673764 c.856G>T p.Glu286Ter Stop gained 2% - Likely Pathogenic Pathogenic - 1 Pathogenic
4-6 Somatic variants were not found
7 TP53 17 7675109 c.503A>T p.His168Leu Missense 2% - VUS Likely Pathogenic - 1 Likely Pathogenic
ARID1A 1 26773716 c.4003C>T p.Arg1335Ter Stop gained, Splice region 2% - Pathogenic Likely Pathogenic - 2 Likely Pathogenic
FAT4 4 125449221 c.8205A>C p.Lys2735Asn Missense 2% - VUS NA VUS
PTEN 10 87952216 c.595_597delATG p.Met199del Inframe deletion 2% - VUS Uncertain Significance - 1 VUS
PTEN 10 87958013 c.800delA p.Lys267ArgfsTer9 Frameshift Indels 2% - Pathogenic Pathogenic - 1 Pathogenic
9 TP53 17 7674238 c.725G>T p.Cys242Phe Missense 2% - VUS Likely Pathogenic – 2 Likely Pathogenic
ARID1A 1 26780111 c.6214delG p.Asp2072ThrfsTer63 Frameshift Indels 2% - Likely Pathogenic NA VUS
CTNNA1 5 138824612 c.671delC p.Ala224AspfsTer20 Frameshift Indels 2% - Likely Pathogenic NA VUS
TP53 17 7674221 c.742C>T p.Arg248Trp Missense 4% Very Rare Global (0,002%) Pathogenic Likely Pathogenic - 3 Likely Pathogenic
CDH1 16 68819423 c.1709A>G p.Asn570Ser Missense, Splice region 2% - VUS NA VUS
TP53 17 7674947 c.584T>C p.Ile195Thr Missense 2% Very Rare Global (0,002%) VUS Likely Pathogenic - 2 Likely Pathogenic
12 APC 5 112842961 c.7367T>A p.Leu2456Ter Stop gained 2% - Likely Pathogenic NA VUS
13-15 Somatic variants were not found
ARID1A 1 26771131 c.3216delA p.Lys1072AsnfsTer21 Frameshift Indels 2% - Likely Pathogenic NA VUS
FAT4 4 125451167 c.10151C>T p.Ala3384Val Missense 2% - VUS NA VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
PTEN 10 87933147 c.388C>T p.Arg130Ter Stop gained 2% Very Rare Global (0,002%) Pathogenic Pathogenic - 1; Likely Pathogenic - 1 Likely Pathogenic
PTEN 10 87961042 c.955_958delACTT p.Thr319Ter Frameshift Indels 2% - Pathogenic Pathogenic - 1 Pathogenic
ATM 11 108244846 c.721A>T p.Lys241Ter Stop gained 2% - Likely Pathogenic NA VUS
17 Somatic variants were not found
ARID1A 1 26774926 c.4703delC p.Pro1568LeufsTer44 Frameshift Indels 2% - Likely Pathogenic NA VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
ARID1A 1 26779533 c.5635C>T p.Arg1879Trp Missense 2% Very Rare Global (0,008%) VUS NA VUS
MSH6 2 47803500 c.3261dupC p.Phe1088LeufsTer5 Frameshift Indels 4% - Pathogenic Pathogenic - 1 Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
20 TP53 17 7675228 c.380_384delCCCCT p.Ser127CysfsTer20 Frameshift Indels 2% - Likely Pathogenic NA VUS
21 TP53 17 7674250 c.713G>T p.Cys238Phe Missense 2% - VUS Likely Pathogenic - 2 Likely Pathogenic
FAT4 4 125450920 c.9904C>A p.Leu3302Ile Missense 2% - VUS NA VUS
TP53 17 7674208 c.743_755delGGAGGCCCATCCT p.Arg248ProfsTer93 Frameshift Indels 2% - Likely Pathogenic NA VUS
1
3
8
10
11
16
18
19
22
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Table 16 (cont.). Somatic Variants identified in FIGC families by multiplex custom-panel based sequencing. 
 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Frequency Illumina's Classification Annotator's Classification
Integrated 
Classification
ARID1A 1 26766552 c.2974G>T p.Glu992Ter Stop gained 2% - Likely Pathogenic NA VUS
ARID1A 1 26772565 c.3472G>T p.Gly1158Ter Stop gained 2% - Likely Pathogenic NA VUS
MSH2 2 47480873 c.2634+4delT - Splice donor 2% - Likely Pathogenic Likely Pathogenic - 1 Pathogenic
TGFBR2 3 30688506 c.1594C>A p.His532Asn Missense 2% - VUS NA VUS
MLH1 3 37040259 c.1632A>T p.Gln544His Missense 2% - VUS NA VUS
FAT4 4 125451730 c.10714A>G p.Ile3572Val Missense 2% - VUS NA VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
APC 5 112837681 c.2087A>G p.Glu696Gly Missense 2% - VUS NA VUS
CTNNA1 5 138783232 c.161G>A p.Arg54His Missense 2% Very Rare Global (0,005%) VUS NA VUS
CTNNA1 5 138824597 c.656C>T p.Pro219Leu Missense 2% Very Rare Global (0,003%) VUS NA VUS
AKAP12 6 151350826 c.2435C>A p.Pro812His Missense 2% - VUS NA VUS
ATM 11 108259061 c.2452A>G p.Ile818Val Missense 2% - VUS NA VUS
ATM 11 108271249 c.2922-2A>C - Splice acceptor 2% - Likely Pathogenic NA Likely Pathogenic
ATM 11 108304802 c.5624G>A p.Arg1875Gln Missense 2% Very Rare Global (0,002%) VUS Uncertain Significance – 1 VUS
BRCA2 13 32398361 c.9848T>A p.Val3283Asp Missense 2% - VUS NA VUS
PALB2 16 23629845 c.2309C>A p.Ala770Asp Missense 2% - VUS NA VUS
24 Somatic variants were not found
APC 5 112838478 c.2884G>C p.Asp962His Missense 2% - VUS NA VUS
TP53 17 7675139 c.473G>A p.Arg158His Missense 2% Very Rare Global (0,002%) Pathogenic Likely Pathogenic - 2 Likely Pathogenic
26 TP53 17 7675235 c.377A>G p.Tyr126Cys Missense, Splice region 2% - VUS Likely Pathogenic - 1 Likely Pathogenic
MSH6 2 47803501 c.3261delC p.Phe1088SerfsTer2 Frameshift Indels 6% - Pathogenic Pathogenic - 1 Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
CTNNA1 5 138781963 c.39G>A p.Trp13Ter Stop gained 2% - Likely Pathogenic NA VUS
CTNNA1 5 138930610 c.2150dupA p.Gln718AlafsTer16 Frameshift Indels 2% - Likely Pathogenic NA VUS
28 TP53 17 7673802 c.818G>A p.Arg273His Missense 2% Very Rare Eur (0,2%), Very Rare Tusc (0%) Pathogenic Likely Pathogenic - 3 Likely Pathogenic
29 TP53 17 7674240 c.723delC p.Cys242AlafsTer5 Frameshift Indels 2% - Likely Pathogenic NA VUS
30 TP53 17 7674246 c.716dupA p.Asn239LysfsTer25 Frameshift Indels 2% - Likely Pathogenic Likely Pathogenic - 1 Likely Pathogenic
ARID1A 1 26762296 c.2402dupG p.Gln802SerfsTer15 Frameshift Indels 2% - Likely Pathogenic Likely Pathogenic - 1 Likely Pathogenic
ARID1A 1 26774648 c.4424delA p.Asn1475ThrfsTer6 Frameshift Indels 2% - Likely Pathogenic Likely Pathogenic - 1 Likely Pathogenic
MLH1 3 36993588 c.41C>T p.Thr14Ile Missense 2% Very Rare Global (0,002%) VUS Uncertain significance - 1 VUS
FAT4 4 125316934 c.523C>T p.Arg175Cys Missense 2% Very rare Global (0,002%) VUS NA VUS
APC 5 112842672 c.7078G>T p.Gly2360Cys Missense 2% - VUS NA VUS
HSPA5 9 125240909 c.123-2A>G - Splice acceptor 2% - Likely Pathogenic NA VUS
32 TP53 17 7674250 c.713G>C p.Cys238Ser Missense 2% - VUS Likely Pathogenic – 2 Likely Pathogenic
MSH6 2 47795898 c.465delA p.Lys155AsnfsTer19 Frameshift Indels 2% - Likely Pathogenic NA VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
APC 5 112838594 c.3000C>A p.Tyr1000Ter Stop gained 2% - Likely Pathogenic NA Likely Pathogenic
APC 5 112839979 c.4393_4394delAG p.Ser1465TrpfsTer3 Frameshift Indels 2% - Pathogenic Pathogenic - 1; Likely Pathogenic - 1 Likely Pathogenic
BRCA2 13 32339700 c.5351delA p.Asn1784ThrfsTer7 Frameshift Indels 2% - Pathogenic Pathogenic - 1 Pathogenic
34 TP53 17 7675161 c.451C>T p.Pro151Ser Missense 2% - Pathogenic Likely Pathogenic - 3 Likely Pathogenic
31
33
27
23
25
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Table 16 (cont.). Somatic Variants identified in FIGC families by multiplex custom-panel based sequencing. 
  
 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Frequency Illumina's Classification Annotator's Classification
Integrated 
Classification
ARID1A 1 26771197 c.3281delA p.Lys1094SerfsTer67 Frameshift Indels 2% - Likely Pathogenic NA VUS
MSH2 2 47412449 c.687delA p.Ala230LeufsTer16 Frameshift Indels 2% - Pathogenic Likely Pathogenic - 1 Likely Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
APC 5 112839978 c.4393_4394dupAG p.Ser1465ArgfsTer9 Frameshift Indels 2% - Likely Pathogenic Likely Pathogenic - 1 Likely Pathogenic
APC 5 112840367 c.4778delA p.Lys1593SerfsTer57 Frameshift Indels 2% - Likely Pathogenic NA VUS
CTNNA1 5 138924599 c.1636C>T p.Arg546Ter Stop gained 2% - Likely Pathogenic NA VUS
CTHRC1 8 103378048 c.394C>T p.Arg132Cys Missense 2% Very Rare Global (0,08%) VUS NA VUS
ATM 11 108227807 c.104G>A p.Arg35Gln Missense 2% - VUS Uncertain Significance - 1 VUS
CDH1 16 68801883 c.377C>T p.Pro126Leu Missense 2% Very Rare Global (0,004%) VUS Uncertain Significance - 1 VUS
STK11 19 1220399 c.491T>C p.Leu164Pro Missense 2% - VUS NA VUS
MSR1 8 16155129 c.833C>T p.Pro278Leu Missense 2% - VUS NA VUS
TP53 17 7674221 c.742C>T p.Arg248Trp Missense 4% Very Rare Global (0,002%) Pathogenic Likely Pathogenic - 3 Likely Pathogenic
37 MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
CTNNA1 5 138824800 c.858+1G>A - Splice donor 2% - Likely Pathogenic NA VUS
TP53 17 7674230 c.733G>A p.Gly245Ser Missense 2% Very Rare Global (0,002%) Pathogenic Likely Pathogenic - 3 Likely Pathogenic
39 APC 5 112839702 c.4108A>T p.Lys1370Ter Stop gained 2% - Likely Pathogenic NA Likely Pathogenic
MSH6 2 47800177 c.2194C>T p.Arg732Ter Stop gained 2% Very Rare Global (0,002%) Pathogenic Pathogenic - 1 Pathogenic
MSH6 2 47803500 c.3261dupC p.Phe1088LeufsTer5 Frameshift Indels 4% - Pathogenic Likely Pathogenic - 1 Pathogenic
FAT4 4 125321047 c.4636G>A p.Val1546Ile Missense 2% Very Rare Global (0,002%) VUS NA VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
ATM 11 108229320 c.329_330delGA p.Arg110LysfsTer4 Frameshift Indels, Splice region 2% - Likely Pathogenic NA VUS
BRCA2 13 32394815 c.9383G>A p.Arg3128Gln Missense 2% Very Rare Global (0,002%) VUS Uncertain Significance - 1 Likely Pathogenic
TP53 17 7675157 c.455delC p.Pro152ArgfsTer18 Frameshift Indels 2% - Likely Pathogenic NA VUS
41 TP53 17 7673787 c.833C>T p.Pro278Leu Missense 2% - VUS Likely Pathogenic - 2 Likely Pathogenic
MCCC1 3 183037239 c.1573A>T p.Thr525Ser Missense 2% - VUS NA VUS
FAT4 4 125448714 c.7698A>C p.Lys2566Asn Missense 2% - VUS NA VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
ITIH2 10 7705109 c.86T>G p.Phe29Cys Missense, Splice region 2% - VUS NA VUS
ATM 11 108247071 c.1009C>T p.Arg337Cys Missense 2% Very Rare Global (0,002%) VUS Likely Pathogenic - 1; Uncertain Significance - 1 Conflicting
BRCA2 13 32337305 c.2957dupA p.Asn986LysfsTer2 Frameshift Indels 2% - Likely Pathogenic Pathogenic - 1 Pathogenic
BRCA2 13 32356499 c.7507G>A p.Val2503Ile Missense 2% Very Rare Global (0,002%) VUS Uncertain Significance - 1 VUS
MSH6 2 47803501 c.3261delC p.Phe1088SerfsTer2 Frameshift Indels 6% - Pathogenic Likely Pathogenic - 1 Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
MSH6 2 47803501 c.3261delC p.Phe1088SerfsTer2 Frameshift Indels 6% - Pathogenic Likely Pathogenic - 1 Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic Likely Pathogenic - 2 Likely Pathogenic
45 TP53 17 7674220 c.743G>A p.Arg248Gln Missense 2% Very Rare Global (0,01%) Pathogenic Likely Pathogenic – 3 Likely Pathogenic
46 PTEN 10 87952122 c.499dupA p.Thr167AsnfsTer13 Frameshift Indels 2% - Likely Pathogenic NA VUS
47-52 Somatic variants were not found
42
43
44
35
36
38
40
Description of somatic variants, including both frequency in the cohort (freq cohort: % of mutated families), ExAC and 1000genomes and Clinical Significance classification 
from Illumina's Variant Interpreter, Annotator (in 3 databases) and integrated classification. Eur: Europe; Tusc: Tuscany; VUS: Variant of Unknown Significance; NA: Not 
available; Very Rare: <1%; Rare: >1, <5; Not Rare: >5. 
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Figure 41. Oncoprint of somatic variants. Columns represent families that harbored somatic variants. Grey: 
somatic variant not found; 1/3 of the rectangle green: 1 somatic variant; 2/3 of the rectangle green: 2 somatic 
variants; complete rectangle green: 3 somatic variants. % of variants in each gene/115. 
 
Table 17. Differences of somatic landscape between families with and without germline variants. 
 
  
With germline variants Without germline variants
24 families 28 families
16 (67%) families harbored somatic variants 20 (71%) families harbored somatic variants
12 (50%) families displayed MSI phenotype 9 (32%) families displayed MSI phenotype
TP53 (18%) and ARID1A (15%) were the most 
frequently altered genes
TP53 (20%) and APC (12%) were the most 
frequently altered genes
10 (63%) families harbored more than one 
somatic variant
7 (35%) families harbored more than one 
somatic variant
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V. Conclusions 
During the last decade, next generation sequencing technologies have revealed the genetic 
landscape of classic predisposition syndromes and contributed to the definition of cancer 
risks (93). 
Whilst germline defects were found for HDGC and GAPPS, FIGC remains without a genetic 
risk factor identified.  
Working under the hypothesis that the rare FIGC syndrome is caused by germline co-
occurrence of moderate-risk alleles and represent a polygenic, rather than a classical 
monogenic disease, the work described in this master thesis was an attempt to dissect the 
germline and somatic landscapes of the largest FIGC cohort ever studied.   
A panel of genes was used to sequence both the normal (germline) and tumor (somatic) 
DNA from the probands of 52 FIGC families.  The choice of using a panel of genes was 
made based on a clinical perspective by directing to genes associated with gastrointestinal 
tract cancers or syndromes in which GC is predominant. Using a custom panel-based 
sequencing approach instead of whole genome or whole exome sequencing had also 
several advantages, such as:  less false discovery rate, i.e, fewer variants discovered with 
no implication in the clinic; less bioinformatics analysis complexity and less data volume 
and storage. 
One of the main findings of this thesis was the co-occurrence of germline variants in 10 out 
of 24 (42%) FIGC families that carried germline variants. However, it should not be discard 
that other important variants located in other genes (absent in the panel), could also occur 
in concomitance with the variants found, thus potentially increasing the number of FIGC 
families with co-occurrence of variants.  
 
   Main Findings 
• Thirty-six germline variants, affecting 17 genes, were found in 24 families;  
• The 36 germline variants were classified as: Likely Pathogenic (1), Conflicting (11), 
Likely Benign (3), and Variants of Unknown Significance (21); 
• The most frequently mutated genes were MSH6 (17%), MAP3K6 (11%), SDHD 
(11%), ATM (8%) and MTUS1 (8%); 
• 50% (12/24) of the families had germline variants in DNA repair genes; 
• 25% (6/24) of the families had germline variants in genes associated with metabolism; 
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   Main Findings (cont.) 
• 10/ 24 FIGC families (42%) carried co-occurrence of germline variants; 
• DNA repair genes were frequently altered in co-occurrence with metabolism 
associated genes (F1, F4 and F11); 
• Three families harbored germline variants in chromosomes 2 and 11 (F1, F4 and 
F11); 
• Two families displayed, potentially, a second inactivation hit in the wild-type allele: 
second somatic mutation (in F1 – MSH6 and F16 – FAT4);  
• One family displayed increased CTHRC1 mRNA expression in the tumor, in 
comparison with normal stomach and a decreased APC mRNA expression in the 
tumor associated with APC somatic variant; 
• Impairment of the same pathways recurrently appeared in families with co-occurrence 
of germline variants: MMR (MSH6 and MSH2), HR (ATM, BRCA1 and BRCA2), 
MAPK (MAP3K6) and PCP (CTHRC1 and FAT4), as well as, same genes, MTUS1 
SDHB and SDHD; 
 
• One hundred and fifteen somatic variants, affecting 23 genes, were found in 36 
families;  
• The 115 somatic variants were classified as: Pathogenic (12), Likely Pathogenic (54), 
and Variants of Unknown Significance (49); 
• The somatic landscape of families with and without germline variants was similar; 
• The most frequently mutated genes were TP53 (18%), MSH3 (11%), ARID1A (10%), 
FAT4 (7%), APC (8%), MSH6 (7%), ATM (7%), BRCA2 (6%) and CTNNA1 (6%); 
• The MSI phenotype was more frequent in families with germline variants; 
• The majority of families with germline variants (63%) harbored somatic variants in 
more than one gene, comparing with families without germline variants (35%). 
 
In conclusion, the work described in this thesis pinpointed FIGC as a polygenic rather than 
a monogenic disease, where co-occurrence of low or moderate risk alleles that interact with 
family history and other non-genetic factors (environmental) can affect the risk of cancer of 
each individual.   
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VI. Future Directions 
The work developed during this master thesis was the first attempt to dissect the genetic 
cause underlying FIGC using a relatively large and homogeneous cohort. Nevertheless, 
several issues and unanswered questions still need to be clarified and future experiments 
should be done for a better understanding of the genetic risk factors underlying FIGC and 
to prove its potential polygenic nature.  
Further experiments may include: 
1) Loss of heterozygosity analysis as a potential somatic second inactivation hit, in families 
that harbored germline variants, but neither second mutation nor promoter methylation 
revealed to be the inactivation mechanisms; 
2) Analysis of the impact of somatic second hits by quantifying the mRNA and protein levels 
of potentially inactivated genes, using real time PCR and immunohistochemistry, 
respectively; 
3) Immunohistochemistry analysis of protein partners of genes carrying germline variants;  
4) Dissecting the pathogenicity of the germline variants found to be in co-occurrence in each 
family. For example, intestinal GC cell lines could be transfected with expression vectors 
carrying those variants and further analyzed for proliferation, invasion, apoptosis and other 
cancer-related properties;   
5) In parallel, segregation analysis in all families, to better understand if the germline 
variants found in the proband are reflected in the affected family members. 
 
These approaches may shine a light on the underlying genetic causes of FIGC and envision 
the establishment of a genetic screening protocol for a better management of FIGC families. 
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Description of germline variants, including both frequency in the cohort (freq cohort: % of mutated families), ExAC and 1000genomes and Clinical Significance classification from Illumina's Variant 
Interpreter, UniProt, OMIM, ClinVar, Annotator57 (in the 3 databases) and Integrated classification. Eur: Europe; Tusc: Tuscany; VUS: Variant of Unknown Significance; NA: Not available; Very Rare: 
<1%; Rare: >1, <5; Not Rare: >5. 
VIII. Supplementary Material 
 
Table S1. Germline Variants identified in FIGC families by multiplex custom-panel based sequencing. 
 
 
 
 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Population Frequency Illumina's Classification UniProt Classification OMIM Classification ClinVar Classification Annotator's Classification Cosmic Classification FATHMN prediction HGMD Final Classification
MSH6 2 47799219 c.1236G>C p.Lys412Asn Missense 2% NA VUS NA NA NA NA - - - VUS
MSH6 2 47800241 c.2258C>T p.Ser753Phe Missense 2% NA VUS NA NA Uncertain Significance Uncertain Significance - 1 - - - VUS
SDHD 11 112086941 c.34G>A p.Gly12Ser Missense 4% Very Rare Global (1%), Rare Eur (2%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic Likely Pathogenic Uncertain Significance Likely Pathogenic - 2; Uncertain Significance - 1 - - - Conflicting
2 SDHD 11 112086945 c.38C>T p.Ala13Val Missense 2% Very Rare Global (0,006%), Very Rare Eur (0%) VUS NA NA NA NA - - - Likely Pathogenic
3 MAP3K6 1 27362252 c.1256-2A>G - Splice acceptor 4% Very Rare Global (0,4%), Rare Eur (1,4%), Very Rare Tusc (0,9%) Likely Pathogenic NA NA NA NA - - - Likely Pathogenic
MSH2 2 47429940 c.1275A>G c.1275A>G(p.=) Splice region, Synonymous 2% Very Rare Global (0,02%), Very Rare Eur (0,05%) VUS NA NA Uncertain Significance Uncertain Significance - 1 - - Yes Likely Pathogenic
SDHD 11 112087953 c.149A>G p.His50Arg Missense 2% Rare Global (1,3%), Rare Eur (3,4%), Rare Tusc (2,8%) Pathogenic Likely Pathogenic Likely Pathogenic Uncertain Significance Likely Pathogenic - 2; Uncertain Significance - 1 - - Yes Conflicting
5 ATM 11 108329200 c.7269A>T p.Glu2423Asp Missense 2% NA VUS NA NA Uncertain Significance Uncertain Significance - 1 Yes Pathogenic (0,99) VUS
6 ITIH2 10 7731989 c.1640C>T p.Ala547Val Missense 2% Very Rare Global (0,02%), Very Rare Eur (0,004%) VUS NA NA NA NA - - - Likely Pathogenic
MAP3K6 1 27358259 c.2837C>T p.Pro946Leu Missense 2% Very Rare Global (0,4%), Very Rare Eur (1%), Very Rare Tusc (0,9%) VUS NA NA NA NA - - - Likely Pathogenic
BRCA1 17 43125268 c.-20+2dupT - Splice region, Intron 2% NA VUS NA NA NA NA - - - VUS
MAP3K6 1 27362252 c.1256-2A>G - Splice acceptor 4% Very Rare Global (0,4%), Rare Eur (1,4%), Very Rare Tusc (0,9%) Likely Pathogenic NA NA NA NA - - - Likely Pathogenic
CASP10 2 201193048 c.506G>T p.Cys169Phe Missense 2% Very Rare Global (0,002%), Very Rare Eur (0,02%) VUS NA NA NA NA - - - Likely Pathogenic
9 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Benign Likely Pathogenic - 2; Likely Benign - 1 - - - Conflicting
10 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Benign Likely Pathogenic - 2; Likely Benign - 1 - - - Conflicting
MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Benign Likely Pathogenic - 2; Likely Benign - 1 - - - Conflicting
ATM 11 108289671 c.4306C>T p.His1436Tyr Missense 2% Very Rare Global (0,04%), Very Rare Eur (0,2%), Very Rare Tusc (0,9%) VUS NA NA Uncertain Significance Uncertain Significance - 1 - - - Likely Pathogenic
CTHRC1 8 103371707 c.57_62dupCCTGCT p.Leu20_Leu21dup Inframe insertion 2% NA VUS NA NA NA NA - - - VUS
BRCA2 13 32337163 c.2812_2815dupGCAA p.Thr939SerfsTer7 Frameshift Indels 2% NA Likely Pathogenic NA NA NA NA - - - Likely Pathogenic
SDHB 1 17027802 c.487T>C p.Ser163Pro Missense 4% Rare Global (1,9%), Rare Eur (3,4%), Rare Tusc (3,7%) Pathogenic Likely Pathogenic Likely Pathogenic Uncertain Significance Likely Pathogenic – 2; Uncertain Significance - 1 - - - Conflicting
MTUS1 8 17655975 c.2996A>G p.Glu999Gly Missense 2% Very Rare Global (0,6%), Rare Eur (2,6%), Rare Tusc (3,7%) VUS NA NA NA NA - - - Likely Pathogenic
MTUS1 8 17755177 c.631T>G p.Ser211Ala Missense 2% Very Rare Global (0,8%), Rare Eur (3,4%), Rare Tusc (3,7%) VUS NA NA NA NA - - - Likely Pathogenic
ATM 11 108267198 c.2494C>T p.Arg832Cys Missense 2% Very Rare Global (0,04%), Very Rare Eur (0%), Very Rare Tusc (0%) VUS NA NA Uncertain Significance Uncertain Significance - 1 Yes Neutral - Likely Pathogenic
15 MTUS1 8 17684434 c.2732A>C p.Lys911Thr Missense 2% Very Rare Global (0,9%), Rare Eur (1,8%), Very Rare Tusc (0,9%) VUS Likely Benign NA NA Likely Benign - 1 - - - Likely Benign
MSH2 2 47475052 c.1787A>G p.Asn596Ser Missense 2% Very Rare Global (0,06%), Very Rare Eur (0,07%) VUS Likely Pathogenic NA Uncertain Significance Likely Pathogenic – 1; Uncertain Significance - 1 Yes Pathogenic (0,99) - Conflicting
TGFBR2 3 30671751 c.643C>T p.Arg215Cys Missense 2% Very Rare Global (0,02%), Very Rare Eur (0%) VUS NA NA NA NA - - - Likely Pathogenic
FAT4 4 125316935 c.524G>T p.Arg175Leu Missense 2% Very Rare Global (0,2%), Very Rare Eur (1%) VUS NA NA Likely Benign Likely Benign - 1 - - - Likely Benign
17 APC 5 112839078 c.3484T>C p.Tyr1162His Missense 2% NA VUS NA NA NA NA - - - VUS
18 MSH6 2 47800616 c.2633T>C p.Val878Ala Missense 8% Very Rare Global (0,8%), Rare Eur (2,6%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Benign Likely Pathogenic - 2; Likely Benign - 1 - - - Conflicting
MAP3K6 1 27356633 c.3481C>G p.Pro1161Ala Missense 2% Very Rare Global (0,005%), Very Rare Eur (0,009%) VUS NA NA NA NA - - - Likely Pathogenic
MSR1 8 16155085 c.877C>T p.Arg293Ter Stop gained 2% Very Rare Global (1,1%), Rare Eur (2,4%), Rare Tusc (1,7%) Pathogenic NA Likely Pathogenic Uncertain Significance Likely Pathogenic - 1; Uncertain Significance - 1 Yes Neutral (0,08) - Likely Pathogenic
20 FAT4 4 125451863 c.10847C>T p.Thr3616Met Missense 2% Very Rare Global (0,3%), Very Rare Eur (0,6%), Very Rare Tusc (0,9%) VUS NA NA Likely Benign Likely Benign - 1 - - - Likely Benign
21 SDHD 11 112086941 c.34G>A p.Gly12Ser Missense 4% Very Rare Global (1%), Rare Eur (2%), Rare Tusc (4,7%) Pathogenic Likely Pathogenic Likely Pathogenic Uncertain Significance Likely Pathogenic - 2; Uncertain Significance - 1 Yes Neutral (0,02) - Conflicting
22 SDHB 1 17027802 c.487T>C p.Ser163Pro Missense 4% Rare Global (1,9%), Rare Eur (3,4%), Rare Tusc (3,7%) Pathogenic Likely Pathogenic Likely Pathogenic Uncertain Significance Likely Pathogenic – 2; Uncertain Significance - 1 - - - Conflicting
23 CDH1 16 68813323 c.1148A>G p.Gln383Arg Missense 2% NA VUS NA NA NA NA - - - VUS
24 MSR1 8 16168606 c.482C>A p.Thr161Asn Missense 2% Very Rare Global (0,08%), Very Rare Eur (0,2%) Very Rare Tusc (0,9%) VUS NA NA NA NA - - - Likely Pathogenic
25-52Germline variants were not found
13
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16
19
1
4
7
8
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Table S2. Somatic Variants identified in FIGC families by multiplex custom-panel based sequencing. 
 
 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Frequency Illumina's Classification UniProt Classification OMIM Classification ClinVar Classification Annotator57's Classification
Cosmic 
Classification
FATHMN prediction HGMD
Integrated 
Classification
ARID1A 1 26771139 c.3219G>A p.Trp1073Ter Stop gained 2% - Likely Pathogenic NA NA NA NA Yes Pathogenic (0,98) - VUS
MSH6 2 47801146 c.3163G>A p.Ala1055Thr Missense 2% Very Rare Global (0,002%) VUS NA NA Uncertain Significance Uncertain Significance - 1 - - - VUS
FAT4 4 125406935 c.5363G>A p.Arg1788His Missense 2% - VUS NA NA NA NA Yes Pathogenic (0,91) - VUS
AKAP12 6 151351864 c.3479dupC p.Asp1161Ter Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
ATM 11 108229266 c.278delA p.Lys93ArgfsTer23 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
BRCA2 13 32339422 c.5073delA p.Lys1691AsnfsTer15 Frameshift Indels 2% - Pathogenic NA NA Likely Pathogenic Likely Pathogenic - 1 - - Yes Likely Pathogenic
IDH2 15 90088686 c.435delG p.Thr146LeufsTer15 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
PALB2 16 23635707 c.839delA p.Asn280ThrfsTer8 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
2 TP53 17 7674953 c.578A>T p.His193Leu Missense 2% - Likely Pathogenic Likely Pathogenic NA Likely Pathogenic Likely Pathogenic - 2 - Likely Pathogenic
BRCA2 13 32332779 c.1310_1313delAAGA p.Lys437IlefsTer22 Frameshift Indels 2% Very Rare Global (0,002%) Likely Pathogenic NA NA Likely Pathogenic Likely Pathogenic - 1 Yes Likely Pathogenic
TP53 17 7673764 c.856G>T p.Glu286Ter Stop gained 2% - Likely Pathogenic NA NA Pathogenic Pathogenic - 1 Yes Pathogenic (1,00) - Pathogenic
4-6 Somatic variants were not found
7 TP53 17 7675109 c.503A>T p.His168Leu Missense 2% - VUS Likely Pathogenic NA NA Likely Pathogenic - 1 Yes Pathogenic (0,97) - Likely Pathogenic
ARID1A 1 26773716 c.4003C>T p.Arg1335Ter Stop gained, Splice region 2% - Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes Pathogenic (0,87) - Likely Pathogenic
FAT4 4 125449221 c.8205A>C p.Lys2735Asn Missense 2% - VUS NA NA NA NA Yes None (0,51) - VUS
PTEN 10 87952216 c.595_597delATG p.Met199del Inframe deletion 2% - VUS NA NA Uncertain Significance Uncertain Significance - 1 Yes None Yes VUS
PTEN 10 87958013 c.800delA p.Lys267ArgfsTer9 Frameshift Indels 2% - Pathogenic NA NA Pathogenic Pathogenic - 1 Yes None - Pathogenic
9 TP53 17 7674238 c.725G>T p.Cys242Phe Missense 2% - VUS Likely Pathogenic NA Likely Pathogenic Likely Pathogenic – 2 Yes Pathogenic (0,99) - Likely Pathogenic
ARID1A 1 26780111 c.6214delG p.Asp2072ThrfsTer63 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
CTNNA1 5 138824612 c.671delC p.Ala224AspfsTer20 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
TP53 17 7674221 c.742C>T p.Arg248Trp Missense 4% Very Rare Global (0,002%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic - 3 - Likely Pathogenic
CDH1 16 68819423 c.1709A>G p.Asn570Ser Missense, Splice region 2% - VUS NA NA NA NA - VUS
TP53 17 7674947 c.584T>C p.Ile195Thr Missense 2% Very Rare Global (0,002%) VUS Likely Pathogenic NA Likely Pathogenic Likely Pathogenic - 2 Yes Pathogenic (0,99) Yes Likely Pathogenic
12 APC 5 112842961 c.7367T>A p.Leu2456Ter Stop gained 2% - Likely Pathogenic NA NA NA NA - VUS
13-15 Somatic variants were not found
ARID1A 1 26771131 c.3216delA p.Lys1072AsnfsTer21 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA Yes None (0,00) - VUS
FAT4 4 125451167 c.10151C>T p.Ala3384Val Missense 2% - VUS NA NA NA NA - VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
PTEN 10 87933147 c.388C>T p.Arg130Ter Stop gained 2% Very Rare Global (0,002%) Pathogenic NA Likely Pathogenic Pathogenic Pathogenic - 1; Likely Pathogenic - 1 - Likely Pathogenic
PTEN 10 87961042 c.955_958delACTT p.Thr319Ter Frameshift Indels 2% - Pathogenic NA NA Pathogenic Pathogenic - 1 Yes None (0,00) - Pathogenic
ATM 11 108244846 c.721A>T p.Lys241Ter Stop gained 2% - Likely Pathogenic NA NA NA NA - VUS
17 Somatic variants were not found
ARID1A 1 26774926 c.4703delC p.Pro1568LeufsTer44 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
ARID1A 1 26779533 c.5635C>T p.Arg1879Trp Missense 2% Very Rare Global (0,008%) VUS NA NA NA NA Yes Pathogenic (0,78) - VUS
MSH6 2 47803500 c.3261dupC p.Phe1088LeufsTer5 Frameshift Indels 4% - Pathogenic NA NA Pathogenic Pathogenic - 1 Yes None (0,00) Yes Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA NA NA Likely Pathogenic - 2 - - - Likely Pathogenic
20 TP53 17 7675228 c.380_384delCCCCT p.Ser127CysfsTer20 Frameshift Indels 2% - Likely Pathogenic Likely Pathogenic NA Likely Pathogenic NA Yes Pathogenic (0,99) - VUS
21 TP53 17 7674250 c.713G>T p.Cys238Phe Missense 2% - VUS NA NA NA Likely Pathogenic - 2 - Likely Pathogenic
FAT4 4 125450920 c.9904C>A p.Leu3302Ile Missense 2% - VUS NA NA NA NA - - - VUS
TP53 17 7674208 c.743_755delGGAGGCCCATCCT p.Arg248ProfsTer93 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA Yes Pathogenic (1,00) - VUS
ARID1A 1 26766552 c.2974G>T p.Glu992Ter Stop gained 2% - Likely Pathogenic NA NA NA NA Yes Pathogenic (0,96) - VUS
ARID1A 1 26772565 c.3472G>T p.Gly1158Ter Stop gained 2% - Likely Pathogenic NA NA Pathogenic NA - VUS
MSH2 2 47480873 c.2634+4delT - Splice donor 2% - Likely Pathogenic NA NA NA Likely Pathogenic - 1 - Pathogenic
TGFBR2 3 30688506 c.1594C>A p.His532Asn Missense 2% - VUS NA NA NA NA - VUS
MLH1 3 37040259 c.1632A>T p.Gln544His Missense 2% - VUS NA NA NA NA - VUS
FAT4 4 125451730 c.10714A>G p.Ile3572Val Missense 2% - VUS NA Likely Pathogenic Likely Pathogenic NA Yes None - VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA NA NA Likely Pathogenic - 2 - Likely Pathogenic
APC 5 112837681 c.2087A>G p.Glu696Gly Missense 2% - VUS NA NA NA NA - VUS
CTNNA1 5 138783232 c.161G>A p.Arg54His Missense 2% Very Rare Global (0,005%) VUS NA NA NA NA - VUS
CTNNA1 5 138824597 c.656C>T p.Pro219Leu Missense 2% Very Rare Global (0,003%) VUS NA NA NA NA - VUS
AKAP12 6 151350826 c.2435C>A p.Pro812His Missense 2% - VUS NA NA NA NA - VUS
ATM 11 108259061 c.2452A>G p.Ile818Val Missense 2% - VUS NA NA NA NA Yes VUS
ATM 11 108271249 c.2922-2A>C - Splice acceptor 2% - Likely Pathogenic NA NA Uncertain Significance NA - Likely Pathogenic
ATM 11 108304802 c.5624G>A p.Arg1875Gln Missense 2% Very Rare Global (0,002%) VUS NA NA NA Uncertain Significance – 1 - VUS
BRCA2 13 32398361 c.9848T>A p.Val3283Asp Missense 2% - VUS NA NA NA NA - VUS
PALB2 16 23629845 c.2309C>A p.Ala770Asp Missense 2% - VUS NA NA NA NA - - Yes VUS
24 Somatic variants were not found
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Description of germline variants, including both frequency in the cohort (freq cohort: % of mutated families), ExAC and 1000genomes and Clinical Significance classification from Illumina's Variant 
Interpreter, UniProt, OMIM, ClinVar, Annotator57 (in the 3 databases) and Integrated classification. Eur: Europe; Tusc: Tuscany; VUS: Variant of Unknown Significance; NA: Not available; Very Rare: 
<1%; Rare: >1, <5; Not Rare: >5. 
Table S2 (cont.). Somatic Variants identified in FIGC families by multiplex custom-panel based sequencing. 
 
Family Gene Chr Position GRCh38 cDNA Protein Consequence Freq cohort Frequency Illumina's Classification UniProt Classification OMIM Classification ClinVar Classification Annotator57's Classification
Cosmic 
Classification
FATHMN prediction HGMD
Integrated 
Classification
APC 5 112838478 c.2884G>C p.Asp962His Missense 2% - VUS Likely Pathogenic NA Likely Pathogenic NA - - - VUS
TP53 17 7675139 c.473G>A p.Arg158His Missense 2% Very Rare Global (0,002%) Pathogenic Likely Pathogenic NA NA Likely Pathogenic - 2 - - - Likely Pathogenic
26 TP53 17 7675235 c.377A>G p.Tyr126Cys Missense, Splice region 2% - VUS NA NA Pathogenic Likely Pathogenic - 1 Yes None (0,00) Yes Likely Pathogenic
MSH6 2 47803501 c.3261delC p.Phe1088SerfsTer2 Frameshift Indels 6% - Pathogenic NA Likely Pathogenic Likely Pathogenic Pathogenic - 1 Yes None - Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
CTNNA1 5 138781963 c.39G>A p.Trp13Ter Stop gained 2% - Likely Pathogenic NA NA NA NA - VUS
CTNNA1 5 138930610 c.2150dupA p.Gln718AlafsTer16 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
28 TP53 17 7673802 c.818G>A p.Arg273His Missense 2% Very Rare Eur (0,2%), Very Rare Tusc (0%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic - 3 - Likely Pathogenic
29 TP53 17 7674240 c.723delC p.Cys242AlafsTer5 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA Yes None - VUS
30 TP53 17 7674246 c.716dupA p.Asn239LysfsTer25 Frameshift Indels 2% - Likely Pathogenic Likely Pathogenic NA NA Likely Pathogenic - 1 - - - Likely Pathogenic
ARID1A 1 26762296 c.2402dupG p.Gln802SerfsTer15 Frameshift Indels 2% - Likely Pathogenic NA NA NA Likely Pathogenic - 1 - Likely Pathogenic
ARID1A 1 26774648 c.4424delA p.Asn1475ThrfsTer6 Frameshift Indels 2% - Likely Pathogenic NA NA NA Likely Pathogenic - 1 - Likely Pathogenic
MLH1 3 36993588 c.41C>T p.Thr14Ile Missense 2% Very Rare Global (0,002%) VUS NA NA Uncertain Significance Uncertain significance - 1 - VUS
FAT4 4 125316934 c.523C>T p.Arg175Cys Missense 2% Very rare Global (0,002%) VUS NA NA NA NA - VUS
APC 5 112842672 c.7078G>T p.Gly2360Cys Missense 2% - VUS NA NA NA NA - VUS
HSPA5 9 125240909 c.123-2A>G - Splice acceptor 2% - Likely Pathogenic NA NA NA NA - VUS
32 TP53 17 7674250 c.713G>C p.Cys238Ser Missense 2% - VUS Likely Pathogenic NA Likely Pathogenic Likely Pathogenic – 2 Yes Pathogenic (0,99) - Likely Pathogenic
MSH6 2 47795898 c.465delA p.Lys155AsnfsTer19 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
APC 5 112838594 c.3000C>A p.Tyr1000Ter Stop gained 2% - Likely Pathogenic NA NA NA NA Yes Likely Pathogenic
APC 5 112839979 c.4393_4394delAG p.Ser1465TrpfsTer3 Frameshift Indels 2% - Pathogenic NA Likely Pathogenic Pathogenic Pathogenic - 1; Likely Pathogenic - 1 Yes None (0,00) Yes Likely Pathogenic
BRCA2 13 32339700 c.5351delA p.Asn1784ThrfsTer7 Frameshift Indels 2% - Pathogenic NA NA Likely Pathogenic Pathogenic - 1 - - Yes Pathogenic
34 TP53 17 7675161 c.451C>T p.Pro151Ser Missense 2% - Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic - 3 - Likely Pathogenic
ARID1A 1 26771197 c.3281delA p.Lys1094SerfsTer67 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA Yes None (0,00) - VUS
MSH2 2 47412449 c.687delA p.Ala230LeufsTer16 Frameshift Indels 2% - Pathogenic NA NA Likely Pathogenic Likely Pathogenic - 1 Yes None (0,00) Yes Likely Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
APC 5 112839978 c.4393_4394dupAG p.Ser1465ArgfsTer9 Frameshift Indels 2% - Likely Pathogenic NA Likely Pathogenic NA Likely Pathogenic - 1 Yes None (0,00) Yes Likely Pathogenic
APC 5 112840367 c.4778delA p.Lys1593SerfsTer57 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
CTNNA1 5 138924599 c.1636C>T p.Arg546Ter Stop gained 2% - Likely Pathogenic NA NA NA NA - VUS
CTHRC1 8 103378048 c.394C>T p.Arg132Cys Missense 2% Very Rare Global (0,08%) VUS NA NA NA NA - VUS
ATM 11 108227807 c.104G>A p.Arg35Gln Missense 2% - VUS NA NA Uncertain Significance Uncertain Significance - 1 - VUS
CDH1 16 68801883 c.377C>T p.Pro126Leu Missense 2% Very Rare Global (0,004%) VUS NA NA Uncertain Significance Uncertain Significance - 1 Yes None (0,00) - VUS
STK11 19 1220399 c.491T>C p.Leu164Pro Missense 2% - VUS NA NA NA NA - VUS
MSR1 8 16155129 c.833C>T p.Pro278Leu Missense 2% - VUS NA NA NA NA Yes None (0,53) - VUS
TP53 17 7674221 c.742C>T p.Arg248Trp Missense 4% Very Rare Global (0,002%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic - 3 - Likely Pathogenic
37 MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
CTNNA1 5 138824800 c.858+1G>A - Splice donor 2% - Likely Pathogenic NA NA NA NA Yes Pathogenic (0,99) - VUS
TP53 17 7674230 c.733G>A p.Gly245Ser Missense 2% Very Rare Global (0,002%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic - 3 - Likely Pathogenic
39 APC 5 112839702 c.4108A>T p.Lys1370Ter Stop gained 2% - Likely Pathogenic NA NA NA NA Yes Pathogenic (0,93) Yes Likely Pathogenic
MSH6 2 47800177 c.2194C>T p.Arg732Ter Stop gained 2% Very Rare Global (0,002%) Pathogenic NA NA Pathogenic Pathogenic - 1 Yes None (0,00) - Pathogenic
MSH6 2 47803500 c.3261dupC p.Phe1088LeufsTer5 Frameshift Indels 4% - Pathogenic NA NA Likely Pathogenic Likely Pathogenic - 1 Yes None (0,00) Yes Pathogenic
FAT4 4 125321047 c.4636G>A p.Val1546Ile Missense 2% Very Rare Global (0,002%) VUS NA NA NA NA Yes Pathogenic (0,78) - VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
ATM 11 108229320 c.329_330delGA p.Arg110LysfsTer4 Frameshift Indels, Splice region 2% - Likely Pathogenic NA NA NA NA - - - VUS
BRCA2 13 32394815 c.9383G>A p.Arg3128Gln Missense 2% Very Rare Global (0,002%) VUS NA NA Uncertain Significance Uncertain Significance - 1 - Likely Pathogenic
TP53 17 7675157 c.455delC p.Pro152ArgfsTer18 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - - VUS
41 TP53 17 7673787 c.833C>T p.Pro278Leu Missense 2% - VUS Likely Pathogenic NA Likely Pathogenic Likely Pathogenic - 2 - Likely Pathogenic
MCCC1 3 183037239 c.1573A>T p.Thr525Ser Missense 2% - VUS NA NA NA NA - VUS
FAT4 4 125448714 c.7698A>C p.Lys2566Asn Missense 2% - VUS NA NA NA NA - VUS
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
ITIH2 10 7705109 c.86T>G p.Phe29Cys Missense, Splice region 2% - VUS NA NA NA NA - VUS
ATM 11 108247071 c.1009C>T p.Arg337Cys Missense 2% Very Rare Global (0,002%) VUS Likely Pathogenic NA Uncertain Significance Likely Pathogenic - 1; Uncertain Significance - 1 Yes Pathogenic (0,95) - Conflicting
BRCA2 13 32337305 c.2957dupA p.Asn986LysfsTer2 Frameshift Indels 2% - Likely Pathogenic NA NA Pathogenic Pathogenic - 1 - - Yes Pathogenic
BRCA2 13 32356499 c.7507G>A p.Val2503Ile Missense 2% Very Rare Global (0,002%) VUS NA NA Uncertain Significance Uncertain Significance - 1 - VUS
MSH6 2 47803501 c.3261delC p.Phe1088SerfsTer2 Frameshift Indels 6% - Pathogenic NA NA Likely Pathogenic Likely Pathogenic - 1 Yes None (0,00) Yes Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
MSH6 2 47803501 c.3261delC p.Phe1088SerfsTer2 Frameshift Indels 6% - Pathogenic NA NA Likely Pathogenic Likely Pathogenic - 1 Yes None (0,00) Yes Pathogenic
MSH3 5 80675096 c.1148delA p.Lys383ArgfsTer32 Frameshift Indels 25% - Likely Pathogenic NA Likely Pathogenic Likely Pathogenic Likely Pathogenic - 2 Yes None - Likely Pathogenic
45 TP53 17 7674220 c.743G>A p.Arg248Gln Missense 2% Very Rare Global (0,01%) Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic Likely Pathogenic – 3 - Likely Pathogenic
46 PTEN 10 87952122 c.499dupA p.Thr167AsnfsTer13 Frameshift Indels 2% - Likely Pathogenic NA NA NA NA - - Yes VUS
47-52 Somatic variants were not found
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